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Helicobacter pylori is an ancient microorganism that co-evolved with humans for 
many years and typically colonizes the human stomach and is being recognized as 
the most common infectious pathogen of the gastroduodenal tract. Some years after 
bacterium isolation, epidemiological studies have revealed a correlation between its 
infection and some diseases localized outside the stomach, such as hematological, 
hepatobiliary, pancreatic, cardiovascular, neurological, dermatological and respiratory 
diseases. Different mechanisms of action have been proposed, ranging from the 
induction of a low-grade inflammatory state to the occurrence of molecular mimicry 
mechanisms. This book is an overview of contributors surrounding the association 
of H. pylori infection with extragastric diseases, based on evidence, bacterial-host 
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Preface
The possible relationship between Helicobacter pylori (H. pylori) infection and the develop‐
ment of extragastric disorders still remains a controversial and arguable topic. Different
pathogenic mechanisms have been hypothesized, including the induction of a low-grade in‐
flammatory state and the occurrence of molecular mimicry mechanisms. Nevertheless, while
some studies are quite large and well conducted, in other cases there are just small or isolat‐
ed case reports concerning the theme.
H. pylori, isolated for the first time in 1983 by Warren and Marshall, is an ancient microor‐
ganism that has co-evolved with humans for over 60,000 years and nowadays affects more
than half of the world population. H. pylori presents well-characterized mechanisms of
adaptation, which were developed over the time. Through selection and coevolution, this
bacterium established measures by which it actively and passively avoids the human im‐
mune response.
H. pylori infection is the main cause of chronic gastritis, peptic ulcer disease, mucosa-associ‐
ated lymphoid tissue (MALT) lymphoma and gastric cancer. In 1994, the International
Agency for Research on Cancer (the World Health Organization) classified H. pylori as a
class I carcinogen because of the epidemiological link of this microorganism infection with a
higher risk of development of gastric malignancy.
The infection is typically acquired during childhood and usually becomes a lifelong infec‐
tion, if left untreated. The host certainly mounts an immune response, but it fails to clear the
infection, and H. pylorisuccessfully establishes a persistent infection leading to chronic in‐
flammation. Nevertheless, it has been estimated that only 10% of people colonized with this
bacterium portray disease symptoms, a fact that suggests that both host and bacterial factors
can contribute to differences in H. pylori pathogenicity. Besides, it is important to consider
that together with the host characteristics and bacterial virulence, the environmental factors
also contribute for the clinical outcome of H. pylori infections.
Recently, H. pylori is increasingly being associated with extragastric diseases, and this associ‐
ation has been reported by several studies which results range from definitive confirmation
of the bacterial responsibility in the pathogenesis of some diseases to overall rather contro‐
versial results. According to the mentioned studies, this microorganism infection has been
associated with hematological diseases, cardiovascular diseases, hepatobiliary and pancreat‐
ic diseases, skin and pulmonary diseases, insulin resistance, diabetes and its complications
and neurodegenerative disorders, among others.
As regards to hematological diseases, there is substantial evidence in favour of an associa‐
tion between H. pylori infection and unexplained iron deficiency anemia, idiopathic throm‐
bocytopenic purpura and vitamin B12 deficiency. Considering it, the principal guidelines for
the management of H. pylori infection recommends that the infection should be sought and
treated.
An association between H. pylori infection and coronary artery disease as well as with athe‐
rosclerosis has been described but remains controversial. In the same way, studies described
a link between this microorganism presence and lung diseases, such as chronic obstructive
pulmonary disease. Despite of it, there is insufficient evidence to draw conclusions regard‐
ing the role of H. pylori infection and these disorders.
The same possible association has been described between this infection and hepatobiliary
and pancreatic disorders. There are many lines of evidence that H. pylori, especially the most
virulent strains, can contribute to hepatocellular carcinoma, cirrhosis and chronic hepatitis,
as well as to pancreatic cancer and chronic pancreatitis. Notwithstanding, some studies sug‐
gest that this pathogen may represent a co-risk factor for these conditions.
Considering the hypothesis and the importance that H. pylori isolation and its studies have
represented to the scientific and medical communities, this book contemplates very impor‐
tant reviews and studies that highlight our view about the influence or responsibility of this
infection in extradigestive disorders. Consequently, this book is compound by seven chap‐
ters, which are divided into following sections: General comments on H. pylori infection and
extradigestive diseases; H. pylori infection and oral cavity; Hematological diseases and H.
pylori infection; and H. pylori and metabolic disorders.
Dr. Kyung Park presents an interesting chapter regarding important aspects reported to H.
pyloriinfection and extragastric diseases. Discussions concerning this infection and dyslipi‐
demia, hypertension, insulin resistance and diabetes, obesity, metabolic syndrome and obe‐
sity, atherosclerosis, autoimmune diseases and other extradigestive diseases such as
migraine and chronic bronchitis are depicted.
Prof. Ki Baik Hahm and colleagues report halitosis as one of extragastric manifestations of
H. pylori, also considering that Korean red ginseng could be a natural product very effective
in relieving halitosis in addition to responsible bacterial suppression.
In the third section of the book, three important chapters describe the relationship between
H. pyloriinfection and hematological diseases. Dr. Campuzano-Maya described the principal
aspects of iron deficiency anemia, vitamin B12 deficiency and immune thrombocytopenia,
besides other hematological diseases not really associated with H. pylori infection, such as
immune neutropenia, antiphospholipid syndrome and plasma cell dyscrasias.
Dr. Miguel reports the interaction between H. pylori and the immune system, describing the
principal aspects of iron deficiency anemia, idiopathic thrombocytopenic purpura and
MALT lymphoma pathogenesis. Topics concerning the principal mechanisms of pathogene‐
sis as well as the principal diagnostic tests, epidemiology and routes of transmission are also
explained.
Dr. Basyigit and colleagues present an interesting chapter concerning H. pylori and iron de‐
ficiency anemia, considering all the important aspects of this disease, including the iron me‐
tabolism, possible mechanisms of iron deficiency related to H. pylori infection and the
management of the disease, among other topics.
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Finally, in the last section of this book, Dr. Muhsen and colleagues report the principal evi‐
dence of the possible relationship between H. pylori and diabetes mellitus, including the
changes in gastric physiology and metabolic homeostasis, besides the possible rule of bacte‐
ria on metabolic syndrome.
“Extradigestive Manifestations of Helicobacter pylori – An Overview” will certainly provide
an updated set of information in all the principal aspects of this so curious and important
relationship, enriching the knowledge of the whole scientific community about this ancient
microorganism, which can really be recognized as a “master of adaptation”.
The editor dedicates this book to Dr. Zeitune, her advisor who unfortunately passed away
in the course of this project. The editor expresses her thankfulness for the excellent work of
the contributing authors. The editor thanks Ms. Danijela Duric and Ms. Ana Pantar for all
their attention and support, making possible the accomplishment of this book. The editor is
especially thankful for the excellent support given by Ms. Iva Simcic in all the steps of this
book, as well as the entire InTech Open Access publishing team.
Dr. Bruna Maria Roesler
Pharmacist Biochemist
Department of Internal Medicine
Center of Diagnosis of Digestive Diseases
School of Medical Sciences, State University of Campinas
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Abstract
Helicobacter pylori (H. pylori) is well known as a group I human gastric cancer carcinogen
by the International Agency for Research on Cancer. Although an exact causal relation‐
ship is unclear, H. pylori is expected to have been associated with non-digestive abnormal
condition and/or diseases, such as metabolic syndrome, atherosclerosis and cardiovascu‐
lar diseases, which have substantially lots of prior studies; adaptive immune response –
related disorders, such as autoimmune thyroid diseases (ATDs), urticaria, atopy and
asthma; and the other extra-digestive diseases, such as chronic obstructive pulmonary
disease (COPD), migraine, anemia and hyperemesis gravidarum. This chapter overviews
several groups of extra-digestive diseases by H. pylori infection and discusses the role of
H. pylori in relation to the diseases in the viewpoint of causality.
Keywords: Helicobacter pylori, non- digestive diseases, overview, causality, relationship
1. Introduction
Helicobacter pylori (H. pylori), gram- negative spiral or curved bacillus, was discovered in 1982
by two pathologists, Barry Marshall and Robin Warren, the 1982 Nobel Prize awardees. Almost
all patients had active chronic gastritis or gastroduodenal ulcer and thus the bacteria got
attention as an important etiological factor of these diseases. Ironically, back to the past,
Freedburg and Barron had first found the spiral organisms among gastrectomy patients in
1940, but the bacteria were forgotten for a long time due to failure to replication in other studies.
H. pylori is an established cause of chronic active or superficial gastritis, gastroduodenal ulcer
disease, gastric adenocarcinoma and the mucosa-associated lymphoid tissue (MALT) lym‐
phoma. The International Agency for Research on Cancer (IARC), a suborganization of the
World Health Organization (WHO), classified the H. pylori as a group I human gastric cancer
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
carcinogen (the meaning of definite carcinogen) in 1994. H. pylori chronic infection to gastric
tissue results in carcinogenic environment or causes chronic inflammation, which leads to
gastric carcinogenesis. Chronic H. pylori infection also induces gastric lymphoid follicles and
trigger MALT lymphomagenesis of lymphoid expansion, which leads to MALT lymphoma.
Although only a few people (1–3%) with H. pylori chronic infection develop gastric cancer, H.
pylori explains a 60–90% of gastric cancer in studies of population attributable fraction (PAF)
estimation.
Prior studies showed that H. pylori is also expected to be associated with extra-digestive
diseases. The first group of diseases is abnormal metabolic profiles such as insulin resistance,
diabetes, hypertension, obesity and dyslipidemia, which are the components of metabolic
syndrome. Consequently, the abnormal profiles are complexly influenced to increase the risk
for cardiovascular diseases by atherosclerosis and vascular dysfunction. The second group of
diseases is adaptive immune response–related disorders, such as autoimmune diseases
including autoimmune thyroid diseases (ATDs), atopic disease, urticaria and asthma. The
other group is on elusive knowledge, such as COPD, glaucoma, migraine, anemia and
hyperemesis gravidarum.
The suggested mechanism, despite of inconclusive causal relationship, is as follows: Chronic
H. pylori infection induces chronic inflammation, a complex biological response of the tissues
to H. pylori. Inflammatory factors including cytokines interleukin (IL) and tumor necrosis
factor (TNF), especially induced from chronic, low-grade inflammation, on the infection-
inflammation pathway are common in pathogenesis of gastritis, atherosclerosis, metabolic
syndrome, obesity and diabetes. These inflammatory factors produced in the inflamed gastric
mucosa are continually secreted into the circulation, and they can affect metabolic profiles.[1]
Therefore, chronic, low-grade inflammation by chronic H. pylori infection may induce extra‐
gastric diseases due to the effect of H. pylori–induced cytokines.
H. pylori infection and its transmission were related to low socioeconomic status (SES) such as
poor hygiene, water contamination, and non-healthy lifestyles such as poor diet, smoking and
physical inactivity. Usually people who were tested with H. pylori infection are those in middle
SES class and over, and therefore, non-gastric diseases are also diagnosed in this class. Poor
hygiene hypothesis seems to be no more proper for these populations in the association of H.
pylori infection with non-gastric diseases.
Therefore, this chapter introduces extradigestive diseases by H. pylori infection and discusses
critical issues in the H. pylori role in extradigestive diseases in the viewpoint of causality of H.
pylori infection for these diseases.
2. Dyslipidemia
Dyslipidemia, such as high total cholesterol and/or triglyceride concentration or low high-
density lipoprotein (HDL) level, is a component for metabolic syndrome (MetS). Abnormal
lipid profile in H. pylori–infected subjects has been reported in several studies. A review paper
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview4
carcinogen (the meaning of definite carcinogen) in 1994. H. pylori chronic infection to gastric
tissue results in carcinogenic environment or causes chronic inflammation, which leads to
gastric carcinogenesis. Chronic H. pylori infection also induces gastric lymphoid follicles and
trigger MALT lymphomagenesis of lymphoid expansion, which leads to MALT lymphoma.
Although only a few people (1–3%) with H. pylori chronic infection develop gastric cancer, H.
pylori explains a 60–90% of gastric cancer in studies of population attributable fraction (PAF)
estimation.
Prior studies showed that H. pylori is also expected to be associated with extra-digestive
diseases. The first group of diseases is abnormal metabolic profiles such as insulin resistance,
diabetes, hypertension, obesity and dyslipidemia, which are the components of metabolic
syndrome. Consequently, the abnormal profiles are complexly influenced to increase the risk
for cardiovascular diseases by atherosclerosis and vascular dysfunction. The second group of
diseases is adaptive immune response–related disorders, such as autoimmune diseases
including autoimmune thyroid diseases (ATDs), atopic disease, urticaria and asthma. The
other group is on elusive knowledge, such as COPD, glaucoma, migraine, anemia and
hyperemesis gravidarum.
The suggested mechanism, despite of inconclusive causal relationship, is as follows: Chronic
H. pylori infection induces chronic inflammation, a complex biological response of the tissues
to H. pylori. Inflammatory factors including cytokines interleukin (IL) and tumor necrosis
factor (TNF), especially induced from chronic, low-grade inflammation, on the infection-
inflammation pathway are common in pathogenesis of gastritis, atherosclerosis, metabolic
syndrome, obesity and diabetes. These inflammatory factors produced in the inflamed gastric
mucosa are continually secreted into the circulation, and they can affect metabolic profiles.[1]
Therefore, chronic, low-grade inflammation by chronic H. pylori infection may induce extra‐
gastric diseases due to the effect of H. pylori–induced cytokines.
H. pylori infection and its transmission were related to low socioeconomic status (SES) such as
poor hygiene, water contamination, and non-healthy lifestyles such as poor diet, smoking and
physical inactivity. Usually people who were tested with H. pylori infection are those in middle
SES class and over, and therefore, non-gastric diseases are also diagnosed in this class. Poor
hygiene hypothesis seems to be no more proper for these populations in the association of H.
pylori infection with non-gastric diseases.
Therefore, this chapter introduces extradigestive diseases by H. pylori infection and discusses
critical issues in the H. pylori role in extradigestive diseases in the viewpoint of causality of H.
pylori infection for these diseases.
2. Dyslipidemia
Dyslipidemia, such as high total cholesterol and/or triglyceride concentration or low high-
density lipoprotein (HDL) level, is a component for metabolic syndrome (MetS). Abnormal
lipid profile in H. pylori–infected subjects has been reported in several studies. A review paper
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview4
for dyslipidemia using 8 related articles[1] showed that H. pylori infection patients had higher
levels of plasma total cholesterol, low-density lipoprotein (LDL)-cholesterol and/or triglycer‐
ide, but lower levels of high-density lipoprotein (HDL)-cholesterol relative to non-infected
patients. These conditions were significantly replicated in 5,077 Japanese men only in a large
population study for H. pylori eradication therapy, but failed to replicate it in women due to
small number of woman patients.[1, 2] However, Satoh et al. showed significant associations
between H. pylori infection and LDL or HDL levels only in male subjects and there was no
significant association between H. pylori seropositivity and triglyceride concentration in the
same study.[2] It is postulated that overexpression of various cytokines, such as IL-6 and TNF-
α by H. pylori infection, may stimulate production of fatty acids by activating lipoprotein lipase
in adipose tissue. Successful eradication treatment of H. pylori may induce an increase of HDL
and decrease of LDL and triglycerides, but the alteration of blood lipid profiles before and
after eradication therapy is not consistent in the total five observational studies and clinical
trials.[1]
3. Hypertension
Hypertension is a component of MetS. Various cytokines induced by H. pylori infection in
gastric mucosa may stimulate the hypothalamus and brain stem, which leads to sympathetic
activation by secretion of cortisol and adrenaline. The subsequent pathway may induce the
high blood pressure.[3] Although Harvey et al. reported the significantly positive association
of H. pylori infection with hypertension in the community-based Bristol helicobacter project
with the 10,537 subjects, the relationship is likely to be the result by residual confounding
factors. Although a paper for African people showed decreased levels of blood pressure levels
after three weeks of H. pylori eradication treatment,[4] it is likely to be not causally related
because the study is not placebo controlled and remains misclassification bias because H.
pylori test is not performed after treatment.
4. Insulin resistance and diabetes
Insulin resistance (IR) is one of important componnents on type 2 diabetes mellitus (DM)
pathogenesis. In a systematic review published in 2011, a significantly high homeostatic model
assessment-insulin resistance (HOMA-IR) score in H. pylori–infected population than non-
infected population was reported in seven cross-sectional analyses.[5] In two non-randomized
trials for H. pylori eradication therapy, a study showed a beneficial effect of H. pylori eradication
therapy with decreased IR score in successfully eradicated patient group, but the other study
failed to prove it. The potential mechanisms are suggested as follows: Lipopolysaccharides
from H. pylori link to the activation of Toll-like receptors (TLRs), expressed mainly in macro‐
phages and dendritic cells, which results in energy harvesting, fat accumulation and conse‐
quently IR.[6] And higher inflammatory cytokines can inhibit insulin action on its receptor
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through phosphorylation of serine residues on the insulin receptor and consequently induce
insulin insensitivity and resistance.[5]
However, despite of statistical association between H. pylori infection and IR, there is contin‐
ually arguing among investigators. The reasons are due to inconsistent result in comparison
of IR status in pre– and post–H. pylori eradication therapy in a systematic review.[5] There
were three non-randomized trials: two reported beneficial effects of H. pylori eradication
therapy in decreasing IR score,[7] but the others [8] reported non-association and non-changes
in the levels of IR in pre- and post-therapy regardless of eradication treatment.[5-7]
Three meta-analysis papers were reported up to date. In a meta-analysis using 41 diabetes and
non-diabetes comparison studies in 2013, H. pylori infection was reported to be higher in
patients with diabetes compared with non-diabetic patients,[9] and in the other meta-analysis
using 13 case-control studies published in the same year, H. pylori infection was also associated
with a 2-fold higher risk for diabetes among 13 case-control studies and at 1.6-fold higher risk
for diabetic nephropathy among 6 case-control studies.[10] Both meta-analyses showed the
action of H. pylori infection was stronger in type 2 diabetes than in type 1 diabetes.[9, 10]
The first prospective cohort study, published in 2012, of 782 diabetes-free subjects with 5-year
follow-up presented that H. pylori–infected subjects had 2.7-fold higher risk for type 2 diabetes
relative to non-infected people.[10, 11] However the other prospective cohort study, published
in 2012, with 10-year follow-up did not show significant association between H. pylori infection
and DM.[10–12] Moreover, meta-analysis of two cohort studies did not show any relationship.
The inconsistency across the studies is due to non-overcoming reverse causation and recall
bias. The positive result in the first cohort study may be due to the finding secondary to the
higher proportion of other risk factors of diabetes in H. pylori–infected group relative to non-
infected group. Considering the results of the two cohort studies, it can be inferred that the
significant effect of H. pylori infection on the development of diabetes may exist in only earlier
life within 5-year follow-up and disappear or weaken due to risk factors of diabetes for long-
term follow-up. Thus, the debate in causality for the association between H. pylori infection
and diabetes has been still around.
5. Obesity
Although changes in ghrelin, a peptide hormone produced in the gastrointestinal tract, in
relation to appetite or weight gain and in leptin, a hormone secreted from adipose tissue, in
relation to inhibition of hunger and storage of triglycerides in adipocytes are suggested to be
associated between obesity and H. pylori infection, there was inconsistent association across
prior observational studies. Although the data regarding association between obesity and H.
pylori infection are uncommon, most of the studies are cross-sectional design, non-overcoming
reverse causation. The prior results are controversial across studies such as positive relation‐
ship (more obese in H. pylori infected people relative to non-infected people) and non-
relationship.[1] Body mass index (BMI) after successful H. pylori eradication is expected to be
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decreased. However two non-randomized[13, 14] and a randomized placebo-controlled trial
studies showed that BMI after successful H. pylori eradication was rather increased.[12]
6. Metabolic syndrome
The metabolic syndrome (MetS) is a group of five components: central obesity (waist circum‐
ference ≥102cm or 40 inches in male and ≥ 35 inches in female); high blood pressure (≥130/85
mmHg, and fasting plasma glucose ≥6.1 mmol/L); triglyceride dyslipidemia (triglyceride levels
≥1.7mmol/L); HDL-cholesterol dyslipidemia (high density lipoprotein-C (HDL-C) <40mg/dl
in male and <50mg/dL in female); and hyperglycemia (fasting plasma glucose ≥6.1 mmol/L).
By the standard of the US National Cholesterol Education Program Adult Treatment Panel III
(NCEP III), MetS requires at least three of the five components. Many studies concerned the
association between H. pylori infection and extradigestive manifestation. Relation of H. pylori
infection with the MetS was evaluated in several studies.
Nabiour et al. first evaluated the association between H. pylori infection and MetS in 2006.[13]
Compared with the group not infected by H. pylori, the group with H. pylori infection showed
1.5-fold significantly elevated risk for the MetS in both men and women. Association between
H. pylori eradication treatment and remission of the MetS was evaluated to investigate the
effect of H. pylori infection on the pathogenesis of the MetS. According to the study among
Black people by Longo-Mbenza et al.,[4] three components such as plasma glucose, systolic
and diastolic blood pressure and HDL-cholesterol levels were significantly improved com‐
pared with baseline values after three weeks of H. pylori eradication treatment. However, the
two studies are cross-sectional small-numbered design; it is not obvious whether the observed
difference is due to the anti-inflammatory or confounded effects by other risk factors than H.
pylori eradication effects.[4] Also prior studies for the association of H. pylori infection for each
MetS component failed to show its clear relationship. Therefore, further cohort studies with
larger sample size need to be performed to confirm the relationship between MetS and its
components and H. pylori infection, especially infection to highly virulent H. pylori such as
CagA-strain.
7. Atherosclerosis and related diseases
Recent data have implicated H. pylori in atherosclerosis. Atherosclerosis, arteriosclerotic
vascular disease, is a condition of artery wall thickness by complex pathogenesis of invasion
and accumulation of white blood cells (WBCs) and proliferation of intimal smooth muscle cells
by fatty fibrinogen plaque. It occurres due to chronic inflammation of WBCs and is promoted
by residues of dead cells, including cholesterol and triglycerides. It can increase cardiovascular
and cerebrovascular morbidity and mortality.
Biologically, H. pylori infection to gastric tissue can induce inflammatory cytokines, such as c-
reactive protein (CRP), IL-series including 1, 6, 18, etc, and TNF-α, which leads to systemic
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inflammation. H. pylori infection can modify asymmetric dimethylarginine (ADMA) and
inhibit absorption of vitamin B12 and folic acid in stomach, which also causes hyperhomocys‐
teinemia.
Moreover, a virulent H. pylori strain, vacuolating cytotoxin A (VacA)-secreting H. pylori,
infection can directly stimulate hyperhomocysteinemia. Cross-reaction between H. pylori
antigens such as cytotoxin-associated gene A (CagA) and heat shock proteins (HSPs) produces
autoimmune response by realizing it as a molecular mimicry of autoimmune antigen. Systemic
inflammation by cytokine reaction, cytokines themselves as pro-atherogenic mediators,
prohyperhomocysteinemia and autoimmune response complexly affect, thereby causing
dysfunctional microvessels and inducing growth of vascular epithelial cells. H. pylori infection
can also increase dyslipidemia, oxidative stress, and platelet aggregation. Subsequently these
processes complexly induce and aggravate atherosclerosis.[14, 15] Additionally, pro-athero‐
genic cytokines activate hypothalamus and brain stem, which subsequently increase sympa‐
thetic hormones such as cortisol and adrenalin and result in hypertension, insulin resistance
and dyslipidemia. These sequential pathological conditions finally lead to the cardiovascular
diseases such as ischemic heart disease and ischemic stroke.[17, 18]
A prior case-control study of atherosclerosis measured by carotid intima-media thickness
showed that H. pylori–infected people had higher carotid intima-media thickness than non-
infected people and H. pylori infection increased the risk for atherosclerosis.[14] A prospective
cohort study for 5-year follow-up showed the CagA-strain–infected group had much higher
changes in intima-media thickness of common carotid arteries (IMT-CCA) and even developed
new atherosclerotic lesions.[16] This study suggests that H pylori infection, in particular the
more virulent H. pylori infection of CagA-strain, can be associated with atherosclerosis risk,
perhaps due to an enhanced immune inflammatory response.
In contrast, the link between H. pylori infection and ischemic heart disease and stroke seems to
be still left as unresolved issue due to divergent results. There are two meta-analyses for ischemic
heart disease and two meta-analyses for coronary heart disease (CHD) events or death up to
date. For ischemic heart disease, the meta-analyses of 10 case-control studies published in 2006
and of 26 case-control studies published in 2015 presented that H. pylori infection was associat‐
ed with 1.87-fold and 2.1-fold higher risk for ischemic heart disease, respectively.[17, 18] Liu et
al.’s summary risk was consistent, regardless of ethnicity and age (range 1.75–2.29).[18] For
CHD, a meta-analysis of 15 case-control studies, published in 2008, presented that CagA had a
2.1-fold higher risk for CHD (Zhang et al.), and the other meta-analysis of 3 cohort studies,
published in 2008, also presented a 1.26-fold higher risk for CHD (Pasceri et al., 2006). Howev‐
er, most recent meta-analysis, published in 2015, of 19 prospective cohort studies reported a
debatable result: the significant effect was weaker (only 11% increase in the risk of CHD) and
existed in only patients’ early lives within follow-up of 5 years and the association was not seen
at 10-year follow-up due to masking effect by CHD risk factors (Sun).
Meta-analyses for ischemic stroke, two published in 2008 and one in 2006, respectively,
summarized results from case-control and cross-sectional studies and reported an increasing
risk for ischemic stroke by H. pylori infection (Wang et al., 2008, a 1.6-fold higher risk by H.
pylori infection including CagA; Pasceri et al., 2006, a 2.4-fold higher risk by CagA strain
infection; Zhang et al., 2008, a 2.7-fold higher risk by CagA strain infection). However, a recent
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meta-analysis of six cohort studies and four nested case-control/case-cohort studies failed to
prove the association (Yu), regardless of CagA virulence, study design, number of pathogens,
and study quality (Yu). Case-control or cross-sectional designs have a higher possibility in
overwhelming risk by their small size and consequently selection bias and insufficient
adjustment for confounders. Therefore, the summary risk in meta-analysis of prior case-control
and cross-sectional studies may be augmented relative to real risk value. Association between
H. pylori infection and the risk of ischemic stroke up to date seems to be inconclusive.
8. Adaptive immune response relating disorders
Autoimmune disease develops when adaptive immune response induced by H. pylori–infected
cells develops and autoantibodies are pronouncing against self-antigens, such as thyroid
antigens,[19] circulating IgE or alpha-chain of the high-affinity IgE receptor.[20] Autoimmune
diseases by H. pylori infection, autoimmune thyroid diseases (ATDs) and chronic urticaria (CU)
have been reported. For ATDs, a meta-analysis of seven observational studies involving a total
of 862 patients, published in 2013, indicated that H. pylori infection, especially CagA, was
associated with 1.92-fold higher risk for total ATDs, and there is no heterogeneity and
publication bias. In subgroup analysis, H. pylori infection was at 4.35-fold higher risk for
Graves’ disease, while Hashimoto’s thyroiditis was not associated with H. pylori infection.[19]
For urticaria, a meta-analysis of nine case-control studies with high quality indicated that H.
pylori infection was at 1.36-fold higher risk for CU (no heterogeneity and publication bias).[20]
However, both meta-analyses fundamentally did not overcome the possibility of confounders
and the problem of reverse causation and bias in meta-analysis using case-control studies,
although the findings suggest H. pylori potentially plays a part in the development of ATDs
and CU.[22, 23]
For atopy/allergic disease, a meta-analysis of 17 case-control studies performed in Western
countries, published in 2014, showed a significant inverse association of H. pylori infection,
perhaps by link of a better hygiene related to decrease of H. pylori infection and the large
spreading of atopic diseases.[21] The mechanism of allergy is different from ATD. H. pylori
infection may evoke immune tolerance, which is an overactive Th2 response by lack of the Th1
response, which facilitates persistent infection and inhibits allergic T-cell responses.[21] This
mechanism is applied to asthma. A meta-analysis, published in 2012, of five case-control
studies failed to show an association between H. pylori infection and asthma,[22] while the
other meta-analysis, published in 2013, of 14 case-control and cross-sectional studies showed
the opposite result, which is a significant reduced risk for asthma by H. pylori infection
(OR=0.84), but had significant heterogeneity across studies.[23]
9. Other extra-digestive diseases
For COPD and CB, a meta-analysis, published in 2015, of 16 studies demonstrated that H.
pylori infection had a 2.07-fold and 1.57-fold increased risk for Chronic obstructive pulmonary
Extra-digestive Manifestations of Helicobacter pylori Infection – An Overview
http://dx.doi.org/10.5772/63226
9
disease (COPD) and chronic bronchitis (CB) risk, respectively. CagA-strain H. pylori infection
had much higher risk for COPD up to 3.46-fold. There are no heterogeneity and publication
bias.[24] Although H. pylori infection on the etiology of CB and COPD remains controversial,
two hypothetical mechanisms are suggested: 1) H. pylori infection may cause direct lung tissue
damage, which leads to COPD and chronic bronchitis; 2) H. pylori infection triggers both
diseases through sequential reaction of inflammatory cytokines.[24]
For migraine, a meta-analysis[25], published in 2014, of five cross-sectional studies showed
that H. pylori infection had significantly 1.92-fold higher risk. However there are heterogene‐
ity  and publication bias  across  studies.  Despite  of  its  inconclusive  result,  the  suggested
mechanism is that H. pylori infection in stomach triggers inflammation, which stimulates the
gastrointestinal neuroendocrine cells to secrete neuroendocrine peptides because migraine
originates from the gastrointestinal organ. This sequential process may result in migraine by
the brain-gut axis.[25]
For iron deficiency anemia (IDA), a meta-analysis,[26] published in 2010, of 15 case-control
studies showed that H. pylori infection had significantly 2.22-fold higher risk. However, H.
pylori eradication therapy in five RCTs was not efficient in improving hemoglobin and ferritin
levels.[26] Both meta-analysis results had a publication bias and heterogeneity across the
studies. The association is not causally related because IDA is specifically related to H. pylori
infection and confounded by other risk factors.
For hyperemesis gravidarum (HG), a meta-analysis,[27] published in 2015, of 32 cross-sectional
and case-control studies demonstrated a significantly 3.34-fold higher risk by H. pylori
infection; however, there is heterogeneity across the studies. Hypothetical pathogenic mech‐
anism is that H. pylori infection induces oxidative stress status by increasing reactive oxygen
species (ROS) and decreasing plasma antioxidants, such as vitamin C and antioxidant
enzymes, such as superoxide dismutase (SOD), catalase (CT) and glutathione peroxidase
(GSH-Px).[27]
10. Summary and Conclusion
Most studies for extra-digestive diseases up to date are cross-sectional or case-control studies,
with small sample size. There are several cohort studies, but the results are diverse. Cross-
sectional or case-control designs are more susceptible to bias than cohort or clinical trial design.
H. pylori infection was diagnosed by different methods up to date, which cause different H.
pylori infection prevalence according to each assay method and affect heterogenous meta-
analysis result across studies. Therefore, evidence as to what impact the H. pylori infection,
especially highly virulent H. pylori infection such as CagA-strain infection, would have on the
development of extra-digestive diseases concerned in lots of prior studies seems to be
inconclusive. Large-scale, multicenter-based prospective cohort or clinical trial studies are still
required to clarify the etiology between H. pylori and extra-digestive diseases because of the
limited number of studies included in meta-analysis, their small sample sizes and inclusion of
study design with low quality on causality reasoning evidence.
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Abstract
Halitosis is a common and ignored condition, but in some, it is a disease-associated
health problem, suggestive of overt disease conditions and hasaffected about 25–30% of
world’s population, bothering nonmedical social disturbance in many people. Although
two kinds, pseudohalitosis and halitophobia, are also concerned, genuine halitosis origi‐
nated from the oral cavity, such as gingivitis, caries, and poor oral hygiene, in 80% and
the remaining 20% are extraoral sources of halitosis, which should not be ignored be‐
cause of stigmata suggestive of overt tissue dysfunctions, for instance, poor nutrition and
hygiene, alcohol abuse, smoking, and systemic illness such as chronic obstructive pulmo‐
nary disease, liver cirrhosis, diabetes mellitus, and chronic renal diseases. In this chapter,
Helicobacter pylori (H. pylori)–associated halitosis as one of the extragastric manifestations
is introduced. Since diagnostics of halitosis includes subjective methods (examiner’s
sense of smell) and objective methods (instrumental analysis), under the hypothesis of a
possible relationship between H. pylori infection and objective halitosis, the real levels of
volatile sulfur compounds (VSCs) in the breath showed significant correlation between
VSC levels and the degree of H. pylori–associated erosive gastritis as well as gastric can‐
cer. These findings are further validated through either measuring H2S level in gastric jui‐
ces of H. pylori–infected gastritis or checking the expressions of cystathionine-γ-lyase
(CSE) and cystathionine-β-synthase (CBS) responsible for H2S generation in biopsied
stomach. The eradication of H. pylori significantly ameliorated halitosis, accompanied
with significant reductions in gastric H2S levels (p<0.01). Korean red ginseng was very ef‐
fective in either reducing H. pylori–associated H2S or alleviating halitosis in patients with
H. pylori–associated chronic atrophic gastritis. Conclusively, H. pylori infection demon‐
strates to have an important relationship with the development of halitosis, and its eradi‐
cation could possibly promote the improvement of this condition.
Keywords: Halitosis, Helicobacter pylori, volatile sulfur compounds, hydrogen sulfide,
gastritis, gastroesophageal reflux disease
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1. Introduction
1.1. Halitosis, pseudohalitosis, and halitophobia
Halitosis is a very common and unpleasant condition, affecting around 1/4–1/3 of the general
population, which can be classified into the following three conditions, genuine halitosis,
pseudohalitosis,  and halitophobia based on their pathogenesis [1,  2];  genuine halitosis is
usually related to an organic pathology, such as periodontitis, gingivitis, gastritis, and other
systemic illness, and malodor molecules such as volatile sulfur compounds (VSCs) that arise
usually from bacterial  interactions generate the basis of oral  malodor,  such as hydrogen
sulfide (H2S), methyl mercaptan (CH3SH), and dimethyl sulfide [(CH3)2S]. In addition, sulfur
compounds,  short-chain fatty acids,  such as butyric  acid (CH3CH2CH2COOH),  propionic
acid  (CH3CH2COOH),  and  valeric  acid  (C5H10O2),  diamines,  including  cadaverine
[NH2(CH2)5HN2]  and  putrescine  [NH2(CH2)4HN2],  1-proxy-2-propanol,  phenyl  com‐
pounds,  such  as  indole,  skatole,  phyridiene,  alkalines,  ketones,  and  nitrogen-containing
compounds, such as urea [(NH2)2CO2] and ammonia (NH3), may contribute to malodor of
halitosis  [3,  4].  When the  concentration of  these  molecules  in  halitotic  breath  exceeds  a
threshold  detected  by  objective  methods,  genuine  halitosis  can  be  diagnosed.  Further‐
more, pathologies of the tongue, poor oral hygiene, deep caries, and postnasal drainage are
primarily associated with halitosis,  in which condition, species such as Peptostreptococcus
anaerobius,  Bacteriodes  spp.,  Centipedia  peritontii,  Eubacterium  spp.,  Topbium  parvulum,
Camplyobacter  rectus,  Eikenella  corrodens,  Eubacterium  sulci,  Fusobacterium  nucleatum  or
periodonticum,  Porphyromonas  endodontalis  or  gingivalis,  Solobacterium  moorei,  Bacteriodes
forsythus,  Treponema denticola,  and Streptococcus salivariou  are well-known bacterial strains
responsible for halitosis [5, 6]. Next, pseudohalitosis can be described as a situation where
obvious  malodor  is  not  perceived by others,  but  only  perceived by the  patient,  that  is,
patients  who consider  to  have  bad breath,  but  who does  never  been acknowledged by
others, the patients with pseudo-halitosis often coinciding with depression and anxiety [7].
Finally,  halitophobia  is  a  situation  when  a  patient  complains  about  halitosis  after  the
treatment of  either genuine halitosis  or pseudo-halitosis,  even though no objective clues
were  documented.  Therefore,  patients  with  halitophobia  are  usually  accompanied  with
vague psychiatric disturbance [2]. Although 0.5–1% of the adult population is affected with
halitophobia during their social life,  most patients with halitophobia frequently hop and
hop from clinic/specialist  to  clinic/specialist  in  order  to  find an argument  for  their  self-
esteemed problem [8].
Halitosis relevant with practical clinical problems can be classified into the following two
clinical situations according to origin, one is oral halitosis, around 90% in all, and the other
is extraoral halitosis, remaining 10% among whole halitosis [9]. Since VSCs are responsi‐
ble for halitosis irrespective of origin, in case of extraoral halitosis, VSCs generally generated
from the body, travel to the lung through the vascular system, and pull out through breath
from the alveoli. As another systemic diseases causing extraoral halitosis, liver disease, such
as  cirrhosis,  hepatoma,  and  hepatic  failure,  uremia  from  end-stage  renal  disease,  and
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metabolic disorder,  such as diabetic ketoacidosis and other kinds of  metabolic disorders
had been reported. Also, excess food intake (food factors) like garlic or onion can be common
etiology for halitosis [10, 11]. Among these system diseases, it must be kept in mind that
halitosis can be a clue symptom suggestive of serious cancers, especially gastric, liver, and
pancreatic cancer. Furthermore, halitosis can be one of the prominent extragastric manifes‐
tations suggestive of Helicobacter pylori (H. pylori)–associated ulcer or cancer because of the
evidence showing correlation between VSCs levels and these gastric lesions [12, 13], about
which  detailed  description  will  be  followed.  As  nonoral  cause  of  halitosis,  sinusitis,
tonsillitis,  bronchiectasis,  subphrenic  abscess,  esophageal  diverticulum,  pyloric  stenosis,
gastroesophageal reflux disease (GERD), and hepatitis are very common diseases relevant
to halitosis encountered in clinic.
2. Halitosis provoked by gastrointestinal (GI) diseases
Apart  from  oral  cavity,  the  GI  tract  diseases  caused  halitosis  as  presenting  symptoms,
though physician and patients still abusively believe that halitosis originates from the oral
cavity or stomach. For instance, almost all patients suffering from some erosive changes in
esophago-gastric organ, halitosis might be very common and earliest manifestation. In our
earlier investigation [15], almost all patients with GERD or some degree of erosive gastritis,
real levels of VSCs were significantly increased. Other examples of clinical diseases, such
as pyloric stenosis, duodenal obstruction, aorto-enteric anastomosis, pharyngeal pouches,
Zenker’s diverticulum, and hiatal hernia, usually led to halitosis as usual clinical manifes‐
tations. Especially, GERD, achalasia, or other malabsorption syndromes may cause halitosis
accompanied  with  other  symptoms  of  retching  and  flatulence.  In  cases  of  intestinal
obstruction,  halitosis  may be detectable  because the first  sign noticed to either  patient’s
relatives or physician. Halitosis is usually noted after consuming dietary products, such as
garlic, onions, and some spiced foods cause transient unpleasant odor or halitosis [14]. Yoo
et  al.  [15]  found  that  erosive  changes  in  the  esophago–gastro–duodenal  mucosa  were
significantly correlated with increased levels of VSCs, suggesting that halitosis could be a
symptom suggestive of the erosive diseases of the upper gut mucosa. In detail, as shown
in Figure 1, erosive changes in the esophageal mucosa, erosive type GERD, were strongly
associated with  VSC levels,  ascertaining the  hypothesis  that  halitosis  can be  a  potential
biomarker for the discrimination between erosive GERD and nonerosive GERD, assuring
the presence of erosive change in the lower EG junction [16]. In summary, GI pathology
was  very  common in  patients  with  halitosis  as  extraoral  origin  [17],  approximately  50–
60% among all gastroenterology patients. Conclusively, halitosis symptom, usually ignored
as  insignificant,  should  be  investigated  to  search  for  etiology  even  in  nondental  area.
Accompanied with halitosis, there has been a report [18] describing that H. pylori coloniza‐
tion  of  tongue  mucosa  increased  incidence  of  atrophic  glossitis  and  burning  mouth
syndrome, especially accompanied with halitosis.








Figure 1. Correlation between EG lesion and halitosis. (A) Halitosis measurement with Halimeter in 72 patients with
halitosis. Significant differences in Halimeter ppb were noted between patients with superficial gastritis and patients
with erosive/ulcerative lesion (p<0.0001) (B) halitosis measurement with gas chromatography (GC) in same 72 patients
with halitosis. Significant differences in VSCs ppm were noted between patients with superficial gastritis and patients
with erosive/ulcerative lesion (p<0.000006). (C) The expressions of CSE and CBA according to EG mucosal changes.
The mean expressions of CBS or CSE were significantly increasingly noted in patients with erosive changes. All of
these results consistently suggested “halitosis” as possible biomarker predicting the presence of mucosal destruction
and resulting putrefactive process in stomach.
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3. Hydrogen sulfide (H2S) biogas: Good, bad, ugly in its biology, and
halitosis
Although biologic gas such as H2S as principal gas molecule is responsible for causing halitosis,
there are contradictory biological implications of three major biogas, nitric oxide (NO), H2S,
and carbon monoxide (CO), in anti-inflammatory substances, promoting resolution of
inflammatory processes, imposing several situations, including ischemic-reperfusion injury,
cardioprotection, sepsis, hemostasis, fibrosis, pancreatitis, separately, but sometimes interact‐
ing each other [19, 20]. Interestingly, H2S stands for dual functions, inflammatory mediator or
anti-inflammatory mediator [21], gaseous intracellular transducer implicated in either
abnormal pathology or normal physiology [22], positioning homeostasis as friend or foe [23].
H2S and their responsible enzymes, cystathionine-β-synthase (CBS) and cystathionine-γ-lyase
(CSE), played good or bad, but ugly biological implications dependent on cellular context and
disease conditions.
Though many new technologies to detect endogenous H2S production and to develop novel
H2S-delivery compounds have been invented [24], simple gas with complex biology of good,
bad, and ugly aspect, in this chapter, the way to detect VSCs, the implication of H2S among
VSCs, and their regulations will be introduced. The Halimeter (Interscan corporation, Chats‐
worth, CA, Figure 1A) and OralChroma (Abimedical corporation, Kanagawa, Japan) are
electronic devices available to detect some of the VSCs in expired air easily in clinic. These two
devices are a portable gas chromatograph featuring easy to handle, lower cost, higher
performance, time saving, fast results, very accurate, and reproducible even compared with
conventional gas chromatographs. However, the limitation is that they limitedly target three
gases: H2S, CH3SH, and (CH3)2S. With the Halimeter measurement, the total amount of VSCs
in parts per billion (ppb) in breathing air is shown. In normal situations, this value is less than
100 ppb. When 300–400 ppb are detected in the mouth air, objective halitosis can be confirmed,
of course, the changes of ppb level can be traced after some interventions to mitigate halitosis
[25]. Though they are rather inexpensive and can be controlled by untrained staff, the limited
diversity in the explored gasses and inconvenienceby examiner’s cooperation should be
further improved. On the other hand, the OralChroma may produce a more comprehensive
assessment of VSCs production by oral microflora compared to Halimeter [26]. Of course, gas
chromatography (GC) analysis can be performed on diverse sources, such as saliva, tongue
debris, aspirated gastric juices, and even biopsied tissues, in addition to breath and almost all
different air components can be detected, golden standard for halitosis, but not easy to measure
and expensive [27]. In expired air, almost 500 different substances can be measured with GC
(Figure 1B). Although GC has been used since the late 1960s, GC is still in an experimental
stage, infrequent use for clinic [28]. Though GC has several advantages, such as an analysis of
almost all components, high sensitivity, specificity, and noninvasive, it is very expensive, hard
to handle because a well-trained staff is mandatory and not portably used [29]. Besides of these
measurements, the scientific and practical value of additional or alternative measurement
methods, such as benzoyl-DL-arginine-naphthylamide (BANA) test, chemical sensors,
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salivary incubation test, quantifying galactosidase activity, ammonia monitoring, Ninhydrin
method, and PCR, has been applied in clinic.
3.1. H2S as dual-edged sword, is it neurotransmitter or inflammatory mediator?
H2S is a well-known toxic gas that is synthesized from the amino acids, cysteine and homo‐
cysteine, by two enzymes, CBS and CSE [30, Figure 1C]. Like other biogas, CO or NO, H2S is
a signaling molecule implicated in either physiological actions of the cardiovascular or
digestive system or pathophysiological actions in homeostasis, proliferation, and apoptosis of
vascular smooth muscle cells, insulin release, nociceptive effects, cytoprotection, but contra‐
dictory action of inflammatory mediators, for instance, pancreatitis, chronic obstructive
pulmonary disease, joint inflammation, sepsis, and H. pylori–associated gastritis in gastroen‐
terology [23, 31–33]. In detail, in pancreatitis, especially in a form of severe acute pancreatitis
(SAP), the fact that treatment with DL-propargylglycine (PAG) induced pancreatic acinar cell
apoptosis and decreased the pathological scores as well as inflammatory parameters, whereas
administration of NaHS significantly aggravated SAP suggested the implication of H2S in
pancreatitis [34]. For instance, Bhatia M et al. [35] published that proinflammatory role of H2S
regulated the severity of pancreatitis and even associated lung injury. On the other hand, in
endotoxemia or sepsis model, H2S contributed to recovery or rescuing actions [36–38].
4. Halitosis as one of extragastric manifestations of H. pylori infection
(Figure 3)
H. pylori was shown to produce H2S and CH3SH, major oral malodor, inducing VSCs, sug‐
gesting that H. pylori can contribute to the development of halitosis relevant with tissue
destruction in the GI tract [12]. The findings that as H. pylori–associated chronic gastritis
worsened, it caused significant increase in levels of VSCs, but significant improvement of
halitosis after eradication signified that halitosis can be overtly correlated with extra-gastric
symptoms of H. pylori infection. Taken together with the additional fact that H. pylori infection
was responsible for diverse oral pathologies [39], there are two liaisons between H. pylori
infection and halitosis, one is that H. pylori can provoke halitosis through oral cavity infection
[40] and the other is that gastric pathologies caused by chronic H. pylori infection are respon‐
sible for halitosis as extragastric manifestation [41]. According to literature search, there were
48 articles reporting the association between saliva/plaque and H. pylori infection. As example
showing association between H. pylori infection and various oral diseases, Tiomny et al. [42]
reported that in Israel, when studied six patients with halitosis and five of whom were H.
pylori positive, the symptoms of halitosis disappeared after successful eradication. Similar
results were reported by Ierardi et al. [43] documented with real measurement of VSC in H.
pylori infection. Serin et al. [44] administered triple eradication therapy to subjects with H.
pylori–positive halitosis and found about two third of patients were free from halitosis, all of
these studies consistently signified that halitosis is a frequent and treatable symptom in H.
pylori–positive chronic gastritis and can be a valid indication for H. pylori eradication. Our
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group extended these investigations, in which any erosive or ulcerative lesions relevant with
H. pylori infection provoked higher rate of halitosis and healing from erosive changes war‐
ranted improvement of halitosis in all subjects, in this study objective measurements as well
as subjective changes of halitosis were done with real value of H2S measured by either gas
chromatography or Halimeter. Recently, it was reported that H. pylori infection increased the
risk of BHH (burning, halitosis, and lingual dorsum hyperplasia). H. pylori detection in the
oral cavity by histopathologic diagnosis and molecular biology was confirmed in 87% patients




Figure 2. Halitosis as possible extragastric manifestation of H. pylori infection and relief with KRG. (A) H. pylori infec‐
tion led to several pathogenic changes in gastric mucosa, oxidative stress, inflammatory mediators, apoptosis, and in‐
creasing expression of CBS and CSE, after which increased H2S seems to be responsible for inflammatory, ulcerative,
and halitosis changes. (B) KRG was identified as natural product controlling CBS or CSE expressions followed with
additional action mechanisms of augmenting eradication, lessening gastric inflammation, and ameliorating halitosis.
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There were two translational studies confirming the association between H. pylori infection
and halitosis through real measurements of VSCs in clinical setting: one was the study by
Suzuki et al. [46] that used saliva from the 25 halitosis patients associated with H. pylori
infection; the clinical symptoms associated with halitosis and periodontal symptoms were
significantly greater in the H. pylori–positive subjects and the other from our author’s group
[15] shows that halitosis could be an effective biomarker in predicting H. pylori–associated
erosive and inflammatory changes, of which were significantly correlated with halitosis
improvement after eradication. Reports regarding the long-term outcome that eradication of
H. pylori in patients with functional dyspepsia warranted sustained improvement of halitosis
were available [47] and they strongly supported the existence of a close link between H.
pylori infection and halitosis. Conclusively H. pylori eradication should be considered in
patients with troublesome halitosis, bothering patients with limited social activities due to
halitosis (Figure 2A).
5. Amelioration of troublesome halitosis through suppressing H. pylori–
associated H2S with natural products
Lee et al [41] investigated 88 patients with functional dyspepsia presenting with halitosis, all
of them showed very high levels of Halimeter >100 ppb, on whom tests were repeated after 10
weeks of Korean red ginseng (KRG) administration. As results, most patients with successful
eradication of H. pylori benefited with subjective and objective improvement of halitosis. Before
the current clinical trials, positive outcomes were anticipated in in vitro investigation that KRG
extracts significantly decreased H. pylori- or NaHS-induced CSE expressions concomitant with
attenuated levels of H2S, IL-6, IL-8, as well as IL-1β mRNA. The findings that more than half
of the cases (52.3–65.0%) became free of halitosis with KRG treatment alone, but it was the
combination of a successful eradication regimen with KRG supplementation accompanied
with in vitro proof showing KRG was very effective in suppressing the CSE/CBS gene led to
the following conclusion: H. pylori infection might be closely responsible for halitosis and KRG
supplementation was proven to be very effective in relieving halitosis in addition to being
responsible for bacterial suppression (Figure 2B). In addition, generally good short-term
results were reported with chlorhexidine. Triclosan seems less effective, essential oils and
cetylpyridinium chloride are only effective up to 2 or 3 hours. Metal ions and oxidizing agents,
such as hydrogen peroxide, chlorine dioxide, and iminium, are active in neutralizing volatile
sulfur-containing compounds [48,49], but these are only for lessening halitosis not removing
etiopathogenic background.
In conclusion, though the solution of halitosis problems must include the reduction of the
intraoral bacterial load and/or the conversion of VSCs to nonvolatile substrates [50], targeting
both etiologic organism removal and VSCs generating enzyme suppression seems to be very
ideal modality of halitosis treatment (Figure 3), in which KRG seems to ideal product to deserve
in clinic.
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview24
There were two translational studies confirming the association between H. pylori infection
and halitosis through real measurements of VSCs in clinical setting: one was the study by
Suzuki et al. [46] that used saliva from the 25 halitosis patients associated with H. pylori
infection; the clinical symptoms associated with halitosis and periodontal symptoms were
significantly greater in the H. pylori–positive subjects and the other from our author’s group
[15] shows that halitosis could be an effective biomarker in predicting H. pylori–associated
erosive and inflammatory changes, of which were significantly correlated with halitosis
improvement after eradication. Reports regarding the long-term outcome that eradication of
H. pylori in patients with functional dyspepsia warranted sustained improvement of halitosis
were available [47] and they strongly supported the existence of a close link between H.
pylori infection and halitosis. Conclusively H. pylori eradication should be considered in
patients with troublesome halitosis, bothering patients with limited social activities due to
halitosis (Figure 2A).
5. Amelioration of troublesome halitosis through suppressing H. pylori–
associated H2S with natural products
Lee et al [41] investigated 88 patients with functional dyspepsia presenting with halitosis, all
of them showed very high levels of Halimeter >100 ppb, on whom tests were repeated after 10
weeks of Korean red ginseng (KRG) administration. As results, most patients with successful
eradication of H. pylori benefited with subjective and objective improvement of halitosis. Before
the current clinical trials, positive outcomes were anticipated in in vitro investigation that KRG
extracts significantly decreased H. pylori- or NaHS-induced CSE expressions concomitant with
attenuated levels of H2S, IL-6, IL-8, as well as IL-1β mRNA. The findings that more than half
of the cases (52.3–65.0%) became free of halitosis with KRG treatment alone, but it was the
combination of a successful eradication regimen with KRG supplementation accompanied
with in vitro proof showing KRG was very effective in suppressing the CSE/CBS gene led to
the following conclusion: H. pylori infection might be closely responsible for halitosis and KRG
supplementation was proven to be very effective in relieving halitosis in addition to being
responsible for bacterial suppression (Figure 2B). In addition, generally good short-term
results were reported with chlorhexidine. Triclosan seems less effective, essential oils and
cetylpyridinium chloride are only effective up to 2 or 3 hours. Metal ions and oxidizing agents,
such as hydrogen peroxide, chlorine dioxide, and iminium, are active in neutralizing volatile
sulfur-containing compounds [48,49], but these are only for lessening halitosis not removing
etiopathogenic background.
In conclusion, though the solution of halitosis problems must include the reduction of the
intraoral bacterial load and/or the conversion of VSCs to nonvolatile substrates [50], targeting
both etiologic organism removal and VSCs generating enzyme suppression seems to be very
ideal modality of halitosis treatment (Figure 3), in which KRG seems to ideal product to deserve
in clinic.
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview24






































Figure 3. H. pylorii infection caused halitosis as well as overt clinical diseases relevant to H2S generation Dietary sour‐
ces of L-cysteine and H. pylori infection provoked CBS/CSE activations, leading to increased H2S generation. Currently
dual edged biological actions of H2S were reported; one was vasodilatation and antioxidative actions, and the other the
aggravation of inflammations and hypoxic condition. In the stomach under H. pylori infection, H2S-driven gastric sur‐
face destruction as well as gastritis finally rendered gastric diseases such as erosive gastritis or ulcerative lesions. Also
halitosis was significantly manifested as extragastric symptoms associated with H. pylori infection due to significant
associations and amelioration of halitosis after eradication.
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Abstract
Helicobacter pylori infection is the most common infection of the human species, with de‐
veloping countries displaying a marked disadvantage in contrast to developing coun‐
tries. While H. pylori infection is asymptomatic in most infected individuals, it is
intimately related to malignant diseases of the stomach, such as gastric cancer and gastric
MALT lymphoma, as well as benign diseases, for example chronic gastritis and duodenal
and gastric peptic ulcers. Since the discovery that gastric mucosa could be colonized by
bacteria, evidence of greater than 50 extragastric manifestations has been reported, link‐
ing H. pylori infection and the development of diseases associated with cardiology, der‐
matology, endocrinology, obstetrics and gynecology, hematology, pneumology,
neurology, odontology, ophthalmology, otorhinolaryngology, and pediatrics. This chap‐
ter presents the extragastric manifestations of H. pylori infection expressed through hema‐
tologic diseases; particularly those included in the international consensus, and discusses
guidelines for the management of H. pylori infection, such as iron deficiency, vitamin B12
(cobalamin) deficiency, and immune thrombocytopenia. Other manifestations reviewed
include immune neutropenia, antiphospholipid syndrome, and plasma cell dyscrasias,
such us monoclonal gammopathy of undetermined significance, multiple myeloma, and
Henoch–Schönlein purpura.
Keywords: Helicobacter pylori, iron deficiency, immune thrombocytopenia, mucosa-associ‐
ated lymphoid tissue lymphoma, vitamin B12 deficiency
1. Introduction
Helicobacter pylori infects greater than 50% of the world population’s stomachs, therefore
constituting the most common infection of the human species [1]. A marked disadvantage
exists between developed countries, where the prevalence ranges between 30% and 50%, and
developing countries, where the prevalence ranges between 80% and 90% [2]. Since the
discovery in 1983 that the stomach could be colonized by bacteria [3], sufficient evidence has
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
accumulated implicating H. pylori as a pathogen intimately related to benign stomach diseases,
such us chronic gastritis and duodenal and gastric peptic ulcers [3], and malignant diseases,
for example gastric cancer [4] and gastric MALT lymphoma [5]. Furthermore, during the last
three decades following the discovery [3], approximately 50 extragastric diseases have been
reported in medical specialties such as cardiology, dermatology, endocrinology, obstetrics and
gynecology, pneumology, neurology, odontology, ophthalmology, otorhinolaryngology,
pediatrics, and hematology [6-20], the last of which is the subject of this review.
From a practical standpoint, hematological associations with H. pylori infection can be
arbitrarily divided into two groups: (1) hematological diseases with sufficient scientific
evidence to be recognized by the consensus and guidelines for the management of H. pylori
among the indications of study and eradication and (2) hematological diseases where there is
suspicion, with greater or lesser scientific evidence, of an association with H. pylori infection.












Other manifestations: acute leukemia, myelodysplastic syndrome, thrombocytosis
Table 1. Hematologic manifestations of H. pylori infection
2. Hematological diseases recognized as related to H. pylori
Until September 2015, the scientific community has recognized three hematologic diseases as
extragastric manifestations of H. pylori infection: iron deficiency [21-30], vitamin B12 deficiency
[27, 29], and immune thrombocytopenia (ITP) [21, 23-31]. These will be carefully analyzed in
the following subsections. Gastric MALT lymphoma, although considered a disease in the
oncohematologic field and is associated with H. pylori infection, is not presented in this review
because it is recognized as gastric manifestation.
2.1. Iron deficiency
Iron deficiency, with or without anemia (anemia sine anemia), is a serious public health problem,
which affects approximately 25% of the world’s population (greater than two billion people),
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according to the World Health Organization (WHO). Importantly, it mainly affects disadvan‐
taged populations, such as children and women of gestational age [32, 33]. Iron deficiency,
with or without anemia, is associated with increased morbidity due to high susceptibility to
infections, decreased labor productivity, delayed weight–height and cognitive development,
and other conditions [34].
It is important to note that iron deficiency is a chronic process: an iron imbalance can take
several years to become established and manifest clinically or through hemogram (blood cell
count) parameters, such as morphological alterations of erythrocytes or anemia, according to
the WHO criteria [32]. Three stages of iron deficiency are clearly established: prelatent (Stage
1), when serum ferritin is between 12 µg/L and 30 µg/L; latent (Stage 2), when serum ferritin
is below 12 µg/L; and iron deficiency anemia (Stage 3), when anemia is observed in addition
to diminished or depleted iron storage levels determined by serum ferritin [35].
2.1.1. H. pylori and iron deficiency
In 1991, in Belgium, Blecker et al. described the first association between iron deficiency and
H. pylori infection. The patient was a 15-year-old young with iron deficiency anemia (hemo‐
globin 8.5 g/dL) secondary to chronic active hemorrhagic gastritis, positive to H. pylori, without
prior gastrointestinal manifestations, in whom after H. pylori eradication the hematologic
parameters and ferrokinetics test returned to normal without requiring supplemental iron
treatment [36]. Two years later, in France, Bruel et al. reported a second case of iron deficiency
anemia (hemoglobin 5.6 g/dL), in an 11-year-old child, which manifested as an upper gastro‐
intestinal hemorrhage with documented infection with H. pylori. The anemia was resolved
after eradication of the infection, again without supplemental iron treatment [37]. In the same
year, in Italy, Dufour et al. presented the case of a 7-year-old boy diagnosed with refractory
iron deficiency anemia (hemoglobin 5.1 g/dL), who had been treated with oral iron, the
presence of H. pylori was reported and was asymptomatic from the viewpoint of gastrointes‐
tinal manifestations. As in the preceding cases, the infection was eradicated without supple‐
mentary iron treatment and the hematologic parameters, including hemoglobin (13.0 g/dL),
returned to normal after 6 months [38].
After these first reports, where iron deficiency disappeared after the eradication of H. pylori
[36-38], new isolated cases were published in last century [39-43], which as the first series
demonstrate the association of H. pylori with iron deficiency and iron deficiency anemia [40,
44, 45]. The first decade of the twenty-first century provided most of the studies that currently
support the five meta-analyses associating H. pylori infection with iron deficiency and the
resolution of disease following infection eradication [46-50] in children [51-60], in pubescent
males and females [61, 62], in prepubertal girls [63], in adult men and women [40, 45, 64-75],
in seniors [76], in pregnant women [63], and in non-pregnant women [77]. In addition, these
studies have provided scientific support to the different consensus and guidelines for incor‐
porating iron deficiency into the medical management of H. pylori infection as an extragastric
manifestation and indication for eradication [21-30].
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2.1.2. Pathophysiology of iron deficiency by H. pylori
The pathophysiological mechanisms through which H. pylori is associated with the etiology
of iron deficiency, with or without anemia, has not been fully elucidated, and more questions
remain than answers. Possible explanations proposed to clarify the association between H.
pylori and iron deficiency will be enunciated. However, it is not yet known why this association
exists in some patients but not in others, where a different association is presented or the
infection is asymptomatic, as happens in most cases [78].
In the past decade, H. pylori infection and iron deficiency have been linked through a recently
discovered hormone called hepcidin [79]. Hepcidin is a hormone of hepatic origin that
regulates iron absorption at the enterocyte level in the small intestine and the liberation of
stored iron from the macrophages of reticuloendothelial system [80]. Hepcidin is elevated, as
an acute phase reactant, in response to inflammation in the gastric mucosa. This in turn
translates into a physiological iron deficiency, known clinically as anemia of chronic inflam‐
mation [81-85]. Preliminary studies show that serum hepcidina levels are elevated in patients
infected with H. pylori [85-87] and return to normal after eradication of the infection [88],
thereby permitting iron absorption in enterocytes and liberation from entrapment in the
macrophage reticuloendothelial system.
Other possible causes of iron imbalance in patients infected with H. pylori can result from
chronic gastritis, which occurs in all infected individuals [78]. This condition can generate
bleeding when transforms into erosive gastritis [89], especially in patients with bleeding
duodenal or gastric peptic ulcers [90, 91] and in patients who chronically consume non-
steroidal anti-inflammatory drugs (NSAIDs), including aspirin, for the purpose of cardiopro‐
tection [92-95]. Other mechanisms invoked to explain iron deficiency in patients infected with
H. pylori are related to changes in gastric physiology, particularly changes in gastric pH and
the presence of achlorhydria, which significantly reduces the solubility and intestinal absorp‐
tion of inorganic iron [40].
Beyond the aforementioned evidence, certain highly virulent strains of H. pylori, such as those
with cytotoxin-associated gene A (CagA) and vacuolating cytotoxin gene A (VacA), which act
through molecular mimicry mechanisms, are more likely to develop or magnify iron deficiency
in infected patients, compared with infected patients with strains not carrying these genes [71,
96-98]. This situation could explain, in part, the marked differences from one region to another
and the large discrepancies observed in different studies.
2.1.3. Management of iron deficiency in the post-Helicobacter era
Regarding to the management of iron deficiency in the post-Helicobacter era, it is important to
clarify that H. pylori is not the only cause of iron deficiency, and its incorporation into the
consensus and management guidelines of H. pylori as an indication to investigate and eradicate
the infection is not a substitute for an adequate study of the most common causes of iron
deficiency. These situations are particular to each region, according to prevalence of iron
deficiency and H. pylori infection, which vary from place to place. Thanks to over 250 referenced
studies in the literature aiming to clarify different aspects of the association between H.
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pylori and the development of iron deficiency, five meta-analyses are now available that
demonstrate the impact of infection on the development of iron deficiency and that infection
eradication improves hematological parameters and ferrokinetics [46-50]. These analyses have
enabled the scientific community, particularly the consensus and management guides, to
incorporate iron deficiency of unexplained origin as an indication to evaluate and eradicate
H. pylori infection, when present, in adults as well as children [21-30].
Before initiating treatment for a patient with iron deficiency, an assessment of the prevalence
of H. pylori infection should be performed according to region. Generally, the prevalence is
low in developed countries; these cases should proceed with conventional management of iron
deficiency [32, 35]. In developing countries, the rate of H. pylori infection is high; in these cases
or when the patient, despite living in a country where infection rates are low, comes from a
country where the infection rates are high, it should proceed to determine the status of H.
pylori through a non-invasive test, ideally the 13C-urea breath test [27]. If the patient is negative
for H. pylori, it is necessary to investigate other causes of the iron deficiency and treat the patient
conventionally [32, 35], whereas if the patient is positive for H. pylori, it is indispensable to
eradicate the infection [27].
After 6–8 weeks of treatment, the infection eradication must be confirmed using a non-invasive
test, ideally with 13C-urea breath test [27]. If eradication is not achieved, it is mandatory to
establish a new therapy scheme until eradication is achieved. Once H. pylori eradication is
achieved and an improvement in hematological parameters and ferrokinetics (complete or
partial remission) is obtained, it is important to periodically evaluate the clinical hematological
parameters and the indicators of iron levels. If there is no response, it must establish a
conventional management of iron deficiency [32, 35].
Figure 1 shows a diagnostic and management algorithm of iron deficiency in the post-
Helicobacter era, taking into account the prevalence of infection and H. pylori status.
2.2. Vitamin B12 deficiency
Vitamin B12, also known as cobalamin, is a coenzyme necessary for the metabolism of amino
acids,  such  as  methionine,  threonine,  and  valine,  and  for  DNA  synthesis  through  the
conversion of methyl-tetrahydrofolate to tetrahydrofolate [99]. Vitamin B12 is synthesized in
mammals,  but  for  humans,  their  provision depends exclusively of  diet  intake of  animal
products [99].
Again, as with iron deficiency, it should be noted that vitamin B12 deficiency is a chronic
process, with very slow establishment. It may manifest clinically through neuropsychiatric
symptoms or through hemogram parameters, such as morphological alterations of erythro‐
cytes or anemia, according to the WHO criteria [32]. Four stages of vitamin B12 deficiency are
clearly established: Stage I, reduction of vitamin B12 levels in blood; Stage II, low amount of
vitamin B12 cellular levels and metabolic disorders; Stage III, increase in homocysteine and
methylmalonic acid levels and decrease in DNA synthesis with onset of neuropsychiatric
symptoms; and Stage IV, macrocytic anemia [100].
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Figure 1. Algorithm for the study and management of iron deficiency, with or without anemia, in the post-Helicobacter
era. (1) Before initiating treatment for a patient with iron deficiency, an assessment of the prevalence of H. pylori infec‐
tion should be performed in each region. Generally, it is high in developing countries and low in developed countries
[1]. (2) If the rates of H. pylori infection are low, proceed with a conventional management of iron deficiency [32, 35]. (3)
If the rates of H. pylori infection are high or the patient, despite living in a country where infection rates are low, comes
from a country where the infection rates are high, proceed to determine the status of H. pylori through a non-invasive
test, ideally the 13C-urea breath test (13C-BUT) [27]. (4) If the patient is negative for H. pylori, investigate other causes of
the iron deficiency and treat conventionally [32, 35]. (5) If the patient is positive for H. pylori, proceed with eradication
of the infection [27]. (6) Confirm infection eradication 6–8 weeks after the treatment using a non-invasive test, ideally
with the 13C-urea breath test [27]. (7) If eradication is not achieved, establish a new scheme of eradication therapy until
it is achieved. (8) Once H. pylori eradication is achieved, (9) if a response is obtained in the hematological parameters
and ferrokinetics (complete or partial remission), periodically evaluate the clinical hematological parameters and indi‐
cators of iron. (10) If there is no response, proceed with a conventional management of iron deficiency [32, 35].
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Vitamin B12 deficiency is defined in terms of the serum values of vitamin B12 and two compo‐
nents of its metabolic pathway, homocysteine and methylmalonic acid [101]. The diagnosis of
vitamin B12 deficiency is established in accordance with the following criteria: (1) serum
vitamin B12 < 150 pmol/L (< 200 pg/mL) with clinical manifestations and/or hematological
alterations related to vitamin B12 deficiency; (2) serum vitamin B12 < 150 pmol/L, measured on
two separate occasions; (3) serum vitamin B12 < 150 pmol/L and serum homocysteine > 13
mmol/L or urinary methylmalonic acid > 0.4 mmol/L (in the absence of renal failure, folic acid
deficiency, and vitamin B6 deficiency); and (4) levels of serum holotranscobalamin < 35 pmol/
L [102].
The prevalence of vitamin B12 deficiency is highly variable and represents a serious public
health problem, depending on the populations analyzed. Epidemiologic studies show that, in
the general population of industrialized countries, vitamin B12 deficiency has a prevalence of
approximately 20%, with a range between 5% and 60%, depending on the definition of vitamin
B12 deficiency that is utilized [101, 102]. The prevalence of vitamin B12 deficiency expressed as
pernicious anemia is higher in Latin American countries than in the rest of the world; further‐
more, in Latin America, the disease occurs in younger persons [103], while it is associated with
advanced age in remaining countries [104].
In addition to its close association to the etiology of pernicious anemia [105] and subacute
combined degeneration [106], vitamin B12 deficiency is related, through homocysteine, with
dissimilar diseases such as Alzheimer’s disease [107, 108], dementia [109, 110], depression
[111], stroke [112, 113], pulmonary embolism [114, 115], acute myocardial infarction, and
coronary heart disease [116].
2.2.1. H. pylori and vitamin B12 deficiency
The possibility that pernicious anemia, rather than vitamin B12 deficiency, was associated with
H. pylori was the first extragastric association postulated within the scientific community. This
postulation was made by O’Connor et al. in 1984 [117], a year after Warren and Marshall inform
the scientific community that the stomach could be colonized by bacteria [3]. Despite this
premature interest, the association has been difficult to sustain and, rather, has been denied
by many authors. Fong and colleagues performed what is considered the first well-founded
study to clarify the probable link between H. pylori infection and pernicious anemia. In this
study, the authors concluded that patients that suffer pernicious anemia are protected against
H. pylori infection and that the bacteria not invade the inflamed mucosa by isolated processes
[118]. These data were ratified in a Japanese study made by Saito et al. [119] and have been
shared by other authors, however, with the wrong conclusion [120].
It is currently known that when vitamin B12 deficiency becomes clinically relevant, the bacteria
are no longer at the site of the lesion due to changes in the gastric mucosa that result in a hostile
environmental niche. In cases of vitamin B12 deficiency and pernicious anemia, H. pylori
disappears as a result of changes mediated by the immunological response. These changes can
be evidenced by the presence of antibodies against parietal cells and intrinsic factor after the
bacteria have left the gastric mucosa [121, 122]. Moreover, H+/K+ ATPase autoantibodies,
which are closely linked to classical autoimmune gastritis, are also important indicators of
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mucosal atrophy in H. pylori chronic gastritis [123]. H. pylori also disappears from the gastric
mucosa as a result of the histological and physiological changes induced by chronic atrophy
in the case of gastric cancer [124].
Infection with H. pylori can also cause malabsorption of different micronutrients [125] like
vitamin B12 [125-127]. A systematic review and meta-analysis of 17 studies with 2454 patients
demonstrated a significant reduction in serum vitamin B12 levels in patients infected with H.
pylori when compared with uninfected persons [128]. Marino et al. demonstrated a correlation
between the decrease in serum vitamin B12 levels and the increase in serum homocysteine due
to H. pylori infection in 62 older patients: in these same patients, following infection eradication,
an increase in serum vitamin B12 levels and a decrease in serum homocysteine levels occurred
until normalization was reached [127].
The intimately association of pernicious anemia with the probability to develop stomach
cancer was widely recognized by scientific community many years before the relationship
between H. pylori and stomach cancer was known [129-132]. Recently, Vanella et al. validated
this association through a systematic review and meta-analysis, establishing that patients with
pernicious anemia (vitamin B12 deficiency) have a relative risk of developing gastric cancer of
6.8 (95% CI: 2.6–18.1) [133].
2.2.2. Pathophysiology of vitamin B12 deficiency
The pathophysiological mechanism by which H. pylori is related to the etiology of vitamin
B12 deficiency has not been fully clarified, and many questions remain. Possible explanations
aiming to clarify the association of H. pylori with vitamin B12 deficiency are described below.
It is not yet known why this association occurs in some patients but not in others, where a
different association is presented or the course of the infection is asymptomatic, as happens in
most cases [78].
Vitamin B12 deficiency manifests as antibodies against intrinsic factor and the parietal cells in
the stomach, achlorhydria, and decreased pepsinogen I and gastrin, thereby presenting an
histological picture of chronic type A gastritis (autoimmune) [105]. The lack of intrinsic factor,
which occurs as result of these changes in the gastric mucosa, reduces the absorption and
transport of vitamin B12 that comes from the diet. Chronic atrophic gastritis, induced immu‐
nologically, evolves over a period of 10–30 years, until reaching gastric atrophy and the
development of pernicious anemia, to the extent that the stores of vitamin B12 are depleted
[105]. Vitamin B12 deficiency, parallel to the development of pernicious anemia, causes
peripheral neuropathy and lesions in the posterior and lateral columns of the spinal cord,
known as subacute combined degeneration, that progresses with demyelination and axial
degeneration and eventually neural death [105].
2.2.3. Management of vitamin B12 deficiency in the post-Helicobacter era
Respect to the management of vitamin B12 deficiency in the post-Helicobacter era, it must be
clarified that H. pylori is not the only cause of vitamin B12 deficiency, and its incorporation into
the consensus and management guidelines of H. pylori as an indication to investigate and
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eradicate the infection is not a substitute for an adequate study of the most common causes of
vitamin B12 deficiency. These situations are particular to each region, according to the preva‐
lence of vitamin B12 deficiency and H. pylori infection, which vary from place to place.
A recent systematic review and meta-analysis with the aim of clarifying the association
between H. pylori and the vitamin B12 deficiency evaluated the serum vitamin B12 levels from
17 studies involving a total of 2454 patients, infected or not with H. pylori. This study revealed
that serum vitamin B12 levels are significantly lower in infected patients than in uninfected
patients and that H. pylori eradication significantly increases vitamin B12 levels [128]. This has
enabled the inclusion of vitamin B12 deficiency in the consensus and management guides of
H. pylori infection as an indication to evaluate and eradicate the bacteria [27, 29].
Before initiating treatment for a patient with vitamin B12 deficiency, an assessment of the
prevalence of H. pylori infection should be performed according to region. Generally, the
prevalence is low in developed countries; in these cases should proceed with conventional
management of vitamin B12 deficiency [134]. In developing countries, the rate of H. pylori
infection is high; these cases or when the patient, despite living in a country where infection
rates are low, comes from a country where the infection rates are high, it should proceed to
determine the status of H. pylori through a non-invasive test, ideally the 13C-urea breath test
[27]. If the patient is negative for H. pylori, it is necessary to investigate other causes of the
vitamin B12 deficiency and treat the patient conventionally [134], whereas if the patient is
positive for H. pylori, it is indispensable to eradicate the infection [27].
After 6–8 weeks of the treatment, the infection eradication must be confirmed using a non-
invasive test, ideally with 13C-urea breath test [27]. If eradication is not achieved, it is manda‐
tory to establish a new therapy scheme until eradication is achieved. Once H. pylori eradication
is achieved and an improvement in hematological parameters and vitamin B12 levels (complete
or partial remission) is obtained, it is important to evaluate them for a certain time. If there is
no response, it must establish a conventional management of vitamin B12 deficiency [134].
Figure 2 shows a diagnostic and management algorithm of vitamin B12 deficiency in the post-
Helicobacter era, taking into account the prevalence of the infection and H. pylori status.
2.3. Immune thrombocytopenia (ITP)
ITP is the most frequent immunological disease in hematology [135]. The annual incidence of
ITP is 5.5 per 100000 persons when the platelet count cut-off point is 100 × 109/L and 3.2 per
100000 persons when the platelet count cut-off point is 50 × 109/L [136]. The chronic form of
ITP increases with age, being twice as high in people older than 60 years with respect to those
younger than 60 years [136, 137], with a higher incidence in women (2:1) than in men (3:1) [138].
Primary ITP, formerly known as idiopathic thrombocytopenic purpura (ITP) and autoimmune
thrombocytopenic purpura, has recently been redefined and adjusted in light of new knowl‐
edge represented in the Vicenza Consensus [139]. ITP was established as an autoimmune
disorder characterized by isolated thrombocytopenia (peripheral blood platelet count below
100 × 109/L) in the absence of another possible causes or conditions related to thrombocytopenia
[139]. Primary ITP diagnosis continues to be one of the exclusions due to current lack of robust
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Figure 2. Algorithm for the study and management of vitamin B12 deficiency in the post-Helicobacter era. (1) Before ini‐
tiating treatment for a patient with vitamin B12 deficiency, an assessment of the prevalence of H. pylori infection should
be performed in each region. Generally, prevalence is high in developing countries and low in developed countries [1].
(2) If the rates of H. pylori infection are low, proceed with a conventional management of vitamin B12 deficiency [134].
(3) If the rates of H. pylori infection are high or the patient, despite living in a country where infection rates are low,
comes from a country where the infection rates are high, proceed to determine the status of H. pylori through a non-
invasive test, ideally the 13C-urea breath test (13C-BUT) [27]. (4) If the patient is negative for H. pylori, investigate other
causes of vitamin B12 deficiency and treat conventionally [134]. (5) If the patient is positive for H. pylori, proceed with
eradication of the infection [27]. (6) Confirm infection eradication 6–8 weeks after treatment using a non-invasive test,
ideally the 13C-urea breath test [27]. (7) If eradication is not achieved, establish a new scheme of eradication therapy
until it is achieved. (8) Once H. pylori eradication is achieved, (9) if a response is obtained in the hematological parame‐
ters and the serum levels of vitamin B12 and homocysteine (complete or partial remission), periodically evaluate the
clinical hematological parameters and indicators of vitamin B12. (10) If there is no response, proceed with a convention‐
al management of vitamin B12 deficiency [134].
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview42
Figure 2. Algorithm for the study and management of vitamin B12 deficiency in the post-Helicobacter era. (1) Before ini‐
tiating treatment for a patient with vitamin B12 deficiency, an assessment of the prevalence of H. pylori infection should
be performed in each region. Generally, prevalence is high in developing countries and low in developed countries [1].
(2) If the rates of H. pylori infection are low, proceed with a conventional management of vitamin B12 deficiency [134].
(3) If the rates of H. pylori infection are high or the patient, despite living in a country where infection rates are low,
comes from a country where the infection rates are high, proceed to determine the status of H. pylori through a non-
invasive test, ideally the 13C-urea breath test (13C-BUT) [27]. (4) If the patient is negative for H. pylori, investigate other
causes of vitamin B12 deficiency and treat conventionally [134]. (5) If the patient is positive for H. pylori, proceed with
eradication of the infection [27]. (6) Confirm infection eradication 6–8 weeks after treatment using a non-invasive test,
ideally the 13C-urea breath test [27]. (7) If eradication is not achieved, establish a new scheme of eradication therapy
until it is achieved. (8) Once H. pylori eradication is achieved, (9) if a response is obtained in the hematological parame‐
ters and the serum levels of vitamin B12 and homocysteine (complete or partial remission), periodically evaluate the
clinical hematological parameters and indicators of vitamin B12. (10) If there is no response, proceed with a convention‐
al management of vitamin B12 deficiency [134].
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview42
clinical and laboratory parameters, with high accuracy to establish its diagnosis [139]. The
main clinical concern of primary ITP is the elevated risk of bleeding; however, bleeding
symptoms are not present all the time [139].
H. pylori infection is included as a new disease at the list of diseases potentially associated with
the development of ITP; therefore, it must be ruled out in cases where thrombocytopenia by
H. pylori infection is suspected [139], according to the establishment by the British Society for
Haematology at beginning of 2003 [140]. In addition, the Vicenza Consensus conserved the
acronym ITP to refer to the disease itself to avoid confusion and chose the term “primary
immune thrombocytopenia” or “primary ITP” as a substitute name for ITP (idiopathic
thrombocytopenic purpura) or autoimmune thrombocytopenic purpura, referring to cases
where any associated causes are excluded. For cases where an underlying disease is present,
it is recommended to use the term “secondary immune thrombocytopenia” or “secondary
ITP,” followed by the name of the associated condition. For example, for the cases possibly
initiated by H. pylori infection, it must be used with the extent “secondary ITP H. pylori–
associated,” which required the demonstration of complete resolution of ITP after proving the
eradication of the bacteria. This form in clinical practice could be called “ITP H. pylori–
associated” [139].
2.3.1. H. pylori and immune thrombocytopenia
The association of H. pylori with ITP was first reported by Garcia-Perez et al. in Spain in 1993;
this report described a patient whose platelet count returned to normal values after eradication
of H. pylori [141]. The medical literature subsequently reported similar cases in Japan [142-146],
Italy [147-149], and Turkey [150].
In Italy, in 1998, Gasbarrini et al. presented the first series of cases demonstrating the associ‐
ation of H. pylori with adult ITP, reporting a recovery in platelet counts with disappearance of
autoantibodies against platelets in six of eight ITP patients infected with H. pylori, after
successful eradication of the bacteria [151]. Including this first series [151], 40 series have been
described in the medical literature until now, and these reports consistently demonstrate the
association between H. pylori infection and platelet count recovery following eradication. Ten
of these series were reported in Europe: eight in Italy [151-158], one in Turkey [159], and one
in Serbia [160], with a total of 495 ITP patients, 288 (58.2%) of whom were infected with H.
pylori. Of these, 242 received eradication therapy. Successful eradication was achieved in 222
(91.7%) patients, and a platelet response was observed in 108 (48.6%) patients. Asian countries
have provided 28 published series: 23 in Japan [161-183], two in China [184, 185], two in Iran
[186, 187], and one in South Korea [188], with 1525 total ITP patients, 1089 (71.4%) of whom
were infected with H. pylori. A total of 929 patients received eradication therapy, it was
successful in 811 (87.3%) and 472 (58.2%) patients demonstrated a platelet response. In
America, only two series have reported an association between H. pylori and ITP: the first in
Colombia [189] and the second in Canada [190]. The series in Colombia presented 32 patients
with ITP, 29 (90.6%) of whom were infected with H. pylori. Those 29 patients received eradi‐
cation therapy, and it was successful in 26 (89.7%) and 21 (80.8%) patients demonstrated a
platelet response [189]. The association of H. pylori infection with ITP has not been reported in
adults or children from Oceania or the continent of Africa.
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A consolidated analysis of the 40 series reported worldwide reveals a total of 2074 patients
with ITP, 1410 (68.0%) of whom are H. pylori-positive. A total of 1204 received eradication
therapy, which succeeded in 1062 (88.2%); 604 (56.9%) of these patients demonstrated a platelet
response. In general, Europe has a mean infection rate of 59.2% in patients with ITP and a mean
platelet response in 48.6% of those patients; respective rates in Asia are 70.7% and 58.2%, and
those in America (Colombia) are 90.6% and 80.8%. When consolidated, the 40 series exhibit a
mean infection rate of 68.0% in patients with ITP, with a mean platelet response in 56.9% of
those patients [191]. Table 2 summarizes the results of these series demonstrating an associa‐
tion between H. pylori infection and ITP development in adults and its response to H. pylori
eradication [191]. Nevertheless, additional studies in Spain [192], France [193], the United
States [193, 194], and Mexico [195] found no association between H. pylori infection and adult






















Europe 10 [151-160] 495 288 (58.2) 242 222 (91.7) 108 (48.6)
Asia 28 [161-188] 1525 1089 (71.4) 929 811 (87.3) 472 (58.2)
America 2 [189, 190] 54 33 (90.6) 33 29 (87.9) 24 (82.8)
Worldwide total 40 [151-190] 2074 1410 (68.0) 1204 1062 (88.2) 604 (56.9)
Source: Modified from Campuzano et al. [191]
Table 2. Helicobacter pylori and immune thrombocytopenia in adults
Regarding to the association of H. pylori infection with ITP in children, it is important to clarify
that childhood ITP has a different course than ITP in adults [135]. The few studies that have
thus far addressed the relationship between ITP and H. pylori in children are contradictory:
certain groups in China [196], Japan [197], Iran [198], Finland [199], Netherlands [200], and
Italy [201, 202] have identified an association between infection and ITP in children, with
platelet count recovery in an average of 35.2% of the patients [191]. This rate is much lower
than the response rate observed in adult patients with ITP, which is greater than 50% [151-190].
Meanwhile, other groups in Turkey [203], Italy [204, 205], Thailand [206], and Hungary [207]
found no association and the response to eradication ranged from none [203, 204, 208] to very
poor [205, 207].
2.3.2. Pathophysiology of secondary ITP (associated with H. pylori infection)
The origin of primary ITP is associated with congenital or acquired immune changes that lead
to an immune system response against platelets or megakaryocytes that cannot be attributed
to other causal changes. In secondary ITP, alternative primary events are identified that lead
to the development of this autoimmune response [209]. In the case of H. pylori as causal agent
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of this disease, several mechanisms have been described that contribute to the development
of the autoimmune response. One of these mechanisms is a change in the balance of Fcγ
receptors, involved in the activation of monocytes, and their relation to the inhibitory Fc
receptor FcγRIIB. H. pylori infection decreases the levels of FcγRIIB, leading to increased
activated monocytes through Fcγ receptors, with elevated non-specific phagocytosis, resulting
in overactivation of B and T lymphocytes. These results were confirmed by reversing monocyte
activation following H. pylori eradication treatment, with reducing generation of autoantibod‐
ies by B lymphocytes and overactivation of innate and acquired autoimmune response, and
increasing the amount of circulating platelets [179].
In conjunction with the overeactivation of monocytes, autoantibody production has also been
described in ITP, which can opsonize the platelets and induce antibody-mediated phagocytosis
by the reticuloendothelial system in the spleen. This response is attributed to molecular
mimicry of infection-related bacterial proteins. The principal antigens associated with the
autoimmune response against the platelets include the amino acid sequences of virulence
factors such as VacA, CagA [17, 178] and urease B, which are present during H. pylori infection
[210]. The similarities shared between these antigens and platelet surface glycoproteins, like
the glycoprotein IIIa among other platelet antigens not yet identified, are associated with anti-
CagA antibody production [178] and demonstrate the importance of H. pylori infection in ITP.
2.3.3. Management of ITP in the post-Helicobacter era
Concerning to the management of ITP in the post-Helicobacter era, it is important to clarify that
H. pylori is not the only cause of thrombocytopenia, and although the indication, investigation,
and treatment of infection should be considered, it is no substitute for an adequate study of
the etiologies more frequently associated with thrombocytopenia, which are particular to each
region. The 40 series of cases previously discussed, a meta-analysis [211] and two systematic
reviews [212, 213] demonstrated the burden of H. pylori infection on the development of ITP
and that eradicating the infection improves the platelet count in more than 50% of the adult
patients with chronic ITP [211-213]. This has permitted the scientific community, in particular
the consensus and management guides of H. pylori infection, to include ITP as an indication
for evaluating and eradicating the infection prior to proceeding with other traditional inter‐
ventions in both adults and children [21, 23-30].
The American Society of Hematology (ASH) recognized H. pylori as a new cause of ITP and
established to investigate and eradicate the bacteria during the basic evaluation of patients
before applying conventional treatments for the disease [209]. In addition, the International
Working Group for standardization of terminology, definitions and outcome criteria in
immune thrombocytopenic purpura of adults and children, of the same Society, created a new
ITP-associated group denominated “secondary ITP H. pylori–associated” [139]. Likewise, since
2003, the British Society for Haematology incorporated the study and eradication of H. pylori
into their ITP management guidelines [140].
Before initiating treatment for a patient with ITP, an assessment of the prevalence of H.
pylori infection should be performed according to the region. Generally, the prevalence is low
in developed countries; these cases should proceed with conventional management of ITP
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Figure 3. Algorithm for the study and management of immune thrombocytopenia (ITP) in the post-Helicobacter era. (1)
Before initiating treatment for a patient with ITP, an assessment of the prevalence of H. pylori infection should be per‐
formed in each region. Generally, prevalence is high in developing countries and low in developed countries [1]. (2) If
the rates of H. pylori infection are low, proceed with a conventional management of ITP [140, 209]. (3) If the rates of H.
pylori infection are high or the patient, despite living in a country where infection rates are low, comes from a country
where the infection rates are high, proceed to determine the status of H. pylori through a non-invasive test, ideally a
13C-urea breath test (13C-BUT) [27]. (4) If the patient is negative for H. pylori, investigate other causes of thrombocytope‐
nia and treat conventionally [140, 209]. (5) If the patient is positive for H. pylori, proceed with eradication of the infec‐
tion [27]. (6) Confirm infection eradication 6–8 weeks after treatment using a non-invasive test, ideally a 13C-urea
breath test [27]. (7) If eradication is not achieved, establish a new scheme of eradication therapy and continue treat‐
ment until it is achieved. (8) Once H. pylori eradication is achieved, (9) if a platelet response is obtained (complete or
partial remission), periodically evaluate the platelet count. (10) If there is no platelet response, proceed with a conven‐
tional management of ITP [140, 209]. Reprinted from “Proof of an association between Helicobacter pylori and idiopathic
thrombocytopenic purpura in Latin America” by G. Campuzano-Maya, 2007, Helicobacter, 12, p. 270. Copyright 1999–
2015 by John Wiley & Sons, Inc. Reprinted with author permission [189].
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[140, 209]. In developing countries, the rate of H. pylori infection is high; in these cases or when
the patient, despite living in a country where infection rates are low, comes from a country
where the infection rates are high, it should proceed to determine the status of H. pylori through
a non-invasive test, ideally the 13C-urea breath test [27]. If the patient is negative for H. pylori,
it is necessary to investigate other causes of thrombocytopenia and treat the patient conven‐
tionally [140, 209], whereas if the patient is positive for H. pylori it is indispensable to eradicate
the infection [27].
After 6–8 weeks of treatment, the infection eradication must be confirmed using a non-invasive
test, ideally with 13C-urea breath test [27]. If eradication is not achieved, it is mandatory to
establish a new therapy scheme until eradication is achieved. Once H. pylori eradication is
achieved and obtained a platelet response (complete or partial remission), it is important to
periodically evaluate platelet count. If there is no platelet response, it must establish a
conventional management of ITP [140, 209].
Figure 3 shows a diagnostic and management algorithm for ITP in the post-Helicobacter era,
taking into account the prevalence and status of H. pylori infection [189].
3. Hematological diseases not recognized as related to H. pylori
This group includes autoimmune neutropenia, antiphospholipid syndrome, Henoch–Schön‐
lein purpura, plasma cell dyscrasias, such as monoclonal gammopathy of undetermined
significance (MGUS) and multiple myeloma, and other diseases possibly associated or
implicated, such as leukemia and hemorrhagic manifestations with hematologic origin, like
congenital and acquired coagulopathies and anticoagulation.
3.1. Immune neutropenia
This association was first proposed in 2002 by Gupta et al. in England, who reported the case
of a patient with neutropenia (400 neutrophils/µL) that rapidly returned to normal values
following the eradication of H. pylori infection [214]. Since then, two new studies have been
reported, which include eight and 69 patients [215, 216] and coincide with the original report
of Gupta et al. [214]. In the future, it is recommended that in patients with neutropenia that is
suspected of being immunological the H. pylori status be established and proceed to eradicate
if positive [214] as part of good medical practice.
3.2. Antiphospholipid syndrome
Similarly to immune neutropenia, antiphospholipid syndrome, a coagulation disorder of
immunologic origin characterized by both arterial and venous thrombosis and associated with
pregnancy complications, such as abortion, premature childbirth, and pre-eclampsia [217], was
proposed as an extragastric association of H. pylori infection in 2001 by Cicconi et al. in Italy.
These authors reported the case of a woman in whom antiphospholipid syndrome disappeared
after the eradication of H. pylori infection [218]. At the moment, there are no new reports of
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this association in the medical literature possibly only because it is not being considered or
investigated. However, it is worth recalling that antiphospholipid syndrome has been
associated with other diseases of immunologic origin that in turn are associated with H.
pylori infection, such as ITP [189, 219, 220], systemic lupus erythematosus [221], and central
serous chorioretinitis [222, 223].
3.3. Henoch–Schönlein purpura
Henoch–Schönlein purpura is an immunologic disease of unknown etiology manifested by
small vessel leukocytoclastic vasculitis with deposits of immunoglobulin A (IgA) in the skin,
joints, gastrointestinal tract, and kidneys [224]. Henoch–Schönlein purpura is included in this
review because it is part of the differential diagnosis of thrombocytopenia, particularly ITP
discussed previously, which manifests as purpuric lesions on the skin. The association of H.
pylori with Henoch–Schönlein purpura was proposed in the case of a 21-year-old man by
Rainauer et al. in Germany in 1996 [225]. Since then, many studies have confirmed the
association in adults [226-231], children, and adolescents [229, 232, 233], with the disappear‐
ance of clinical manifestations in H. pylori-positive cases after eradication [229-231].
3.4. Plasma cell dyscrasias
Plasma cell dyscrasias are among the most frequent clonal diseases in elderly persons and
include MGUS, multiple myeloma, solitary plasmacytoma, plasma cell leukemia, Walden‐
ström’s macroglobulinemia, and other chronic myeloproliferative syndromes of B lympho‐
cytes [234]. Plasma cell dyscrasias may present an asymptomatic course or pass from one
disease to another; for example, MGUS, a completely benign and asymptomatic condition that
does not require treatment, can transform into a more severe and potentially fatal disease, such
as multiple myeloma [234].
The association of plasma cell dyscrasias with stomach diseases has been known for many
years, before the discovery that the stomach could be colonized by bacteria [3]. Gastrointestinal
plasmacytomas were documented by the father of modern medicine, Sir William Osler, in 1920
[235], and for many years, the association of these and multiple myeloma with pernicious
anemia [236, 237] and gastric cancer [238-242], entities clearly correlated with H. pylori
infection, has been known. Perhaps, the most important evidence of the association of H.
pylori infection with plasma cell dyscrasias is that some plasmacytomas disappear after the
eradication of H. pylori. The authors who have analyzed this facet of infection by H. pylori have
agreed to recommending that in all patients with these manifestations be offered the oppor‐
tunity of evaluated and eradicate the infection if present [243-245]. Other associations descri‐
bed include a clear interaction between MALT lymphoma of the stomach and MGUS [246] as
well as Waldenström’s disease and MALT [247].
The relation of multiple myeloma with gastric MALT type lymphomas [248-254] was identified
many years before H. pylori was known. Today, it is known that in MALT lymphoma, H.
pylori antigens can also stimulate plasma cells. The plasmacytomas discussed previously could
be the expression of a localized myeloma, and once disseminated, it would not be possible to
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differentiate one from another. Wöhrer at al. have shown an association of gastric lymphomas
with gastric myelomas [255]; besides, they described a case of plasmacytoma of the orbit, which
completely remitted after the eradication of H. pylori [256]. Therefore, it is logical that all
patients with a disease diagnosis related to plasma cells should be studied for H. pylori and if
positive, be treated with eradication therapy prior to starting conventional treatment.
According to Malik et al., MGUS, important in the study of patients with plasma cell dyscrasia,
may be related to H. pylori as result of chronic antigenic stimulation of B lymphocytes in the
gastric mucosa by the bacteria. Resolution of the gammopathy is observed in up to 30% of
cases by eradicating the bacteria [257], a relationship confirmed by some authors [246, 258] but
not by others [215, 259].
3.5. Other hematologic manifestations
According to the medical literature, other hematologic manifestations demonstrate possible
associations with H. pylori infection, which despite the low abundance of information entailed
important clinical implications. Lehtine et al. reported that in Iceland, anti-H. pylori immuno‐
globulin G was associated with increased risk of childhood leukemia in offspring (OR = 2.8,
95% CI: 1.1–6.9), whereas in Finland, it is not associated. Because anti-H. pylori immunoglo‐
bulin G indicates chronic carriage of the bacteria, early colonization of the offspring probably
differs between Iceland and Finland, two affluent countries [260]. This type of study should
be replicated at other sites, especially those where the prevalence of H. pylori is high, such as
in Asian countries and Latin America. Diamantidis et al. reported that although there is no
evidence for a causal relationship between H. pylori infection and myelodysplastic syndrome
(MDS), an increased prevalence of H. pylori infection among MDS patients has been found.
This is an interesting finding that deserves further investigation because it may indicate a
common factor causing susceptibilities to both MDS and H. pylori infection or that H. pylori
might influence the pathophysiology of MDS [261]. Recently, Kawamata et al. described the
case of a patient with H. pylori-induced thrombocytosis clinically indistinguishable from
essential thrombocythemia, which disappeared after the eradication of the infection [262].
Another problem emerging in clinical practice is the inherent increased risk of hemorrhage in
patients with hematologic diseases; H. pylori, according to preliminary studies, would be a risk
factor for the occurrence of these events. This is the case for patients with acute leukemia who
are infected with H. pylori: the risk of gastrointestinal hemorrhaging during treatment is greater
than in non-infected patients. This would be reduced if all patients with leukemia are offered
the screening and eradication of H. pylori when treatment begins [263]. In patients with
potentially hemorrhagic diseases, such as hemophilia (A and B) and von Willebrand’s disease,
H. pylori infection should be considered as an important cause of upper gastrointestinal
bleeding. It is recommended a stool antigen test as a new and non-invasive screening test for
diagnosis of H. pylori infection in all patients with hereditary hemorrhagic disorders [264].
These procedures are cost efficient for the health system, if one takes into account that the
screening, followed by treatment of all infected patients, yields a reduction of direct costs over
a 5-year period of 130 US$ per screened patient [265]. Therefore, due to increased bleeding
complications, H. pylori screening and therapy appear mandatory in patients with bleeding
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disorders [266]. This conduct would also be applicable for patients undergoing prophylactic
anticoagulation therapy [267] like aspirin [95]. The study and eradication of H. pylori in patients
with chronic idiopathic neutropenia are also suggested, wherein splenomegaly, it is probably
associated with H. pylori, as evidenced by correlation between splenic volume and infection
period [215, 216].
4. Conclusions
The recognition of hematologic diseases associated with H. pylori infection and its incorpora‐
tion as an indication for study and eradication in the consensus and management guides for
H. pylori infection represent a profound paradigm shift in the management of these diseases
and a great advance for humanity. In addition to the benefits that eradication brings to the
infected people, especially those related to gastric cancer [4] and peptic ulcer disease [3], the
paradigm shifts introduced into medical practice and the medico-social impact expected from
these new paradigms are summarized in the following paragraphs.
4.1. Iron deficiency
The management of iron deficiency is palliative and based on iron supplementation [32], where
there is often no impact on the direct cause associated with ferropenia [35]. With the incorpo‐
ration of iron deficiency, with or without anemia, into the consensus and management guides
for H. pylori infection as an indication to investigate and eradicate the bacteria [21-30], a new
paradigm was generated, where the etiology of ferropenia can be infectious and the eradication
of H. pylori may be sufficient to cure the deficiency, in the strict sense of the word [46-50]. Under
the new paradigm, where eradication of the infection corrects the iron deficiency, in addition
to restoring health [46-50] and increasing productivity [32], the prevalence of H. pylori infection
and the diseases associated with it, such as gastric cancer [4] and gastric acid disease [3],
decreases.
4.2. Vitamin B12 deficiency
The management of vitamin B12 deficiency is also palliative and based on vitamin supplemen‐
tation, where there is little impact on the initial cause of the deficiency [134]. With the incor‐
poration of vitamin B12 deficiency into the consensus and management guides for H. pylori
infection as an indication to investigate and eradicate the bacteria [27, 29], a new paradigm
was generated, where the etiology of vitamin B12 deficiency can be infectious and the eradica‐
tion of H. pylori may be sufficient to correct it [127]. Under this new paradigm, where eradi‐
cation of infection corrects the vitamin B12 deficiency by a curative rather than palliative
treatment [127], the patient is released from a chronic disease [134] closely related to gastric
cancer and from diverse diseases such as Alzheimer’s disease [107, 108], depression [111],
stroke [112, 113], pulmonary embolism [114], acute myocardial infarction, and coronary heart
disease [116], which are regulated through homocysteine and generate high morbidity,
mortality, and costs for health systems.
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4.3. Immune thrombocytopenia
The treatment of ITP is palliative, not curative, and is oriented toward controlling the produc‐
tion of antibodies against platelets using medication or through the removal of organs that
sequester platelets, such as the spleen [140, 209]. With the incorporation of ITP into the
consensus and management guides for H. pylori infection as an indication to investigate and
eradicate the bacteria [21, 23-30], a new paradigm was generated, where the etiology of ITP
can be infectious and the eradication of H. pylori may be sufficient to cure it, in the strict sense
of the word [151-190]. Under the new paradigm, where the eradication of infection leads to
correction of the platelet count with definitive cure of ITP, the patient is freed from a chronic
disease [140, 209] by a curative rather than palliative treatment [151-190]. Furthermore, the
eradication of the infection in these patients reduces the prevalence of gastric cancer and peptic
acid disease, with which it is closely related and which contribute to high morbidity, mortality,
and costs for health systems.
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Abstract
Helicobacter pylori infects more than 50% of the world population and is acquired in infan‐
cy. Higher prevalence is found in developing countries, and within geographic areas the
predominance correlates inversely with socioeconomic status, especially with living con‐
ditions during childhood. Initially, in adults, H. pylori was only associated with gastric
diseases, such as peptic ulcer, gastritis, gastric adenocarcinoma, and gastric mucosa-asso‐
ciated lymphoid tissue (MALT) lymphoma, and in childhood, with chronic gastritis and
duodenal ulcers in children. Recently, H. pylori has been related to non-gastric diseases,
including hematological disorders such as iron deficiency anemia (IDA), chronic idio‐
pathic thrombocytopenia (cITP), and vitamin B12 deficiency. H. pylori can trigger autoim‐
mune atrophic gastritis and be responsible initially for an oral iron refractory anemia.
Other hematological associations have been made, such as an increased risk of childhood
leukemia in children of H. pylori-infected mothers and gastric bleeding in children with
coagulation pathologies. H. pylori infection is important in the immune pathogenesis of
chronic gastric inflammation and hematological diseases. The diagnostic methodology is
based on non-invasive (serology, C-urea breath test, stool HP antigen) and invasive tests.
The scientific community discussed and incorporated in international consensus for the
investigation and management of these hematological extragastric pathologies (IDA,
cITP, vitamin B12 deficiency, and MALT lymphoma). In children, a similar attitude was
obtained in all of these pathologies except for cITP, in which the investigation for H. pylo‐
ri is not indicated.
Keywords: Helicobacter pylori, iron deficiency anemia, immune thrombocytopenia, MALT
lymphoma, vitamin B12 deficiency
1. Introduction
Helicobacter pylori is a gram-negative spiral bacterium, responsible for one of the most frequent
gastrodigestive infections in the world. In 1883, Bizzozero reported spirochetes inhabiting the
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
gastric glands of dogs [1]. However, in 1954, after examining 1000 gastric biopsies, Palmer
concluded that no microorganisms could survive in an acidic gastric environment [2]. This
was contradicted by Marshall and Warren in 1982 [2].They isolated the microorganism from
the specimens of gastric mucosa in patients with gastritis and peptic ulcers, and for the first
time it was isolated in vitro culture. As previously stated, at that time, it was thought that the
acidic gastric environment was not compatible with the survival of this bacterium. In 1991, an
association between H. pylori infection and gastric mucosa-associated lymphoid tissue (MALT)
lymphoma was found [3]. Then, in 1994, The National Institute of Health consensus conference
in the United States declared an association between H. pylori infection and peptic ulcer disease
[4]. In that same year, H. pylori was identified with gastric adenocarcinoma and gastric non-
Hodgkin lymphoma [3, 4].
After the discovery made by Marshall and Warren, histological features of chronic gastritis in
upper gastrointestinal endoscopy were revealed. Moreover, a Canadian group also found H.
pylori in the gastric mucosa of children with gastritis and duodenal ulcers [5].
Although over 80% of infected subjects remain asymptomatic, H. pylori chronic infection is
associated with different clinical manifestations, including chronic gastritis, peptic ulcer
disease, lymphoid tissue (MALT) lymphoma, and gastric adenocarcinoma. Furthermore, in
1994, H. pylori was classified as a type 1 carcinogen by the World Health Organization (WHO)
[6-8]. In children, H. pylori has been considered a cause of chronic gastritis and duodenal ulcers.
Recently, it has been related to diseases outside the stomach, namely those characterized by
persistent and low-grade systemic inflammation: iron deficiency anemia (IDA), chronic
idiopathic thrombocytopenia (cITP), vitamin B12 deficiency, growth retardation, and diabetes
mellitus [9, 10]. Although a relationship between the H. pylori infection and autoimmune
atrophic gastritis (AAG) is not possible, studies conducted by Hershko proved that H. pylori
can be the trigger of AAG and be responsible in the initial phase of the disease for an oral
refractory iron anemia [11-14]. More debated hematological associations have been made with
monoclonal gammopathy, non-Hodgkin lymphomas of the stomach, myelodysplastic
syndromes, increased risk of childhood leukemia in the children of H. pylori-infected mothers,
and gastric bleeding in children with coagulation pathologies [15-17].
The H. pylori infection is acquired during childhood (before the age of 10) and in the absence
of antibiotic therapy the host can carry it for life. In contrast to the great majority of bacterial
infections, in which virulence is temporary due to an immune system mechanism, which
results in the clearance of the pathogen, H. pylori can survive for many years [15-18]. H.
pylori has mechanisms to escape the clearance of the innate and adaptive immune system, and
the development of a symbiotic relationship between the bacteria and the human host is also
a possibility [9-12]. Moreover, H. pylori has an important urease activity, leading to ammonia
production in order to protect itself from gastric acidity. Also, H. pylori produces enzymes,
such as phospholipase A2 and C as well as glycosulphatase, which leads to gastric mucosa
damage [6].
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2. The interaction between H. pylori and the immune system
Epithelial and myeloid cells form the initial line of the innate immune system response against
H. pylori infection. They recognize the bacteria through a limited number of microbial pattern
recognition receptors (PRRs), which include membrane associated Toll like receptors (TLRs),
cytoplasmic Nod-like receptors (NLRs) and retinoic acid inducible gene I-like helicase receptor
(RLRs). They recognize bacteria constituents termed pathogen-associated molecular patterns
(PAMPs), present in the microbial proteins, nucleic acids, lipids and carbohydrates. These
PAMPs contain molecules that act as ligands to trigger PRRs dependent intracellular signaling
pathways, inducting the expression of pro-inflammatory molecules and cytokines as the first
response to the bacteria infection. TLRs are the most studied of the larger family of the PRRs
and participate in the first line of host defense against pathogens, with subsequent activation
of adaptive immune response [17-21]. Ten TLRs have been identified in humans and can be
identified by the type of ligand [12-14]. TLRs are type I transmembrane proteins characterized
by an extracellular leucine-rich ectodomain involved in PAMP recognition from bacteria,
fungi, parasites, and viruses, including lipid components of wall cell bacteria such as lipopo‐
lysaccharides (LPS) and lipopeptides, microbial components such as flagellin and nucleic acid
components, as well as an intracytoplasmatic domain that shows similarity to the IL1 receptor
family termed a toll-IL1 receptor (TIR), which is involved in the activation of downstream
signaling pathways. TLRs are expressed on the surface of cells or in intracellular vesicles like
endosomes [18, 19, 22, 23]. Some TLRs recognize only one type of PAMP, while others such as
TLR2 recognize bacterial lipoproteins, lipoteichoic acid and peptidoglycans [21]. The Goldberg
Group revealed the role of TLRs during H. pylori infection, showing an overexpression of TLR2
and TLR5 in the gastric epithelial cells HEK293 of H. pylori-infected patients, as well as an
increase of the activation of transcriptional factors: (1) nuclear factor-κB (NF-κB) and inter‐
leukin-8 (IL-8), (2) macrophage inflammatory protein 3α (MI-3α), and (3) the growth-regulated
protein-α (GRO-α mRNA expression) [8]. The understanding of the role of TLRs in response
to H. pylori infection requires an elucidation of cell-signaling events. After PAMP recognition,
TLRs trigger the signaling pathways resulting in: (1) activation of the transcription of NF-B,
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dependent, responsible for pro-inflammatory cytokine production as well as MyD88 inde‐
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macrophage cells is essential for the induction of anti-inflammatory cytokines (IL-6, IL-1B,
IL-10, and IL-12) [19]. Recently, a new group of innate immune molecules, including activating
receptors involved in modulating the intensity of innate immune response in myeloid cells
(TREM), has been described [24, 25]. TREM family receptors (TREM-1 to TREM 4), are cell
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surface activating receptors with a transmembrane region containing charged lysine residues
and a short cytoplasmatic tail lacking signaling motifs. TREM-1, a 30-Kda glycoprotein of the
Ig family is the most well-known member of the TREM family and is responsible for inflam‐
mation amplification and activation of antigen-presenting cells (APC). TREM-1 is exhibited in
neutrophils and monocytes and linked to innate immunity by phagocyte secretion of pro-
inflammatory chemokines and cytokines such as IL-8 and TNF-α. TREM-1 is involved in the
amplification of TLR-dependent signals and in the improvement of NOD-like receptors
(NLRs)–mediated responses, including NOD-1, involved in the protection against H. pylori
infection [19]. An up-regulation of TREM-1 in gastric epithelial cells of H. pylori infected adults
patients was found in a study by Schmausser et al. using immunohistochemistry in nine of
twelve patients. No TREM-1 was found in non-inflamed gastric epithelium, in accordance with
mRNA, TREM-1 also strongly expressed in H. pylori gastritis. [19, 26]. These results are not in
accordance with Michalkiewics study done in 78 children with H. pylori infection. The gastric
expression of TREM-1 and TREM-2 was not affected by H.pylori infection, reflecting the
tolerance status of leucocytes present in gastric mucosa of H pylori infected children [19].
TREM-2 is expressed in macrophage and dendritic cells, acts antagonistically to TREM-1 and
its activation results in anti-inflammatory reactions. This receptor has not yet been observed
in H. pylori-infected patients. M1 macrophage cells are linked to strong pro-inflammatory and
cytotoxic responses induced by INFγ, tumor necrosis factor (TNF), and IL-6. M2 macrophage
cells show markers of an anti-inflammatory process through CD163, a cell surface glycoprotein
whose expression is induced by inflammatory mediators, such as glucocorticoides and IL-10.
Also, they are inhibited by pro-inflammatory mediators, such as INFγ, TNF-α, as well as others
[18, 19, 22, 23]. The CD14 receptor is a cell surface molecule expressed on monocytes and
macrophages and linked to the recognition of H. pylori LPS, which leads to the production of
many pro-inflammatory cytokines. The interaction of H. pylori and CD14 shows that its
expression in gastric mucosa may indicate infiltration by monocytes/macrophages [27]. On the
other hand, H. pylori has two major factors for virulence, vacuolating cytotoxin (VacA) and H.
pylori neutrophil-activating protein (H. pylori-NAP), related to the stimulation of radical
oxygen production by neutrophils. H. pylori-NAP is a 150-KDa oligomeric protein, a TLR2
agonist that exhibits chemotaxis for the neutrophils and monocytes, increasing the synthesis
of tissue factor and type-2 plasminogen inhibitor, IL-23, and IL-12, a key cytokine for the
differentiation of naïve T helper (TH) cells into the TH1 cytotoxic phenotype. Naïve T CD4+
helper TCD4+ cells can be called to differentiate towards TH1, TH2, TH17, and regulatory T
cells (Tregs) phenotypes according to the cytokines. Classically, TH cells are divided into two
functional subsets: Th1 and Th2, responsible for the production of a distinct pattern of cytokine
secretion. The adaptive system produced by the host against H. pylori includes Th1 and Th17
components that are implicated in the control of infection. Despite these data, a number of
reports suggest that this Th1-biased response is dysfunctional and can be considered as an
important role in pathogenesis of H. pylori-related diseases [23, 27, 28]. Indeed the immuno‐
modulatory properties of the pathogen can reprogram the host’s immune tolerance and H.
pylori escapes [19]. In a study published by Michalkiewics, 78 children, ranging in ages between
7 and 18 years, with a confirmed H. pylori infection in 40 patients (50% without symptoms), a
Th1 profile of H. pylori-mediated inflammation was found [28]. H. pylori can modulate MyD88
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expression. In other words, the lack of significant amounts of MyD88 can explain the persis‐
tence of the infection and the endotoxin tolerance [19]. Furthermore, the exact role of T Helper
cells in H. pylori infection is not fully understood. Recent studies revealed that a deficiency in
Th1 response may be responsible for the persistence of H. pylori infection [28, 29]. The role of
H. pylori in pathogenesis of extra-gastroduodenal diseases may be based on the systemic effects
of chronic gastric inflammation immune responses, which can induce lesions outside of the
stomach and can be reversed after H. pylori eradication [10, 14-16].
3. Epidemiology and risk factors
More than 50% of the world’s population is infected with H. pylori [7, 8, 30]. Although infection
occurs worldwide, its prevalence shows a marked discordance within and between developed
and developing countries. Overall prevalence oscillates between 30 and 50% in industrialized
countries, in contrast with the ranges of 80–90% found in the developing countries. Within
geographic areas, the predominance correlates inversely with socioeconomic status, especially
those related with living conditions during childhood. The improvement in hygiene, sanitary
conditions, and the active treatment of the H. pylori carrierships implemented in developed
countries may be the responsible for the difference in these two worlds [6, 7, 17, 31-34]. Reports
regarding racial and ethnic differences in the prevalence of H. pylori infection in children and
adults have been carried out. Everhart et al. reported an overall seropositivity rate of H.
pylori infection in 32.7% of 7465 adult participants in the United States. Higher prevalence was
observed in non-Hispanic blacks and Mexican Americans (51.1 and 57.9%, respectively),
compared with the values observed among non-Hispanic whites (26.9%) [29]. A study
conducted by Nguyen et al. in two ethnic groups (Kinh and Khmer), with different cultures,
involving 1596 individuals, 485 households, the seroprevalence was higher in adults than in
children ≤18 years (40.2 and 32.1%, respectively). Variables related to promiscuity such as
taking foods by hands, absence of good practice of hand washing after defecation, having
mother or siblings infected by H. pylori were risk factors. There were no differences in H.
pylori seropositivity based on sex (P>0.05) or ethnicity (P>0.05) [31]. In southern China, the
prevalence of H. pylori infection in Chinese people was significantly higher than in Australians
(44.2 vs. 21%). Comparing the prevalence of infection in children aged <10 years, the Chinese
showed 27% and the Australians 4%. In children over the age of 10, a similar rate of H. pylori
acquisition was observed in both countries (1% per annum), according to epidemiological data
[32]. Cherian conducted a cross-sectional study in 193 African refugee children (aged <16 years)
in Western Australia. The mean age was 7.9 years, and 18 children (9%, mean age of 11.3
months, and SD 5.2 months) were breastfeeding. There were 116 children living in refugee
camps and the remaining lived in apartments or houses. The great majority came from
Tanzania or Kenya, 96 of 97 (99%), lived in the camps, whereas 28 originating from Egypt lived
in apartments and houses. H. pylori was present in 82% of children (63% aged <2 years), rising
to 95% for those older than 14 years, confirming a greater risk in Africa. Intrafamilial spread
of H. pylori, particularly mother-to-child transmission or infected older siblings, was a potential
mechanism of this acquisition. Concerning the breastfeeding children, a statistically significant
correlation was not possible because the number of children was small. Curiously, those
children who had done antimalarial treatment seemed to have eradicated H. pylori. It was
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attributed to a probable effect of artemisinin on the iron dependence of the bacteria [33].
Differences in the prevalence of H. pylori infection among racial and ethnic groups have been
described. Besides ethnicity, the difference in the prevalence between developed and devel‐
oping countries seems to be linked to socioeconomic factors. Poverty and bad living conditions
are the principle risk factors for acquiring H. pylori infection within industrialized countries
[6-8, 34-36]. A high number of residents in the same home, sharing the same room or the same
bed with H. pylori-infected children, as well as poor sanitary conditions were identified as
major risk factors [6-8]. This infection is acquired in childhood and they are carrying the same
strain as their parents and maintain this genotype even after moving to a different environment
[37, 38]. In relation to the prevalence based on gender, differences have not been found between
men and women, and no association with smoking or drinking habits has been made [6].
Nutritional status has been described as being associated to H. pylori infection. Goodman et al.
found reduced odds of risk of H. pylori infection in adults and children with an increased
ingestion of fruit, vegetables, and milk. The increased improvement of hygiene at home, as
well as socioeconomic conditions, has resulted in a lower rate of H. pylori infection and an
increase of gastroesophageal reflux disease (GERD) [8, 32, 35-37]. Studies revealed that gastric
corpus inflammation induced by H. pylori, more pronounced with CagA+ strains, has an acid-
suppressive effect, preventing the development of GERD. Also, asthma and allergy disorders
are prevalent in developed countries and inversely associated with H. pylori [8, 14-16, 33, 34,
36]. Hygiene reduces the exposures to microorganism modifiers polarized Th1/Th2 responses
leading to asthma. H. pylori can alter the polarized Th1/Th2 through dendritic cell-mediated
T expression of IL-2, TNF-α, and INF-γ. Longitudinal studies revealed that asthma is a risk
factor to GERD development and GERD can trigger asthma [36, 37]. The most well-known
hematological pathology linked to H. pylori infection in children is IDA. Epidemiological
studies have indicated that seropositivity is associated to low serum ferritin and hemoglobin
levels compared with seronegative controls. Reports have been carried out concerning
refractory iron deficiency anemia (refractory IDA), normalized after the H. pylori eradication
therapy and also the improvement of anemia without iron supplementation [11-13].
3.1. Routes of transmission
A number of studies propose environmental sources, such as animal and water exposure, as
potential forms of H. pylori infection. Also, a human-to-human transmission through oral-oral,
fecal-oral, or both has been described. H. pylori has been detected in saliva, vomitus, gastric
reflux, and feces [6, 8, 33, 34, 39-42].
3.1.1. Animals as potential source of H. pylori
Two epidemiological studies reported that the exposure to sheep was implicated in H. pylori
infection. Goodman et al. [35] described a higher risk of H. pylori infection, in the Colombian
Andes, in children who played with sheep. Dore et al. reported an association between a
prevalence of infection in 98% of Sardinian shepherds and the contact with sheep and
sheepdogs. In that study, the individuals had a significant increase of infection prevalence not
observed in their family members, with no regular contact with sheep (73%) or sheepdogs
(43%). A subsequent recovery of H. pylori in sheep milk led Dore to suggest that H. pylori may
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be a commensal of sheep and thus the last ancestral host of H. pylori. The isolation of H.
pylori in the stomach of cats led Handt et al. to suggest that cats may also represent a reservoir
of the bacteria [27, 29, 43]. Rothenbacher et al. found that adults, who owned cats as children,
had a higher prevalence of H. pylori infection. Contradicting these studies were El-Zaatari et
al. who reported, in 25 stray cats, no infection by H. pylori. They found another strain,
Helicobacter heilmannii to be responsible for chronic gastritis in cats. Two seroepidemiological
studies in the United States, involving pet owners, failed to support the association of the
relationship between pet owners and an increased prevalence of H. pylori [32]. One large
population-based study in Canada, adjusted for social class, found no association between pet
ownership and peptic ulcer disease. With these results, a relation between cats and H. pylori
infection does not seem possible, and cats are not a health problem for cat owners [34].
3.1.2. Water transmission
H. pylori can survive for several days in milk and tap water in an infectious bacillary form. In
rivers, it can survive in a coccoid form for several months. Under physical or chemical stress,
H. pylori is capable of converting into a viable form. It is not known whether this coccoid form
can revert to its infectious form. Several studies support this form of transmission [34, 39, 40,
44]. In 1993, Westbloom detected H. pylori in the sewage water in Peru [6]. Hulten et al. showed
that in a population of Peruvian children, which consumed an internal source of water at home,
the likelihood of having infection with H. pylori was tripled [39]. In Colombia, children who
swam in rivers, streams, and pools and drank from a stream contaminated with sewage water
had a higher tendency of acquiring the infection. In South America, Hopkins et al. found, in
Chilean children who consumed uncooked vegetables contaminated with water containing
raw sewage, an increased prevalence of the infection [33-35].
3.1.3. Fecal-oral transmission
Some studies support the evidence of the transmission of H. pylori through its elimination in
feces after turnover of gastric mucosa. Thomas et al. in 1992 detected it in the feces of one adult
and 9 of 23 children living in a Gambian village, using the culture method. The isolation of H.
pylori from feces has been controversial. Parsonnet et al. [41] cultured the bacteria in feces, in
7 of 14 H. pylori-infected adults after cathartic-induced diarrhea. Mapstone et al. in 1993
detected H. pylori DNA by polymerase chain reaction (PCR). Some studies reported detection
of H. pylori by DNA, in feces, in 25–90% of H. pylori-infected patients [34]. In 1993, Hopkins et
al. observed that the consumption of fertilized vegetables with human feces was a risk factor
for acquiring H. pylori infection. The spreading through feces is supported by the occurrence
of infection in institutionalized people during gastroenteritis outbreaks [8, 34].
3.1.4. Oral-oral transmission
It is accepted that H. pylori infection acquisition occurs in early childhood by close interfamilial
contact. Many scientists report that oral-oral transmission is the most common form in
developed countries. This was supported by the high prevalence of H. pylori infection observed
in institutionalized people, within families, and in dentists. Megraud found, in Western Africa,
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a higher risk of H. pylori infection in children fed with premasticated foods by their parents
[34]. Parsonnet et al. [41] isolated H. pylori from saliva, vomitus, and cathartic stools in 16
healthy volunteers, infected adults, using culture and PCR methods. Ferguson et al. also
demonstrated by PCR, a low number of H. pylori from the saliva in one of the nine H. pylori-
positive subjects. By using soluble electrophoresis on polyacrylamide slab gels, restriction
endonuclease analysis, and Southern blot hybridization, they confirmed that the same strain
was isolated from both saliva and gastric biopsy [42]. In 1993, Mapstone detected H. Pylori in
the oral cavity, by culture, in one person. Majmudar et al. using PCR diagnosed H. pylori in
dental plaque [6, 8]. Cellini et al. reported the isolation of H. pylori from the dental plaque of
1 in 20 H. pylori-positive patients. Comparing the protein patterns and the restriction endo‐
nuclease pattern of the bacteria, those isolated from gastric biopsy and from dental plaque
showed to be identical [32]. Peach et al. found an association between H. pylori infection with
a high plaque score. However, studies conducted by other investigators did not find a
relationship between dentist visits, number of times that teeth were brushed, and periodontal
status. Doré-Davin et al. found no correlation between H. pylori infection, determined by PCR,
on saliva and dental plaque. They state that the transmission was done by gastro-esophageal
reflux or regurgitation of gastric contents [34, 41, 42].
4. Pathogenesis of H. pylori infection in extradigestive pathologies
It is known that the immunological response triggered by the bacteria is responsible for gastric
mucosa damage. Large amounts of pro-inflammatory substances, such as cytokines, eicosa‐
noids, and acute phase proteins, are released after H. pylori colonization [14-19]. Also, cross
mimicry between bacteria and host antigens may contribute to gastric mucosa damage [8, 22].
Although H. pylori gastric colonization induces histological changes in gastric mucosa, leading
to chronic gastritis in all infected people, most have no symptoms. The risk of developing
symptoms will depend on factors, such as the interaction between the host and the bacterium,
host genetic and immune response, diet and level of gastric acid. Host immune gene poly‐
morphisms and gastric acid secretion determine the bacterium’s ability to colonize a specific
gastric niche. Some bacteria strains are more virulent than others. The increase of pathogenicity
is related to the induction of morphological changes, vacuolation, and successive degeneration
of cells in vitro. The protein vacuolating cytotoxin VacA and the cytotoxin-associated gene
pathogenicity island-encoded protein CagA seem to be essential for the colonization and for
modulating the host’s immune system. The pathogen effects of H. pylori are related to chronic
inflammation, with the promotion of pro-inflammatory and anti-inflammatory mediators.
Host genetics polymorphisms can affect the expression levels of these mediators [8].
4.1. Pathogenesis of H. pylori in extradigestive disorders
The role of H. pylori in the pathogenesis of extradigestive disorders is based on (1) local
inflammation has systemic effects, (2) H. pylori infection is a chronic process that persists for
several decades, and (3) the persistent infection induces a chronic inflammatory and immune
response that can induce lesions locally and remote to the primary site of infection [14]. In
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addition to the above, several reports have revealed the role of H. pylori infection in hemato‐
logical problems [10, 16, 45]. Unexplained ID, IDA, and cITP are the most common problems
encountered in pediatric groups [11, 16]. Vitamin B12 (vit.B12) deficiency was the first
hematological disease associated to H. pylori infection and considered an elderly age group’s
disease. A study conducted by Rogers et al. for the evaluation of risk factors contributing to
low or marginal vitamin B12 concentration in Guatemalan school children revealed that
malabsorption conditions can interfere with vitamin uptake of the diet. A normal vitamin B12
status is expected despite a low intake because of this efficient enterohepatic circulation. An
additional hypo/achlorhydria produced by H. pylori infection can be the trigger to the devel‐
opment of cyanocobalamin deficiency in this young age group [46].
Gastric MALT lymphoma, also known as mucosa-associated lymphoid tissue (lymphoma),
is a low grade B-cell lymphoma described by Isaac and Wright in 1993 as an adult disease
and extremely rare in children. H. pylori stimulates the B and T lymphocytes of the stom‐
ach. B cells form clones, possibility by trissomia-3 mutations, and can become low-grade
MALT lymphoma. The H. pylori dependence is by-passed to H. pylori independence with
genetic  mutations  t(1:14)  with  a  transformation  to  high-grade  MALT  lymphoma,  not
documented in children [9, 47, 48].
The Scientific community has discussed and incorporated international consensus guidelines
for investigation and management of these hematological extragastric pathologies (IDA, cITP,
vitamin B12 deficiency, and MALT lymphoma) [5, 49-51]. No international consensus was
obtained for other hematological changes. However, autoimmune neutropenia was docu‐
mented in 2002 by Gupta et al. [52] with the report of a patient with a neutropenia (400/µl),
which normalized after H. pylori eradication. Papadaki et al. [53] in 2006, after evaluating 67
adult patients with chronic neutropenia and splenomegaly, found a higher prevalence of H.
pylori infection compared to healthy controls.
According to literature, other hematologic problems may be associated to H. pylori infection.
For example, leukemia in children, whose mothers are chronic carriers of H. pylori, increased
risk of gastric bleeding in children with acute leukemia, H. pylori infected, and in patients with
genetic diseases prone to hemorrhage (Hemophilia A and B and thrombasthenia) [15, 16].
5. Iron deficiency anemia
The World Health Organization (WHO) estimates that approximately 50% of all anemic
patients have a diagnosis of IDA [1, 30, 31, 50, 51, 54]. In infancy, IDA is associated to abnormal
mental and motor development. In developed countries, low intake, increased host require‐
ments to supply the physiological needs for normal development, dietary errors, and blood
loss are the most frequent causes of IDA in children [15, 45]. The evidence to support a causal
association between H. pylori infection and ID or IDA is based on epidemiological studies and
clinical trials. The first clinical case was described by Becker in 1991, in a 15-year-old girl, H.
pylori positive, whose clinical presentation was a chronic active hemorrhagic gastritis, without
gastrointestinal symptoms. In 1993, Dufour et al. reported a 7-year-old child without evidence
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of hemorrhage or clinical symptoms, with refractory IDA to oral iron therapy. The investiga‐
tion revealed an H. pylori-positive patient. High endoscopy showed chronic antral gastritis and
H. pylori eradication reversed the anemia [55]. These case reports were followed by other
studies that have documented an association between H. pylori infection and unexplained or
refractory IDA with reversal of anemia and a normalization of iron stores after successful H.
pylori eradication, with or without iron supplementation [10, 45]. A recurrent ID or an
inadequate response to oral iron therapy implies searching for H. pylori infection. All guide‐
lines and international consensus support that H. pylori should be sought and eradicated in ID
cases [5, 49, 50, 56].
5.1. Pathophysiology of iron deficiency by H. pylori
The intrinsic biological mechanisms by which H. pylori infection induces ID, IDA, or refractory
IDA are not fully understood. However, several pathways are involved: occult blood loss,
changes in gastric physiology as the result of chronic gastric inflammation and of low gastric
acidity and ascorbate, as well as mechanisms used by the bacteria for its growth [11-13, 55].
5.1.1. Occult blood loss
Chronic gastrointestinal blood loss is one of the supposed intrinsic mechanisms. However,
most case series of H. pylori patients with anemia and chronic gastritis do not reveal gastric
bleeding lesions at the time of endoscopy, and positive occult fecal blood tests are not always
present [45, 57]. The occult fecal blood test is a qualitative and highly accurate (98%) form of
detecting human fecal hemoglobin, based on a flow chromatographic immunoassay, it is a
diagnostic approach for the evaluation of gastrodigestive pathology of detecting human fecal
hemoglobin, based on a flow chromatographic immunoassay [58]. A literature review by Susan
Owens et al. about gastrointestinal bleeding in children, considered the H. pylori infection in
children with hemorrhagic hereditary disorders, such as hemophilia A and B as a risk factor
for severe hemorrhage [16]. Also, Campuzano-Maya mentioned that an increased risk of
hemorrhage is observed in patients with acute leukemia infected with H. pylori, which have a
greater risk of gastrointestinal hemorrhage during treatment compared to uninfected patients.
This risk is reduced if a screening and eradication therapy, is offered to all leucemia patients
upon starting leucemia treatment if they are infected [16] Therefore, in patients with potentially
hemorrhagic genetic diseases, such as hemophilias (A and B) and Von Willebrand disease, H.
pylori infection should be considered as an important cause of upper gastrointestinal bleeding.
The authors recommend a stool antigen test as a new and non-invasive screening test for
diagnosing H. pylori infection in all patients with hereditary hemorrhagic disorders [16].
5.1.2. Changes in gastric physiology: gastric inflammation and chronic disease anemia
Gastric mucosal inflammation is an invariable finding in H. pylori-infected patients and
represents the host’s immune response to the bacteria [59]. Several mechanisms have been
postulated: (a) directed mucosal injury enhancing permeability and the antigen exposure; (b)
adherence of bacteria to the gastric mucosal, accompanied by microvilli loss, irregularity of
luminal border, edema and vacuolation; (c) toxic effect of the bacteria on epithelial cells with
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview84
of hemorrhage or clinical symptoms, with refractory IDA to oral iron therapy. The investiga‐
tion revealed an H. pylori-positive patient. High endoscopy showed chronic antral gastritis and
H. pylori eradication reversed the anemia [55]. These case reports were followed by other
studies that have documented an association between H. pylori infection and unexplained or
refractory IDA with reversal of anemia and a normalization of iron stores after successful H.
pylori eradication, with or without iron supplementation [10, 45]. A recurrent ID or an
inadequate response to oral iron therapy implies searching for H. pylori infection. All guide‐
lines and international consensus support that H. pylori should be sought and eradicated in ID
cases [5, 49, 50, 56].
5.1. Pathophysiology of iron deficiency by H. pylori
The intrinsic biological mechanisms by which H. pylori infection induces ID, IDA, or refractory
IDA are not fully understood. However, several pathways are involved: occult blood loss,
changes in gastric physiology as the result of chronic gastric inflammation and of low gastric
acidity and ascorbate, as well as mechanisms used by the bacteria for its growth [11-13, 55].
5.1.1. Occult blood loss
Chronic gastrointestinal blood loss is one of the supposed intrinsic mechanisms. However,
most case series of H. pylori patients with anemia and chronic gastritis do not reveal gastric
bleeding lesions at the time of endoscopy, and positive occult fecal blood tests are not always
present [45, 57]. The occult fecal blood test is a qualitative and highly accurate (98%) form of
detecting human fecal hemoglobin, based on a flow chromatographic immunoassay, it is a
diagnostic approach for the evaluation of gastrodigestive pathology of detecting human fecal
hemoglobin, based on a flow chromatographic immunoassay [58]. A literature review by Susan
Owens et al. about gastrointestinal bleeding in children, considered the H. pylori infection in
children with hemorrhagic hereditary disorders, such as hemophilia A and B as a risk factor
for severe hemorrhage [16]. Also, Campuzano-Maya mentioned that an increased risk of
hemorrhage is observed in patients with acute leukemia infected with H. pylori, which have a
greater risk of gastrointestinal hemorrhage during treatment compared to uninfected patients.
This risk is reduced if a screening and eradication therapy, is offered to all leucemia patients
upon starting leucemia treatment if they are infected [16] Therefore, in patients with potentially
hemorrhagic genetic diseases, such as hemophilias (A and B) and Von Willebrand disease, H.
pylori infection should be considered as an important cause of upper gastrointestinal bleeding.
The authors recommend a stool antigen test as a new and non-invasive screening test for
diagnosing H. pylori infection in all patients with hereditary hemorrhagic disorders [16].
5.1.2. Changes in gastric physiology: gastric inflammation and chronic disease anemia
Gastric mucosal inflammation is an invariable finding in H. pylori-infected patients and
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a gastric epithelial degeneration, access to underlying mucosa, stimulating host non-specific
and specific responses involving several cytokines’ liberation [59].
5.1.2.1. Directed mucosal injury
Two instances should be considered in the invasion of H. pylori in gastric mucosal. In the first,
H. pylori colonizes, living in the mucus layer in proximity to the epithelial surface. This
interaction leads to epithelial cell damage and liberation of pro-inflammatory cytokines [8, [59].
5.1.2.2. Adherence of bacteria to the gastric mucosal
After the initial colonization, H. pylori migrates to the mucosa with stimulation of immune
responses. All H. pylori strains have the gene for vacuolation cytotoxin (VacA), but only 50%
produce the VacA protein, capable of vacuolation eukaryotic cells and prone to insertion into
the membranes of endosomal vesicles forming pores with chloride channel activity. This alters
the anions’ composition within the endosomes, which leads to osmotic swelling, cellular death
and apoptosis, and a more severe degree of inflammation and peptic ulceration [59].
5.1.2.3. Toxic effect
Several enzymes produced by H. pylori may contribute to changes in gastric mucosa permea‐
bility. H. pylori is one of the most powerful urea-splitting organisms. Splitting urea leads to the
release of nitrogen and ammonia, increasing the pH of the gastric antrum, one of the mecha‐
nisms that protects the bacteria from the gastric acidity and has a toxic effect on the mucosa.
Bacterial phospholipases can destroy gastric mucosa phospholipids, and acetaldehyde
dehydrogenase production may have also a toxic mucosal effect [59].
5.1.3. Recruitment of inflammatory chemokines and inflammatory cells
H. pylori is a non-invasive bacterium. However, after the initial phase of the colonization, a
dense infiltration of granulocytes begins and it is followed, in the chronic phase, by a pre‐
dominant infiltration of plasma cells and lymphocytes. It seems that signal transduction
pathways must exist in order to induce the recruitment and immigration of inflammatory cells
to the gastric mucosa. Additionally, soluble bacterial products may initiate the inflammatory
cascade [17, 60]. Gastric H. pylori infection is associated to the epithelium release of several
chemokines [60, 61]. Each chemokine is involved in the recruitment and activation of a specific
immune cell. Potential chemoattractants of the CXC chemokine family, IL-8, GRO-α, and
epithelial cell–derived neutrophil-activating protein 78 (ENA-78), are involved in the recruit‐
ment of neutrophils. Members of the C-C family (RANTES, MIP- 1α) have specificity for
monocyte and lymphocyte recruitment. IL 8 expression has been detected in epithelial cells of
antral biopsy and in the supernatant of antral biopsy samples in H. pylori-infected patients [59,
60]. H. pylori induces gastric epithelial cells to increase transcription and secretion of IL 8. TNF-
α has an effect on leukocyte activation, and IL7 has a regulating role on lymphocytes B and T
[59]. Studies state that cytokine levels, with a pro-inflammatory effect, such as IL-6, IL-8, and
TNF-α are higher in H. pylori-positive patients than in H. pylori negative [49]. Among these,
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IL-6 is the most important pro-inflammatory cytokine inductor of the hepcidin gene tran‐
scription through STAT3 (signal transducer and activator of transcription 3) [61, 62]. Hepcidin
is a small peptide hormone primarily expressed in hepatocytes as a propeptide precursor.
Prohepcidin is processed to a bioactive molecule of 25 amino acids, the hepcidin that is secreted
into the blood stream and eliminated in urine. Hepcidin is the most important regulator of
iron homeostasis [63, 64]. The expression of hepcidin is regulated on a transcriptional level by
two principal pathways. The first is the activation of STAT 3. Upon activation, these proteins
are transferred to the nucleus where they activate transcription of the hepcidin gene, binding
to a sequence of DNA. The second is transcription control dependent on the BMP/Smad
pathway, which involves Smad proteins and bone morphogenetic proteins (BMPs). Factors
that can affect the expression of hepcidin are iron, anemia, hypoxia, and inflammation [61-68].
Hepcidin is a negative regulator of a transmembrane protein, ferroportin, which is expressed
on the surface of all cells that release iron in circulation: enterocytes, macrophages, hepatocytes,
and placental cells. Hepcidin regulates ferroportin at a translational level [67]. Under inflam‐
matory conditions, hepcidin reacts as an acute reagent phase, increasing its expression, binding
to ferroportin for tyrosine phosphorylation and also the internalization and ubiquitin-
mediated degradation in lysosomes, resulting in hypoferremia and no iron availability for
erythropoiesis, the hallmark of inflammatory anemia. In 1932, Locke et al. observed that
infection was associated with low serum iron levels [63, 64]. This finding was corroborated by
Cartwright and Wintrobe with the demonstration that anemia associated with infection was
not different from anemia of inflammation, resulting in a pathology known as anemia of
inflammation or chronic disease anemia [63, 68]. On the other hand, H. pylori can subvert
human iron to benefit itself instead of the host, and recently hepcidin has been identified in
the parietal cells of H. pylori-infected patients with an upregulated gastric hepcidin and a
consequent downregulation of ferroportin [63, 67, 69].
5.1.4. Hypochlorhydria
Iron absorption takes place in the small intestine in accordance with the metabolic demands
that reflect the amount of iron stored for erythropoiesis. Haem iron refers to the pool of iron
incorporated in the protoporfirin ring. Its absorption is more effective than non-haem iron and
the mechanisms for absorption are different. HCP 1 (haem carrier protein) is a protein capable
of the transmembrane transport of haem into the lumen of enterocytes to be catabolized by the
microsomal enzyme haem oxygenase. The non-haem iron (Fe3+) is not soluble and is the most
prevalent alimentary iron. Its absorption is dependent on endogenous factors related to its
reduction to a soluble iron form (Fe2+), such as duodenal cytochrome b reductase, and the
ascorbic acid released by gastric cells [70]. Gastric acidity increases the absorption of Fe 3+ in
two ways: (1) the high concentration of hydrogen ions at acidic pH (pH 3 = 1 mM H+) leads to
an efficient competition for metal iron in bindings sites, on dietary components; (2) mecha‐
nisms related with the release of soluble ferric ions only in acidic pH (pH<4) [71]. In 1905, John
Edkins postulated gastrin as the hormone regulator for gastric acid secretion [72]. Sarker et al.
[65] revealed that the basal and stimulated gastric acid was greatly reduced in H. pylori-infected
children compared to non-infected [10, 16, 71]]. The same author revealed, in a study with H.
pylori-infected children of Bangladesh, that this infection was associated to impaired gastric
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secretion. After H. pylori eradication, improved gastric secretion and hemoglobin concentra‐
tion was observed but no influence on iron absorption was verified. Other possible mechanism
such as competition for oral iron and inflammatory disease was considered a possibility. A
study performed by Harris in 105 children, 33 H. pylori positive and 72 H. pylori negative, found
a significantly higher percentage of H. pylori-infected children with a gastric juice pH above
4.0 (6/33, 18%) compared to H. pylori-negative children (6/10, 60%) [70]. While hypochlorhydria
and acute H. pylori infection in adults is well documented, the mechanisms inducting hypo‐
chlorhydria in children are not well understood [8, 10, 16, 70]. H. pylori can induce hypochlo‐
rhydria through increased gastric IL-1β and TNF-α, both in adults and in children, which
inhibits acid gastric secretion, induces parietal apoptosis, and decreases enterochromafin-like
cell histamine release [10, 70]. Capurso et al. [67] demonstrated that H. pylori-infected IDA
patients, with involvement of corporal gastric mucosa, had an important decrease of gastric
acidity (pH>4) with higher intragastric pH and high serum gastrin levels. Serum gastrin is an
indirect marker of atrophic gastritis [11, 12, 73]. As described by Hartmann et al., iron malab‐
sorption can be confirmed by an oral iron challenge. In fast, 2 mg of iron sulfate is adminis‐
trated, and the dosing of iron serum is done before ingestion and then after the first, second,
and third hour. It is considered poor absorption when at the first hour the iron serum level is
<100 µg/ml (Figure 1) [74]. Recently, H. pylori has been implicated in unexplained refractory
IDA to oral iron treatment. This refractoriness may be defined as a failure of the hemoglobin
increase at least 1 g/dL after 2 months of treatment [13]. Celiac disease is the most known
pathology related with malabsorption conditions. AAG, manifested as hypergastrinemia, with
strongly positive antiparietal cell antibodies, was for many years considered a disease of older
people and vitamin B12 deficiency the only possible presentation. The age, gender, and
severity of the disease are determinants for the presentation in microcytic or macrocytic anemia
[11-13]. Although atrophic gastritis may impair both vitamin B12 and iron, the increase in the
iron demands for the observed growth in children and adolescents as well as the menstrual
blood loss in pubescent females, make IDA easier to develop. H. pylori can trigger AAG by a
molecular mimicry between the bacteria and H+ K+-ATPase. In children, a refractory IDA
without evidence of gastrointestinal blood loss implies in first line, non-invasive tests for Celiac
disease (anti-endomysial antibodies IgG and IgA), AAG (serum gastrin in fasting and anti-
parietal cells antibodies), and H. pylori infection (H. pylori IgG antibodies followed by urease
breath test) [11-13]. IDA in the AAG context was described by Faber in 1909 and then com‐
pletely ignored and forgotten. The role of H. pylori in AAG development is not consensual
because of the high prevalence of this bacteria in the world population. However, eradication
of H. pylori in this context is accompanied by a normalization of hemoglobin, iron stores, and
gastrin levels [13, 16, 75].
5.1.5. Low ascorbic acid level
Vitamin C is an acidic molecule with strong reducing activity. Ascorbic acid (AA) is the
reduced form of vitamin C. It is a potent antioxidant, a protector against gastric carcinogenesis,
neutralizing nitrite-derived mutagens. Vitamin C is essentially absorbed and secreted in the
antral mucosa. It has two major redox forms: AA and dehydroascorbic acid (DHA), the reduced
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and oxidized forms, respectively, and interconvertible. Within the cell, DHA is rapidly
converted to AA by the specific enzyme systems, such as DHA reductase, glutaredoxins, and
protein disulfide isomerase, in the presence of glutathione or other thiols as electron donors
[76, 77]. Unlike AA, DHA is relatively unstable and undergoes rapid, spontaneous, and
irreversible hydrolysis particularly at pH>4. Annibale et al. [73] demonstrated that gastric juice
and ascorbate content are negatively affected by H. pylori infection and a normalization of
ascorbate and gastric pH was obtained with eradication therapy [11-13, 78]. In H. pylori–
infected children, a reduced gastric juice ascorbic acid concentration was found, and this effect
was more evident in patients with CagA-positive strains [10, 30, 66, 71, 77]. A Korean study
with the involvement of 452 patients (228 boys, 224 girls) aged 1–15 years revealed a negative
correlation between gastric vitamin C level, H. pylori concentration, and the degree of active
inflammation in antral mucosa. In this group, data showed that vitamin C levels in whole
blood, plasma and gastric juice as well as the intragastric pH were closely related to the severity
of the H. pylori infection and the histological changes in the stomach. These findings suggest
that vitamin C may play a role in determining infection and progression [76, 79]. Studies have
demonstrated that H. pylori produces gastric vitamin C reduction, promoting its degradation
to DHA, a metabolite that may be oxidized at an irreversible form. This is unstable at high pH
values, and thus hypochlorhydria reduces the bioavailability of this vitamin, essential for iron
reduction to ferrous form, which forms an absorbable molecular complex with ferric iron,
insoluble at pH>5 [10, 30, 45, 80]. Baysoy et al. documented a greater decrease in gastric juice
ascorbate in H. pylori-infected patients with CagA-positive strains compared to those with
CagA-negative strains [10, 45, 70, 71]. However, in this group, no association among CagA-
positive strains and IDA has been found.
Figure 1. Oral iron challenge study. At the time, 0.2 mg/kg of elemental iron as ferrous sulfate was given. The expected
normal response range, derived from 24 iron-deficient children but with normal absorption after given an oral dose of
1 mg /kg of elemental iron. Adapted with permission from Hartman and Barker [74]. Copyright ©1996.
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5.1.6. Utilization/sequestering iron by H. pylori
H. pylori, like other pathogenic bacteria, requires iron as a growth factor [8]. However, H.
pylori does not produce siderophores capable of extracting iron from proteins. Potential iron
sources  for  H.  pylori  are  transferrin,  lactoferrin,  ferritin,  hemosiderin,  heme,  and  iron-
containing enzymes [3, 81]. Lactoferrin is a source of iron for H. pylori in gastric mucosa.
Choe et al. reported an abnormal elevated lactoferrin level in the stomachs of 101 adoles‐
cents with unexplained epigastric pain, ID, and H. pylori positive [10, 45, 82, 83]. A concord‐
ance was obtained with studies published by Dogan et al. [83] related to the gastric issues of
61 children with recurrent abdominal pain, 45 of which were H. pylori positive. It is known
that  lactoferrin captures iron from transferrin.  H. pylori  has a  highly specific  lactoferrin-
binding protein. Thus, iron bound to lactoferrin is directed to H. pylori. The bacteria have a
19 KDa iron-binding protein that resembles ferritin, storing the iron, and making it unavail‐
able for erythropoiesis [8, 67].
5.1.7. Inhibitor effect on duodenal mucosa cells
Duodenal mucosa cells are responsible for iron absorption. H. pylori can exert an inhibitor effect
on the duodenal mucosa [8, 10].
5.2. Diagnosis
Symptoms of H. pylori infection in children are non-specific and can include: abdominal pain
after meals, unexplained anorexia, nausea, recurrent vomiting, hematemesis, and IDA. These
symptoms are considered to be of low predictive value. A meta-analysis of 45 studies con‐
cluded that H. pylori infection is not associated with abdominal pain. Therefore, an H. pylori
infection diagnosing test for abdominal pain is not recommended as the first step of investi‐
gation [5, 49, 50, 56, 84]. In contrary, in a briefing for the European Gastroenterology Review,
Mafertheiner et al. recommend that in children with a family history of peptic ulcer and gastric
cancer, a recurrent abdominal pain should be subjected to testing for H. pylori after exclusion
of other causes [49]. Based on the development of a chronic pangastritis with a consequent
achlorhydria and reduced ascorbic acid, interference with iron absorption, occult blood loss
by erosive gastritis or peptic ulcers, competition for the alimentary iron and sequestering by
the bacteria, it seems reasonable to recommend testing for H. pylori infection on unexplained
ID or IDA. Evidence-based guidelines from European Society for Pediatrics, Gastroenterology,
Hepatology and Nutrition (ESPGHAN) and the Group of the North American Society for
Pediatric Gastroenterology (NASPGHAN) in 2011 for IDA in context of H. pylori infection in
children are in accordance with the Canadian Group Consensus Conference in 1999 [5, 49,
50]. They recommend considering diagnostic tests in children with refractory IDA, after the
exclusion of other causes and in children with first-degree relatives with gastric cancer. In 2007,
the American College of Gastroenterology, in their guidelines for the management of H.
pylori infection, questioned this conclusion. Large studies from North America have reported
that H. pylori infection was an independent risk factor for IDA in 688 school-aged children from
Alaska and 7462 children, adolescents, and adults, all from the United States. A recent
unblended study of 219 H. pylori-infected children, aged between 7 and 11 years, also from
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Alaska, with pretreatment ID, found no difference in the likelihood of iron deficiency or anemia
at 2 months or 14 months following a 6-week course of oral iron and antibiotics or no antibiotics.
These data points support an association between H. pylori infection and IDA, but do not prove
cause and effect. On the other hand, most studies refer to a relationship between H. pylori
infection and IDA as well as a normalization with eradication therapy [11-13, 16, 49]. Antibody
tests for H. pylori infection using whole blood, serum, and saliva are not recommended because
of the low prevalence of H. pylori-related diseases in children and low specificity and sensitivity
of the testes [51, 84].
6. Idiopathic thrombocytopenia purpura (ITP)
Immune thrombocytopenic purpura (ITP) is an autoimmune hemorrhagic disease, character‐
ized by isolated thrombocytopenia, which affects nearly 1:25000 children per year [85-87]. ITP
can present itself as an acute, self-limiting condition or a chronic process. Persistent thrombo‐
cytopenia, for longer than 6 months, may be present in about 20% of children [88-91]. A
controversial issue in children is the designation “Chronic immune thrombocytopenia (cITP),”
because about a third of children with ITP spontaneously cure from 6 months to 1 year later
[87-89]. The International Childhood ITP Study Group recommends that 12 months must be
the cutoff point for defining cITP [88, 90]. ITP is characterized by a premature destruction of
platelets. Autoantibodies interact with the glycoprotein membrane on surface platelets (GIIb/
IIIa or GIb), resulting in accelerated platelet destruction and clearance by mononuclear
phagocytes [86, 91-93]. Increased megakaryocyte number in bone marrow is the marker of ITP
in childhood [91]. However, studies performed in 1980 revealed that in two thirds of adults
the expected increase of megakaryocyte production was not observed. Most of ITP had normal
or depressed platelets turnover [87]. Chang et al. evaluated the effect of plasma, from child‐
hood patients with ITP (44 with an acute form and 9 with chronic ITP), on induced throm‐
boietin production of megakaryocytes in liquid culture. They reported that plasma from
pediatric patients with ITP suppressed in vitro megakaryocyte production. They cultured cord
blood cells as a source of CD34+ cells, which is a thrombopoietic growth factor, and plasma
from control subjects or, children with ITP. After 8 days of culture, nearly 16% of cells were
megakaryocytes. The effect of plasma in three groups was compared: control plasma, antibody
ITP plasma (anti-GPIb, anti-GPIIIa, or both). They observed that in cultures with anti-GPIb
antibodies the number of megakaryocytes were strongly reduced but this did not occur in ITP
plasma negative antibody or in ITP plasma with only anti-GPIIb-IIIa antibody [93, 94].
Recently, thrombocyte kinetic studies have been carried out and autoantibodies affecting the
megakaryocytes production in the bone marrow were observed [87, 91, 93, 95]. Also, studies
using electronic microscopy showed 50–75% of ITP megakaryocytes damaged and in some
cases attached by monocytes [96]. In most cases, ITP in childhood is triggered by a previous
viral disease or a vaccination [87, 90]. HIV, hepatitis C, measles, cytomegalovirus, varicella,
pertussis, and parvovirus can all be found in this context [95, 97]. After a benign viral infection,
a predominant proinflammatory state may trigger ITP. Both proinflammatory cytokines and
T-cells persist, creating a permissive environment for the emergence of autoantibodies that
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bind to platelet membrane antigens [91, 93]. Zehnder et al. highlighted an increased expression
of gamma interferon-dependent genes in early states of ITP, supporting a proinflammatory or
TH1 profile [91, 95]. ITP affects both adults and children. However, the natural course of ITP
in children is different from adults. Spontaneous recovery occurs in one third of the pediatric
patients, months or years after the diagnosis. Several studies in adults reported improvement
in platelet counts after H. pylori eradication therapy [91, 98, 99]. Few studies exist related to
children and the ones that do exist have contradictory findings. In a study developed in
Taiwan, Jaing et al. evaluated 22 cITP children H. pylori infected, after one or two courses of
eradication therapy. They found that 55.6% of patients experienced total or partial remission
after an average of 16 months. In the Netherlands, a study carried out by Niefjes et al. evaluated
47 children with cITP, 3 of them H. pylori infected. They were treated with a 2-week course of
triple therapy and after 6 months all of them acquired complete remission. In an Iranian study
by Hamidieh et al., 31 cITP children were evaluated. Four of them were H. pylori infected and
treated with 2 weeks of triple therapy. None of them acquired partial or complete remission.
In Italy, Bisogno et al. evaluated 25 children with cITP. Nine of them were H. pylori infected
and treated with 1–2 courses of 2 weeks of triple therapy. After 6 months, three patients had
an increase in platelet counts and one had remission. This author also reported complete
remission in 16 H. pylori-negative patients. The follow-up of the last 10 H. pylori-negative
patients presented a platelet count above 50×109 without any treatment [10, 45]. Several studies
revealed a widely variable prevalence among different populations according to the countries’
epidemiology. In Finnish populations, H. pylori was not found in any of the 17 pediatric
patients [100]. Turkish children showed H. pylori infection in 11 of 35 children (31%). Japan
reported a prevalence of H. pylori infection in 2 of 10 (2%). Chinese children from northern
Taiwan showed the presence of infection in 9 of 22 (41%) children. The response to the
eradication therapy was not uniform [101, 102]. H. pylori has been implicated in the pathogen‐
esis of several autoimmune diseases [90, 95, 97]. ITP is a typical organ-specific autoimmune
disease. In adult patients with ITP associated to H. pylori infection, eradication therapy has
been associated to an increase in platelet count. The Maastricht Consensus in Florence in 2012
approved, in adults with ITP and H. pylori infection, a similar approach to the one used in those
with IDA associated to H. pylori infection. In the pediatric age group with cITP, diagnosis tests
for identification of H. pylori infection, such as 13C-urea breath test, stool antigen test, or IgG
serology, are not recommended. According to the guidelines described by Peter Mafertheiner,
the recommendation for H. pylori eradication therapy in diseases like idiopathic thrombocy‐
topenia was approved for adults [49].
Several mechanisms by which H. pylori may be associated to ITP have been proposed.
6.1. Possible mechanisms by which H. pylori may be related to ITP
6.1.1. Molecular mimicry
One theory is that cross-reactive antibodies produce reactions with H. pylori components and
platelet glycoprotein through a molecular mimicry [90, 98]. Michael et al. tested platelet eluates
derived from H. pylori-infected patients and found that platelet eluates with the capacity to react
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with GPIIb/IIIa or GPIb failed to recognize any H. pylori antigens [90]. Recently, it was report‐
ed that monoclonal antibodies generated against H. pylori urease B react with GPIIb/IIIa, on
platelet surface, suggesting that cross-reacting antibodies may be present in ITP patients [90].
6.1.2. Binding between H. pylori to von Willebrand factor/induction of platelet aggregation and
apoptosis
Many diseases associated to platelet aggregation have been described as related to H. pylori
infection [90, 101, 103]. Myocardial infarction, coronary heart disease, and stroke are examples
of this prothrombotic condition. H. pylori may trigger both thrombotic thrombocytopenic
purpura (TTP) and ITP by the induction of the interaction among platelets and von Willebrand
factor (vWF). Studies suggested that vWF is essential for platelet aggregation induced by H.
pylori [90, 103]. The mechanisms that lead to platelet aggregation in this infection are well not
understood. Byrne et al. revealed that not all H. pylori strains can promote platelet aggregation
[96]. H. pylori strain 60190 (ATCC49503) induces platelet aggregation through interaction
between H. pylori, its antibody, platelet receptor FcγRIIA (CD32), and vWF and its glycoprotein
receptor (GP)Ib/IX, produced in endothelium and in megakaryocytes (α2 granules) [103]. H.
pylori virulence factors, the Cag pathogenicity island (CagA), and the VacA are responsible for
ITP, but are not related as a cause of platelet aggregation. Platelet apoptosis has also been
described. H. pylori promotes platelet aggregates and platelet apoptosis, which may explain
the decrease in platelet counts in TTP and ITP cases [101, 103]. This may also explain the
remission observed with the eradication therapy in adults. In childhood, contradictory
findings with discrepancy in the response to eradication therapy suggest that in most pediatric
cases ITP is primary, not secondary to H. pylori infection [16, 89].
6.1.3. Modulation in the monocyte/macrophage function
Change in the balance of the Fcγ receptor, related to the activation of monocytes, leads to
increased monocyte function with phagocytosis and autoreactivity of B and T lymphocytes
[16]. H. pylori can be linked to autoantibodies produced by B lymphocytes and to an over
reactivation of innate and acquired immune response against platelets [16, 85, 89]. CD4+ T
helper cells regulate B cells, which release antithrombocyte antibodies [92, 95]. An upregula‐
tion of the genes involved in cell-related toxicity (granzime, perforin) (CD3+ CD8+ T cell) is
observed [92, 104].
6.1.4. Non-specific activation of immune system
The major antigenic component for antibody production against H. pylori is urease. Urease
antibodies initiate autoimmune responses through autoantibodies produced by the activation
of B1 cells [102].
6.2. Genetic characteristics of the patients
Recently, the role of genetic factors has emerged, indicating that H. pylori patients have a lower
frequency of DRB1*03 and a higher frequency of DRB1*11, DRB1*14, and DQB1*03 compared
to H. pylori-negative patients [1, 10, 90, 101].
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Based on the previously mentioned studies and mechanisms described, which lead to ITP in
H. pylori patients, as well as the discrepancy in the response to the triple therapy in pediatric
cases, to treat or not to treat H. pylori-infected children continues to be an unsolved question
[5, 49-51].
7. MALT lymphoma
For the first time, in 1983, Isaacson and Wright introduced the concept of mucosa-associated
lymphoid tissue (MALT), a marginal, extranodal, indolent B-cell non-Hodgkin lymphoma
[105, 106]. Predominantly found in females over the age of 50, it is quite rare in childhood. In
prospective, multicenter NHL-BFM treatment studies performed since 1986, composed of 2703
children, only in 4 (0.1%) MALT lymphoma was found. H. pylori infection was documented in
two out of four of these patients [106, 107]. The clinical pathological manifestation of extranodal
B cell lymphoma is similar to that presented in the MALT. MALT is a system composed of
small concentrations of lymphoid tissue, containing about half the lymphocytes of the immune
system [106]. Situated along the surfaces of all mucosa tissues, its principal function is to
produce IgA against specific antigens on the mucosal surfaces, TH2-dependent reactions, and
TH1 cytotoxic T-cell–mediated reactions, thus resulting in immune tolerance. Gut-associated
lymphoid tissue (GALT), nasopharynx lymphoid tissue (NALT), and bronchus-lymphoid
tissue are the most well-known examples. Also described are conjunctiva-associated lymphoid
tissue (CALT), lacrimal duct–associated lymphoid tissue (LDALT), larynx-associated lym‐
phoid tissue (LALT), and salivary duct–associated lymphoid tissue (DALT) [105-109].
Although MALT sites are separate, they are functionally connected in what is known as the
“common mucosal immune system”. In other words, the antigen presentation and B-cell
activation at one site can result in IgA secretion at another site in a different organ. MALT
tissue contains B and T cells, as well as plasma cells and macrophages. The B-cell component
(MALT) is found in Peyer’s patches, plasma cells of the lamina propria, and in the B-cell
compartment of the mesenteric ganglia. Gastric MALT lymphoma is a clear example of
lymphoid malignancy associated to chronic inflammation [105]. It can occur in the context of
chronic inflammation caused by some infectious agents, such as H. pylori (gastric lymphoma),
Chlamydia psitacii (ocular adnexal lymphoma), and Borrelia burgdorferi (cutaneous lymphoma)
[105]. MALT lymphomas arise in extranodal sites, frequently found in the stomach, lungs,
ocular adnexa, and thyroid as well as a small percentage in the small intestine [105, 108, 110].
In 1991, Wotherspoon et al. demonstrated, for the first time, that primary gastric lymphoma
was associated to H. pylori infection. Later, in 1993, the same author documented regression
of low-grade B-cell gastric lymphoma of MALT in five of six H. pylori-infected patients after
eradication [9, 110, 111]. Two types of MALT lymphoma have been identified: “native MALT
type” corresponding to lymphoid tissue present in the gut and “acquired MALT type”
developed in response to infectious events, such as H. pylori infection or autoimmune diseases
(Sjogren’s syndrome or Hashimoto thyroiditis). The histological feature of MALT lymphoma
is an infiltration of the marginal zone and diffusion into surrounding tissues, as well as the
presence of lymphoepithelial lesions formed by lymphoma cells in individual mucosal glands
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or epithelial structures. MALT lymphoma cells have the same cytological and immunophe‐
notype features (CD20+, CD21+ CD35+, IgM+, and IgD−) found in marginal zone B cells.
Although gastric MALT lymphoma has an indolent course, rarely it can progress to aggressive
high-grade tumors (extra-nodal large B cell lymphoma—eDLBCL) and, consequently, a drop
in the survival rate from 90 to 40 %, respectively [105].
7.1. Pathogenesis and H. pylori
Gastric MALT lymphoma results from a multistage process that begins with the H. pylori
infection and consequent recruitment of B and T cells [105, 112, 113]. The decrease in gastric
acidity  caused by the  urease  secretion triggers  the  lymphocyte  infiltration and thus  the
establishment of MALT. B-cells are stimulated by H. pylori T-specific cells, acquires genetic
abnormalities forming clones,  possibly by trisomy 3,  becoming H. pylori-dependent low-
grade lymphoma [112,  114].  It  has  been demonstrated that  lymphatic  follicles,  normally
absent in the gastric mucosa, can appear, and consequently, configure the MALT after an
inflammatory process [47]. H. pylori  virulence factors seem to be crucial for the develop‐
ment of gastric lymphoma. CagA-positive strains are frequently related to a more aggres‐
sive  lymphoma (eDLBCL)  [115].  H. pylori  can translocate  the  CagA protein  into  B-cells,
inducing extracellular signal-regulated kinase activation and promoting upregulation of Bcl-2
expression, resulting in the inhibition of apoptosis. Otherwise, H. pylori can induce genetic
mutation leading to the transformation of a normal B-cell to a malignant clone. The most
frequent  genetic  mutations  detected  are  t(11;18)(q21;q21),  t(1;14)(p22;q32),  and  t(14;18)
(q32;q21)  involved in  the  activation of  nuclear  factor-κB (NF-κB),  which plays  a  role  in
immunity, inflammation, and apoptosis [47, 113]. It has been found that positive CagA strains
were higher in patients with t(11;18)(q21;q21) compared to those without such transloca‐
tion (93.3 vs. 51%; P=0.01) [47, 114]. The transformation of low grade to high-grade lympho‐
ma is rare in children, but it is documented in adults [107]. Normally, MALT lymphoma is
a very indolent disease, localized for long periods of time. Systemic dissemination occurs in
a  few  cases.  In  a  large  multicenter  study  of  93  patients  with  low-grade  gastric  MALT
lymphoma in southern Switzerland and northern Italy, 49 H. pylori-infected patients with
stage I of the disease. Eradication therapy was given in 97% of patients, and histological
regression of MALT lymphoma was acquired in 67% of patients [114, 115]. The median time
to achieve histological regression was 5 months (range 3–18 months). International guide‐
lines recommend H. pylori eradication therapy in MALT lymphoma [5, 49, 50].
8. Diagnostic tests for H. pylori
Published consensus developed guidelines for the management of H. pylori infection in
children. In 2000, ESPGHAN, and after NASPGHAN, published recommendations for H.
pylori infection treatment [49, 51]. In 2004, the Canadian Helicobacter Study Group included
consensus about how to approach H. pylori infection in children [5].
About testing H. pylori infection, questions must be asked in this age group:
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Who should be tested? What tests should be used? Testing for H. pylori should be performed
if a positive result is expected. A test and treat strategy is not recommended in children. The
methods of diagnostic tests for H. pylori infection may be divided into two categories: invasive
and non-invasive tests [5, 49-51].
8.1. Invasive tests
Invasive tests require a gastric endoscopy and a biopsy with culture for detecting H. pylori [116,
117]. They are the only tests considered to be 100% specific. The hematoxylin–eosin (HE) stain
usually shows H. pylori strains [114, 118]. Nevertheless, when the results are inconclusive, there
are at least two different stain techniques to be used on biopsied tissue: HE to evaluate
inflammatory cells and Giemsa or Genta stain to detect H. pylori. Although the Genta stain due
to a combination between a silver stain, HE and Alcian blue can visualize both inflammatory
cells and H. pylori strain with higher accuracy, this formulation is technically complex. In
contrast, the Giemsa stain is technically simple, highly sensitive, and inexpensive [117, 119].
8.1.1. Rapid urease test (RUT)
RUT identifies H. pylori through urease activity of the bacteria in gastric mucosa [120, 121].
Gastric biopsies are obtained and placed into an agar gel on a reaction contained urea, a buffer,
and a pH-sensitive indicator. In presence of H. pylori, urea is metabolized to ammonia and
bicarbonate leading to an increase of gastric pH, with changing in color [8, 117, 118]. The low
cost, the simplicity, and rapid results make this test practical and effective, as long as the patient
has not taken proton pump inhibitors or antibiotics. Medication that reduces the density of
bacteria can decrease the sensitivity of the RUT up to 25%. Therefore, proton pumps and
antibiotics must be not taken 1–2 weeks before the procedure [5, 49-51]..
8.1.2. Histology
Histology is considered a standard method for detecting H. pylori infection. The sensitivity
and specificity vary according to the site, number, and size of the biopsies, and also the
experience of the pathologist [82, 117, 118]. False results can be obtained with a low densi‐
ty of bacteria. In these cases, multiple biopsies are needed. The majority of gastroenterolo‐
gists obtained only biopsies of the antrum [122]. Recent studies revealed that the addition of
corpus biopsies to antral biopsies increase the probability of H. pylori  identification in all
infected patients [50, 51, 117, 118].
8.1.3. Cultures
Cultures method has high specificity for the diagnosis of H. pylori infection, normally unnec‐
essary for routine the diagnosis of H. pylori. The principal indication is testing for antimicrobial
sensitivity in order to choose the appropriate antibiotic. Cultures are expensive and not as
sensitive as RUT or histology and not available in many clinical laboratories [119, 120].
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8.1.4. Polymerase chain reaction
PCR is a DNA amplification that uses the rapid production of a target DNA sequence to
identify H. pylori. It is capable of identifying H. pylori strains in biopsies with chronic gastritis
and non-identifiable bacteria. PCR can be performed on samples obtained by invasive and
non-invasive methods using samples obtained of saliva, gastric juice, and stools [82, 119]. It is
simple to perform and can provide additional genotypic information about the strain and
antibiotic susceptibilities. PCR could be complete in 3–4 hours, and it is capable to detect the
point mutations attributed to the development of clarithromycin resistance [119, 123].
8.2. Non-invasive tests
Although the gold standard method for diagnosis is gastric histology and rapid urea test, an
important disadvantage is their invasiveness. Non-invasive tests, such as urea breath test
(UBT), serology, and more recently, fecal H. pylori antigen, have been developed and all of
them are feasible in children [50, 119].
8.2.1. Urea breath test (UBT)
UBT is one of the preferred tests to diagnose active H. pylori infection [5, 124]. It is based on
hydrolyses of urea to ammonia and carbon dioxide, which diffuses into the blood and is
excreted by the lungs. Since it requires the child’s full cooperation, it is difficult to perform in
children, especially toddlers and physically challenged [50]. This test is based on the ingestion
of urea labeled with either non-radioactive isotype (C13) or radioactive isotype (C12). The first
is preferred in children [5]. Labeled urea is dissolved in orange juice without sugar, given in
fasting, and the primary objective is to validate C13 in children and adolescents. The ratio in
exhaled air is measured at 0 and then 30 minutes after the intake, and the test is considered
positive when the difference between these two ratios exceeds 4‰ (cut-off value) [124].
Antibiotics must be withheld at least 28 days and proton pump inhibitor (PPI) for 7–14 days
before UBT [5, 82, 124].
8.2.2. Antibody test
The IgG-specific H. pylori antibodies are present in blood nearly 21 days after the infection and
can persist for a long time after eradication therapy. With a sensitivity of 85% and specificity
of 79%, they are not adequate for documenting H. pylori eradication [6, 50].
8.2.3. Fecal antigen test
The fecal antigen test (FAT) identifies H. pylori in stool by enzyme immunoassay (EIA) based
on polyclonal or monoclonal antibodies, and immunochromatographic tests, so-called rapid
or quick tests. The first commercial EIA test to detect H. pylori antigen in stool was the Premier
Platinum HpSA based on polyclonal antibodies. These tests have a wide range of sensitivity
and specificity both in pretreatment (86, 90–98%) and post-treatment (89, 91–92, 95%) [51]. The
stool antigen tests using polyclonal antibodies demonstrated variable results and seem to have
less accuracy than those using monoclonal antibodies. This diagnostic approach is convenient
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simple to perform and can provide additional genotypic information about the strain and
antibiotic susceptibilities. PCR could be complete in 3–4 hours, and it is capable to detect the
point mutations attributed to the development of clarithromycin resistance [119, 123].
8.2. Non-invasive tests
Although the gold standard method for diagnosis is gastric histology and rapid urea test, an
important disadvantage is their invasiveness. Non-invasive tests, such as urea breath test
(UBT), serology, and more recently, fecal H. pylori antigen, have been developed and all of
them are feasible in children [50, 119].
8.2.1. Urea breath test (UBT)
UBT is one of the preferred tests to diagnose active H. pylori infection [5, 124]. It is based on
hydrolyses of urea to ammonia and carbon dioxide, which diffuses into the blood and is
excreted by the lungs. Since it requires the child’s full cooperation, it is difficult to perform in
children, especially toddlers and physically challenged [50]. This test is based on the ingestion
of urea labeled with either non-radioactive isotype (C13) or radioactive isotype (C12). The first
is preferred in children [5]. Labeled urea is dissolved in orange juice without sugar, given in
fasting, and the primary objective is to validate C13 in children and adolescents. The ratio in
exhaled air is measured at 0 and then 30 minutes after the intake, and the test is considered
positive when the difference between these two ratios exceeds 4‰ (cut-off value) [124].
Antibiotics must be withheld at least 28 days and proton pump inhibitor (PPI) for 7–14 days
before UBT [5, 82, 124].
8.2.2. Antibody test
The IgG-specific H. pylori antibodies are present in blood nearly 21 days after the infection and
can persist for a long time after eradication therapy. With a sensitivity of 85% and specificity
of 79%, they are not adequate for documenting H. pylori eradication [6, 50].
8.2.3. Fecal antigen test
The fecal antigen test (FAT) identifies H. pylori in stool by enzyme immunoassay (EIA) based
on polyclonal or monoclonal antibodies, and immunochromatographic tests, so-called rapid
or quick tests. The first commercial EIA test to detect H. pylori antigen in stool was the Premier
Platinum HpSA based on polyclonal antibodies. These tests have a wide range of sensitivity
and specificity both in pretreatment (86, 90–98%) and post-treatment (89, 91–92, 95%) [51]. The
stool antigen tests using polyclonal antibodies demonstrated variable results and seem to have
less accuracy than those using monoclonal antibodies. This diagnostic approach is convenient
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for children in whom it is easy to collect feces [117]. Nguyen et al. evaluated the sensitivity
and specificity of monoclonal enzyme stool antigen assay for diagnosis of H. pylori in 232
children age range 3–5 years H. pylori infection positive by culture from biopsies. They found
a sensitivity of 96% and a specificity of 94.8% [125, 126]. FAT can be used to screen for infection
before and after treatment [50, 82, 117]. It is considered as acceptable as UBT and is not
dependent on the child´s collaboration. Recent studies indicate that FAT can be done as early
as 14 days after treatment, but should be done more than 4 weeks [50].
Note: PPI must be withheld two weeks before performing RUT, UBT, and FAT [49, 51]
9. Treatment
The goal of treatment is to obtain 90% eradication. The therapeutic regimens are variable and
dependent on local resistance data. Several studies have documented high resistance to
clarithromycin and metronidazole [127]. The first treatment commonly administered in
children and adults is a triple therapy, for 14 days, that includes a PPI and two antibiotics,
amoxicillin and metronidazole or clarithromycin [49-51, 127]. The first line of recommended
eradication therapies are as follows: amoxicillin, 50 mg/kg twice a day for 14 days; clarithro‐
mycin, 15 mg/kg/twice daily for 14 days; and PPI, 1 mg/kg twice daily for 1 month. Alterna‐
tively, amoxicillin, 50 mg/kg twice a day for 14 days; metronidazole, 20 mg/kg twice daily for
14 days; and PPI, 1 mg/kg twice daily for 1 month or clarithromycin, 15 mg/kg/twice daily for
14 days; metronidazole, 20 mg/kg twice daily for 14 days; and PPI, 1 mg/kg twice daily for 1
month [50]. Several studies revealed that the use of probiotics improves the treatment
tolerance, but there is no evidence of higher eradication [82]. Koletzko et al. [122] revealed a
rate of resistance to clarithromycin of 20%, and a rate of resistance to metronidazole of 23%
after a first treatment [82, 127]. In Portugal, a higher clarithromycin resistance rate was reported
in children (44.8%) compared with adults (14.8%) [127]. The main factors for triple therapy
failure are the low compliance and the bacteria’s resistance to antibiotics. The risk for clari‐
thromycin resistance is related with the previous consumption of macrolides, which is
substantially prescribed in children for respiratory tract diseases. Double resistance strains
were found in up to 50% of strains after failure of therapy using both clarithromycin and
metronidazole [128]. The failure after the first therapeutic approach is predictive of resistance
to other therapeutic approaches [50, 51, 128]. NASPHGAN recommend, in case of failure in
the first line of treatment in children, and if possible, to perform culture with testing for
antibiotic sensitivity to guide a second-line therapy. Other options may be taken if a H.
pylori culture is not possible: quadruple therapy composed of PPI + metronidazole + amoxicillin
+ bismuth, triple therapy using fluoroquinolones, but of limited indication in children, or
sequential therapy involving dual therapy with PPI and amoxicillin for 5 days followed
sequentially by 5 days of triple therapy with PPI, clarithromycin, and metronidazole/tinida‐
zole. In 2005, 74 children (randomized) received sequential therapy and triple therapy.
Eradication was 97.3% in those with sequential therapy compared with 75.7% in children with
triple therapy [51].
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10. Conclusion and possibilities of new studies
Approximately 50% of the world’s population is H. pylori infected. Although it has been a part
of human microbiota, it is classified by The World Health Organization as a gastric carcino‐
genic. H. pylori is acquired essentially in childhood and through mechanisms of escape, it
persists in gastric mucosa for life if left untreated. An association has been found between H.
pylori infection and poverty, low socioeconomic conditions, poor hygiene, and nutritional
deficiencies. With higher prevalence in developing countries, the predisposing factors are the
high number of residents in the same home, sharing the same room or the same bed with H.
pylori-infected children, as well as poor sanitary conditions. Hematological extragastric
disorders have been described as being associated to H. pylori infection. Unexplained ID, IDA,
and refractory IDA in childhood are the most well-known pathologies related to H. pylori
infection. Two meta-analysis have supported the association between H. pylori infection and
IDA, showing an increase of hemoglobin levels after H. pylori eradication [10, 45]. Many areas
of the world have high prevalence of both H. pylori infection and IDA. ID in children leads to
major consequences on children’s health and neurodevelopment. Associations have been
reported, in children, between IDA, lower intelligence scores or cognitive functioning in tests,
and behavioral delays in children, showing that treatment can improve these outcomes [127,
129]. As a result, Update of US Preventive Services Task Force (USPSTF) and the Center for
Disease Control and Prevention recommend screening for IDA in children aged 6–24 months,
between 9 and 12 months, 6 months later, and then annually from the ages of 2 to 5 years,
respectively, and to treat the ID by prescribing 3 mg/kg/day of iron drops between feedings
[129-131]. Refractory to iron therapy implies, after the exclusion of ingestion deficiencies,
hemorrhage, absorption problems, and (rarely) metabolic abnormalities, the search for H.
pylori infection using in the first line non-invasive tests (UBT, FAT, and specific IgG H. pylori
antibodies). All non-invasive tests are feasible in clinical use. C13UBT, with a good sensitivity
for the diagnosis of H. pylori infection, shows limitations such as low specificity for very young
children, being affected by previous ingestion of antibiotics or PPI and the requirement of
patient cooperation [49-51]. Stool antigen test shows low sensitivity and good specificity in
children of all ages, limited also by PPI and antibiotics. It is advisable to validate two non-
invasive tests, the C13UBT and stool antigen for the diagnosis of H. pylori infection in pediatric
ages. Serology is based on the immunological response to chronic H. pylori gastric inflamma‐
tion and is not dependent on antibiotics or on the loading of gastric bacteria. International
Guidelines are well defined regarding IDA in the context of H. pylori infection in childhood,
in which eradication therapy is indicated as it is done in adults. Consensus about the approach
of cTPI and H. pylori infection is well defined in adults, in which H. pylori eradication is followed
by platelet recuperation. In childhood, there is no evidence to support a relationship between
this infection and cTPI. Reports about prevalence of H. pylori and TPI seem to be according to
the epidemiological data of the countries. Contradictory findings with discrepancy in the
response to eradication therapy suggest that in most pediatric cases ITP is primary, with a
spontaneous cure from 6 months to 1 year later, and not secondary to H. pylori infection [87-89].
Maastricht IV and other guidelines suggest not searching for or treating H. pylori in this context.
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Gastric MALT lymphoma is a lymphoid malignancy that is quite rare in children. In these
cases, eradication therapy must be performed regardless of the stage of lymphoma. The failure
of H. pylori eradication is predictive of a resistant strain acquisition and also predictive of
subsequent therapeutic failure. A primary H. pylori resistance in children of European
countries has been estimated and ranges from 12.45 to 23.5% [128]. Therefore, clarithromycin-
based triple therapy can be recommended after studies of antibiotic susceptibility or in
countries with low resistance to clarithromycin. The high resistance of H. pylori to clarithro‐
mycin can justify the use, as first-line therapeutic approach in children, of the sequential
therapy which was referred, resulting in eradication rates of 97.3% against 75.7% with triple
therapy [49, 51]. In children, there are particular problems with alternative antibiotics, which
are not approved for the age. Therefore, they are often treated multiple times without cure.
The impact of this infection on public health implies applying active measures toward H. pylori
eradication. A vaccination strategy should be implemented as the best option to eliminate H.
pylori and therefore to improve public health.
11. New studies
Several new antibiotics are under investigation for the treatment of H. pylori in adults. (1)
Rifabutin. Triple therapy for 10 days with rifabutin + pantoprazole + amoxicillin is showing
good results in resistant H. pylori areas. Resulting in eradication rates of 50% [82, 132]; (2)
Nitazoxanide that includes levofloxacin, nitazoxanide, doxycycline, and omeprazole is
showing better efficacy than standard triple therapy [133].
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Abstract
Iron is an essential element for all living organisms. Iron metabolism is mainly
controlled by its absorption. Iron deficiency (ID) is the most common nutritional
deficiency, causing important clinical outcomes. One of the most common results of
ID is iron deficiency anemia (IDA). The ID results from increased physiological needs,
blood losses, inadequate intake, and diminished absorption. Helicobacter pylori (H.
pylori) infection is one of the important causes of IDA, especially in undetermined and
refractory cases.
In the literature, case series, sero-epidemiological studies, and meta-analyses showed
robust evidence about the relationship between IDA and H. pylori. Several mecha‐
nisms have been proposed for IDA in H. pylori infection. In this chapter, we review
clinical evidence regarding the relationships between H. pylori and IDA, iron
metabolism, possible mechanisms of IDA in H. pylori infection, factors involved in
IDA development in H. pylori infection, and IDA management in H. pylori infection.
Keywords: Helicobacter pylori,, iron deficiency anemia, hepcidin
1. Introduction
Iron (Fe) is an essential element for hemoglobin synthesis, oxidation–reduction reactions, and
cellular proliferation. The term iron deficiency (ID) describes a deficit in total body iron,
resulting in reduction of serum ferritin levels below normal limit [1]. ID is the most frequent
nutritional deficiency worldwide.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
ID is associated with impaired cognitive function, diminished work productivity, and
behavioral problems in adults and children. In pregnant women, ID has been linked with
increased risk for low birth weight, prematurity, and maternal morbidity [2].
Iron deficiency anemia (IDA) is defined as low hemoglobin and plasma ferritin values caused
by further decrease in iron stores. IDA is the most common form of anemia worldwide with a
prevalence varying from 2% to 8% in developed countries. IDA may occur at all stages of the
life cycle, but it is more prevalent in mothers and young children [3].
The known causes of ID are inadequate dietary intake, increased physiological needs as seen
in pregnancy and children during rapid growth, increased losses such as bleeding or hemol‐
ysis, and diminished iron absorption as seen in celiac disease and chronic inflammatory
diseases [4, 5]. Because IDA can result from both physiological and pathological events, the
etiology underlying IDA should be determined. The exact cause could not be identified in 20%
of cases, despite all routine examinations including gastrointestinal endoscopy and serologic
markers for celiac disease [3].
Helicobacter pylori (H. pylori) infection has been proven as a cause of IDA, especially in unde‐
termined cases. Exact mechanism for IDA in H. pylori infection is still unclear. However, several
mechanisms have been proposed to explain the relationship between H. pylori infection and
IDA, including gastrointestinal bleeding and bacterial competition for dietary iron and
subversion of the human iron regulatory mechanism [6]. In this chapter, we review clinical
evidence regarding the relationship between H. pylori and IDA, iron metabolism, possible
mechanisms of IDA in H. pylori infection, factors involved in the development of IDA in H.
pylori infection, and IDA management in H. pylori infection
2. Clinical evidences on the relationship between iron deficiency anemia
and H. pylori
The relationship between H. pylori and IDA was first described by Blecker et al. in 1991. Authors
described a 15-year-old patient with IDA due to H. pylori-positive chronic active hemorrhagic
gastritis without prior gastrointestinal manifestations. Hemoglobin value and serum ferritin
level of the patient returned to normal limits unless administration of supplementary iron,
after the infection was eradicated [7]. Subsequently, Bruel et al. in 1993 reported a second IDA
case (hemoglobin 5.6 g/dL) in an 11-year-old child with H. pylori infection complicated with
severe digestive hemorrhage. The anemia resolved after the eradication of the H. pylori
infection without iron replacement [8]. In the same year, the first case with refractory IDA
without the symptomatic gastrointestinal pathology was reported in a 7-year-old child by
Dufour et al., in which H. pylori infection was diagnosed. After the infection was eradicated
without supplementary iron treatment, improvement in hematological parameters was
observed on month six [9].
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Following above-mentioned reports [7-9], further isolated case reports were published in both
adolescents and adults in the literature during the 1990s, indicating an association between
IDA and H. pylori with therapeutic response after H. pylori eradication [10-13].
These preliminary case series in the literature encouraged the epidemiologic studies regarding
the association between H. pylori and IDA. While some studies showed an association between
H. pylori and IDA among women [14], the other studies showed differences in serum iron levels
among H. pylori-infected men [15]. In another large cross-sectional study, it was found that H.
pylori infection was associated with reduction in serum ferritin levels and that this association
seemed stronger among adolescents and women at childbearing age [16]. Most epidemiologic
studies had cross-sectional design. However, national health surveys enhanced the results of
previous reports. Among these, a German study [17] on adult population found a decrease in
serum ferritin levels by 16% in individuals infected with H. pylori [17]. In addition, children
and adolescents were also studied in population-based surveys in South Korea [18-20].
Likewise, these studies showed an association between H. pylori and ID. A recent German
study on pregnant women reported an association between current H. pylori infection and
hemoglobin levels [21].
In this category, the largest study was conducted on 7,462 participants aged >3 years from the
1999–2000 National Health and Nutrition Examination Survey (NHANES). The study showed
that H. pylori infection diagnosed by serology is associated with an increase by 40% in the
prevalence of ID in the United States [22].
Finally, meta-analyses have supported the association between H. pylori infection and IDA
[23-27]. Furthermore, resolution of iron deficiency anemia has been shown following the
successful eradication of H. pylori [26].
All these publications have supported the relationship between H. pylori and IDA.
3. Regulation of iron balance
Steps in iron metabolism and contributing molecules are important for understanding effect
of H. pylori infection on IDA.
Body iron metabolism is a semi-closed system and is critically regulated by several factors.
The total amount of body iron is approximately 3–4 g. Two thirds of iron is found in the pool
of red blood cell (RBC) and recycled by RBC destruction; the remainder is stored. Only 1–2 mg
of iron is absorbed from intestinal tract and circulated in the blood. Since, there is no active
mechanism to excrete iron from the body, iron balance is controlled by absorption [1].
Nearly all absorption of dietary iron occurs in the duodenum. Steps involved in iron metab‐
olism include the reduction of iron into a ferrous state (Fe2+), apical uptake, intracellular storage
or transcellular trafficking, and basolateral release. Several proteins play a role in these steps
[Table 1].
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Table 1. Proteins Involved in Iron Metabolism
Dietary iron is found in two forms; heme iron (10%) that is derived from meat and bound to
hemoglobin (Hb) and myoglobin and nonheme iron (90%) that is ionic and inorganic in form
derived from plants (Figure 1). Both iron forms are absorbed at the apical surface of duodenal
cells through different mechanisms.
Nonheme iron taken on a diet presents initially in oxidized (ferric-Fe3+) form. This form of iron
is not bioavailable, and before it is absorbed by an enterocyte it needs to be reduced to the
Fe2+ form via ferri-reductase enzyme [28]. Fe3+ reduction is optimized by low gastric pH. Gastric
acid, dietary ascorbic acid, and luminal reductases enhance the iron absorption [29]. Iron is
transported across the intestinal epithelium by a transporter called divalent metal transport‐
er-1 (DMT-1) that also transports other metal ions by a proton-coupled mechanism [30] (Figure
1). There is also a siderophore-like iron uptake pathway mediated by lipocalin-2 that seems to
exert an innate immune response against bacterial infection by sequestrating iron. However,
physiological role of lipocalin-2 has not been fully elucidated.
Heme iron is better absorbed than nonheme form. Heme iron is absorbed into enterocytes by
heme carrier protein-1 that is a membrane protein found in the proximal intestine [31] (Figure
1). Heme iron is degraded by hemeoxygenase-1 (HO-1) within enterocyte [32] (Figure 1).
In the intestinal epithelial cell, iron can follow two pathways. Firstly, it may remain in the cell
to be used or stored. This iron is excreted when intestinal cells demise and are molted into the
lumen. Secondly, iron is transported into circulation from basolateral membrane of the
enterocyte. This part is called absorbed iron. Ferroportin-1 is the sole supposed iron exporter
that has been defined so far. Fe2+ is transported from the basal membrane via ferroportin-1;
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thereafter, it is oxidized into Fe3+ by a multi-copper-oxidase protein called hephaestin, an
enzymatic protein similar to plasma ceruloplasmin, before being bound by plasma transferrin
(Tf). Ferroportin-1 is also the putative iron exporter in macrophages and hepatocytes [1, 28].
Iron absorption, mediated by two models, is up-regulated by iron deficiency and increased
erythropoiesis or down-regulated in inflammation and iron repletion. These two models can
be entitled as crypt programming model and the hepcidin model.
The crypt programming model: The intracellular iron level of the duodenal crypt cells
intercommunicate with the iron deposits of the body, which, in turn, establishes the amount
of iron absorbed from the intestinal lumen. The crypt cells express both transferrin receptor-1
(TfR1) and TfR2. The cellular uptake of Tf-bound iron from plasma is mediated by these
receptors [28, 33].
TfR1 is expressed pervasively and Tf-mediated iron uptake is proposed to take place in
majority of the cell types. Despite that, expression of TfR2 is limited in hepatocytes, duodenal
crypt cells, and erythroid cells, suggesting a more privatized mission in iron balance.
Iron regulatory elements (IREs) act as iron sensors and regulate translation or stability of
mRNA-encoding proteins. The intracellular iron level commands the interaction of IREs with
cytosolic iron regulatory proteins (IRPs) 1 and 2. In the absence of iron, IRP1 binds to IREs of
TfR1, DMT-1, and ferroportin-1 mRNA; then, syntheses of these proteins begin in the duode‐
num and dietary iron absorption is increased. Thus, increased IRP-binding activity represents
decreased body iron stores [28].
Figure 1. Regulation of Iron Balance
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The hepcidin model: Liver hepcidin is a 25-amino-acid cysteine-rich peptide. Numerous
factors contribute to the regulation of hepcidin level. Liver iron levels, inflammation, hypoxia,
and anemia can be counted among these factors. Hepcidin regulates the rate of iron absorption
by controlling the expression of ferroportin-1 at basolateral membranes of enterocytes.
Internalization of ferroportin-1 and loss of its function occur after the binding of hepcidin to
ferroportin-1. Ferroportin-1 molecules take place also in macrophages and liver. Hence, it is
suggested that iron release from intestinal crypt cells, liver, and macrophages is reduced, when
hepcidin levels are increased in iron overload or inflammation (via IL-6). In contrast, it is likely
that ferroportin-1 expression and iron release is increased when hepcidin levels are reduced
as is the case in ID, anemia or hypoxia [34].
Iron released into the circulation binds to Tf and is transported to sites of use and storage.
Three forms of Tf can be found in plasma: apo-transferrin that contains no iron, monoferric-
transferrin, and diferric-transferrin. About 30–40% of these iron-binding Tf sites are occupied
under normal physiological conditions. Tf-bound iron is the most important dynamic iron pool
[35]. Tf-bound iron enters into target cells, mainly erythroid cells, but also immune and hepatic
cells via a process of receptor-mediated endocytosis [28]. Tf binds to receptor, which is called
TfR and located on the plasma membrane. Siderosomes, clathrin-coated endosomes, are
formed by invagination of Tf and receptor–ligand complexes at the cell-surface membrane [35].
After that, the siderosomes are acidified by an ATP-dependent proton influx. This process
leads to conformational changes in Tf and TFR1, and promotes iron release of Fe3+ from Tf.
Then, Fe3+ is converted to Fe2+ through a ferri-reductase and moved to the cytoplasm by the
DMT-1, while the TfR is appraised at the cell membrane again and Tf is drained back to the
circulation [28, 36]. Production of hemoglobin by the erythron accounts for most iron use.
High-level expression of TfR1 in erythroid precursors ensures the uptake of iron into this
compartment.
Hemoglobin iron has an important cycle, as aging erythrocytes undergo phagocytosis. In the
phagocytic vesicles of reticuloendothelial system macrophages, heme is metabolized through
heme oxygenase-1 (HO-1). Then, iron is released to the cytoplasm by natural-resistance-
associated macrophage protein-1, a transport protein similar to DMT-1. Macrophages are also
able to gain iron from other apoptotic cells and bacteria [1]. Iron is stored in two forms in the
cell: as ferritin in the cytosol and as hemosiderin originated from degradation of ferritin within
the lysosomes. Hemosiderin is a very small part of body iron stores. It is found mostly in
macrophages and increases in iron overload [35]. Iron export from macrophages to Tf is
accomplished primarily by ferroportin-1, the same iron-export protein expressed in duodenal
enterocytes, and hephaestin [28] (Figure 1). The amount of iron required for daily production
of 300 billion RBCs (20–30 mg) is mostly provided by recycling of iron by macrophages [1].
The liver is a major storage organ of iron, in which excess iron is stored as ferritin and
hemosiderin. The uptake of Tf-bound iron by the liver from plasma is mediated by TfR1 and
TfR2. In iron overload states, Tf is saturated and redundant iron is found in the form of non-
Tf-bound iron. This form of iron is transported along with the hepatocyte membrane through
a carrier-mediated process compatible with DMT-1. The hepatocytes can also warehouse iron
as ferritin, hemoglobin–haptoglobin complexes, and heme–hemopexin complexes. Whereas,
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ferroportin-1 is known to be the only protein that mediates the iron transport from hepatocytes.
Iron is oxidized by ceruloplasmin and attached to Tf after being released from hepatocytes [1,
28] (Figure 1).
Iron is also found at mucosal surfaces as lactoferrin. In addition to these proteins, an additional
fraction of free iron is present in the form of the labile iron pool within cells.
4. Possible mechanisms of iron deficiency in H. pylori infection
The mechanisms by which H. pylori infection contributes to IDA remain unclear. Several
studies have suggested different biologic mechanisms by which infection with H. pylori may
induce depletion in the iron stores of the host. Four explanations can be posted: 1) overt or
occult blood loss due to gastroduodenal lesions [37]; 2) decreased iron absorption due to hypo-
or achlorhydria [38]; 3) increased iron consumption by H. pylori [39]; and 4) iron sequestration
into the gastric mucosa [40,Table 2].
Mechanism Findings






Malabsorption of iron Atrophic gastritis
Reversible hypoclorhydria





Mislocalization of transferrin receptor
Table 2. Possible Mechanisms of Iron Deficiency in Helicobacter pylori Infection
4.1. Blood loss from gastrointestinal lesions
Blood loss is the most important cause of iron deficiency in adults. Each milliliter of blood loss
(if Hb is 15 g/dL) results in loss of 0.5 mg of iron approximately. Gastrointestinal blood loss is
the most important cause in postmenopausal women and men. While menstrual blood loss
commonly causes IDA in premenopausal women, coexistent gastrointestinal lesions have
often been identified [3].
IDA resulting from gastrointestinal bleeding is a common feature of many gastrointestinal
conditions. The most common cause of upper gastrointestinal bleeding is peptic ulcer bleeding,
which is responsible for about 50% of all cases, followed by esophagitis and erosive disease [41].
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H. pylori infection is associated with both duodenal and gastric ulcer disease. Subjects infected
with H. pylori have an average lifetime risk of 10–20% for the occurrence of peptic ulcer disease.
This risk is at least three- to fourfold higher than in noninfected individuals. The bacteria can
be determined in 90–100% of subjects with duodenal ulcer and in 60–100% of subjects with
gastric ulcer. Individuals infected with bacterial strain producing a cytotoxin, or owning
cytotoxin-associated gene A (cagA), have a higher risk of development of peptic ulcer disease.
Other factors affecting the risk of peptic ulcer disease in infected individuals are amount of
gastric acid production, gastric metaplasia in the duodenal bulb, smoking, and genetic factors
(e.g., blood group O and lack of the secretor gene) [42]. Testing for H. pylori is recommended
in all patients with peptic ulcer bleeding [43]; eradication therapy for those who are H. pylori-
positive and then evaluation of the effect of this therapy. Retreatment with subsequent regimen
should also be considered in the patients who had eradication failure. The effectiveness of
eradication treatment and maintenance antisecretory therapy for the prevention of rebleeding
has been evaluated in several studies. A meta-analysis showed that H. pylori eradication group
had significantly decreased risk of rebleeding; even when only patients with successful H.
pylori eradication were evaluated, the rebleeding rate was found significantly lower [44]. Thus,
confirmation of eradication should be tested. Diagnostic tests for H. pylori have a low negative
predictive value in case of active bleeding [45]. Thus, initial negative results on biopsies
obtained in the acute setting should be judged with caution and repetition of the test during
follow-up is recommended [43].
Gastric carcinoma is also one of the important causes of gastrointestinal bleeding accounting
for nearly 4–8% of all cases [46]. The most common histopathological features of gastric
malignancies are adenocarcinoma and lymphoma of mucosa- associated lymphoid tissue
(MALT). Approximately 90% of gastric tumors are adenocarcinoma, whereas gastric MALT
lymphomas are considerably less common (approximately 3% of all gastric tumors) [47]. H.
pylori infection plays an important carcinogenic role in both gastric carcinoma and MALT
lymphoma [48]. It has been calculated that the risk for gastric adenocarcinoma and MALT
lymphoma is three- to sixfold higher in H. pylori-infected individuals than those who are
noninfected [47]. Because of the strong association between gastric cancer and H. pylori
infection, the World Health Organization (WHO) classified H. pylori as a class I carcinogen in
1994 [49]. In gastric carcinogenesis, host-related genetic elements such as a pro-inflammatory
cytokine profile and/or a positive family history as well as bacterial virulence factors play
important roles. Furthermore, environmental factors, like nutrition, and socioeconomic factors
are suggested to be also important. After the initiation by H. pylori and the influence of variable
environmental and host factors, chronic active gastritis may progressively evolve to atrophic
gastritis and intestinal metaplasia. In some individuals, the metaplastic epithelium will
undergo further genomic and phenotypic changes, resulting in gastric dysplasia and eventual
adenocarcinoma [50]. The “test and treat” strategy for H. pylori infection should be considered
effective for prevention of gastric carcinoma only in communities with a high incidence of
gastric carcinoma [51].
H. pylori has been identified as causative agent for chronic erosive gastritis, erosive esophagitis,
and erosive duodenitis [52-54]. These lesions are also among the important causes of occult
gastrointestinal bleeding [3].
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4.2. Decreased iron absorption secondary to hypo- or achlorhydria
Iron malabsorption is one of the most important causes of IDA. Decreased iron absorption
may result  from intestinal  mucosal  disorders  (most  frequently,  celiac  disease),  impaired
gastric acid secretion (including use of proton pump inhibitors), and gastric/intestinal bypass
procedures [3].
As mentioned above, nonheme ferric iron is required to be reduced to a ferrous form before
its absorption in the duodenum and first jejunum. Gastric acid has an important role in
reducing and solubilizing the inorganic form of the iron [30]. Ferric iron has been demonstrated
to be insoluble and precipitates at pH above 3 [55]. Thus, IDA can develop in patients with
hypochlorhydria because of gastric surgery or atrophic body gastritis [56, 57].
Atrophic body gastritis is characterized by atrophy of the gastric body mucosa, hypergastri‐
nemia, and hypo-achlorhydria [58]. Atrophy is a time-related phenomenon and H. pylori
infection is considered an etiologic factor in the development of atrophic body gastritis [59].
This can eventually lead to loss of gastric glands and development of multifocal atrophic
gastritis, which is often accompanied by intestinal metaplasia. A steady increase in the
prevalence of atrophy and metaplasia is seen with advancing age [60]. As with peptic ulcer
disease, the chance for development of atrophic body gastritis depends on the severity of
gastritis and the characteristics of the bacterial strain [59]. Another interesting factor that can
influence the development of atrophic body gastritis is H. pylori lipopolysaccharide mimicking
Lewis x and y antigens. The presence of cross-reacting antibodies against the antigens and the
gastric mucosa may have a great chance to develop atrophy [61]. Atrophic body gastritis may
improve on long-term follow-up after H. pylori eradication, which is thus strongly recom‐
mended in atrophic gastritis [62].
It is well known that H. pylori infection induces gastric acid hyposecretion irrespective of
presence of fundus atrophy when affecting the gastric body [63]. Also, H. pylori gastritis has
been demonstrated to be associated with a reversible reduction in the ascorbic acid levels of
gastric juice [64]. Therefore, a diffuse H. pylori-gastritis could decrease iron absorption by
altering the physiological gastric secretion, even if it is mild [65].
4.3. Increased iron uptake and utilization by bacteria
H. pylori has been shown as a causative agent in IDA that is not attributable to usual reasons
such as intestinal losses or poor intake, malabsorption or diversion of iron in the reticuloen‐
dothelial system, and unresponsive to iron therapy. The possible mechanism may be explained
via bacterial competition for dietary iron.
Iron is an essential trace element in all organisms, even for pathogenic bacteria. Acquisition of
iron by H. pylori from the host is necessary for colonization and infection [66]. Intracellular
bacterial iron is exactly regulated and kept at an optimal level. Mostly, the free iron in the host
is found to be complexes with proteins such as Tf and lactoferrin on mucosal surfaces. Thus,
the available extracellular host iron is at a very low level. Therefore, bacterial pathogens such
as H. pylori have to develop some mechanisms to compete for the restricted extracellular iron
in the host to survive and maintain disease [67, 68].
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In the gastric mucosa, iron is available as lactoferrin, heme compounds arising from damaged
tissues, and iron based on pepsin-degraded food. Iron represents increased solubility in the
acidic fluid, and iron-complexing proteins of eukaryotic organisms exhibit lower binding
capacity under the acidic conditions in gastric juice.
H. pylori produce several iron transport proteins and iron storage proteins [69-72,Table 3].
Fe2+ is the main form of free iron in the gastric medium, and H. pylori keeps this ferrous ion
through the FeoB protein [73]. FeoB-mediated iron acquisition has great importance for H.
pylori. It has been shown that isogenic FeoB mutant mice could not colonize the gastric mucosa
[73]. Ferric reductase activity for conversion of Fe3+ to Fe2+ is transported by the FeoB system





FecA (ferric citrate outer membrane receptor)
FecD (inner membrane permease)
FecE (ATP-binding protein)
FrpB (outer membrane receptor)
CeuE (periplasmic-binding protein)






Table 3. Proteins Involved in Iron Acquision System of Helicobacter pylori
Additionally, H. pylori also has various transport systems for ferric iron [72, 75]. Since the ferric
iron is insoluble, its transport needs an outer membrane receptor to transport the iron over the
outer membrane. H. pylori has three copies of the ferric citrate outer membrane receptor FecA
and three copies of the FrpB outer membrane receptor [69-72]. There are two copies of the
periplasmic-binding protein CeuE and finally a single inner membrane permease (FecD) and
an ATP-binding protein (FecE). ABC transporter system transports the iron from the periplasm
to the cytoplasm [73].
Subsequently, specific outer membrane receptor proteins bind the iron. It has been suggested
that heme-iron-repressible outer membrane proteins (IROMPs) are involved in heme binding
and/or uptake by H. pylori [39]. When the heme is located in the cytoplasm, it can be used by
a heme oxygenase protein. Heme oxygenase catalyzes the NADPH-reductase-dependent
degradation of heme to biliverdin, which is the rate-limiting step leading to the release of iron
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and carbon monoxide. Some researchers have identified a heme oxygenase protein called
HugZ that is responsible for heme iron utilization in H. pylori [76].
A common iron acquisition system present in many pathogens is the secretion of low-
molecular-mass, high-affinity iron chelators, which are called siderophores. These chelators
are able to remove iron from Tf or lactoferrin [77-78].
Two iron storage proteins in H. pylori have been characterized, the Pfr ferritin and H. pylori
neutrophil-activating protein (HP-NAP) bacterioferritin. The 19-kDa Pfr ferritin serves as an
intracellular iron deposit and protects H. pylori against iron toxicity and free iron-mediated
oxidative stress [79-83]. Iron-binding Pfr ferritin can be delivered and reused to maintain
growing up in the iron-limited states [83]. HP-NAP was isolated from neutrophilic granulo‐
cytes as an immuno-dominant protein in vitro [84]. It was demonstrated to mediate adhesion
of H. pylori to mucin [85]. The HP-NAP protein is similar to bacterioferritins [86, 87]. Although
it is suggested, a role of HP-NAP in H. pylori iron storage is yet to be demonstrated [87].
In addition, lactoferrin-binding protein has been suggested to be highly specific for human
lactoferrin in H. pylori infection [40].
All these mechanisms suggest that H. pylori utilize the iron from host and use or store for
colonization and growth.
4.4. Changing molecular mechanisms in iron metabolism
H. pylori may act in changing molecular mechanisms that play a role in iron metabolism.
The best evaluated molecule in the association between H. pylori and ID is hepcidin. Hepcidin
is a protein that is secreted into the blood and interacts with villous enterocytes to regulate the
rate of iron absorption by controlling the expression of ferroportin-1. When hepcidin is
increased, iron release from enterocytes is reduced. The anemia of chronic inflammation is
mediated, in part, by the stimulation of hepcidin by cytokines [35]. Hepcidin has been reported
to be elevated in patients infected with H. pylori, acting as an acute-phase reactant in response
to the inflammation produced in the gastric mucosa and resulting in a pathology known as
“anemia of inflammation or chronic disease” [88-90]. Prohepcidin, hepcidin's precursor, was
also shown to increase in H. pylori infection and is decreased after eradication of H. pylori
infection [91].
HO-1 is an enzyme that is responsible in heme degradation in host enterocytes. H. pylori may
affect levels of HO-1. A significant increase in Keap1 gene expression was found in transfected
AGS cells with H. pylori HspB. The increase in Keap1 was associated to decreased antioxidant
enzymes including HO-1, and phase II detoxifying enzyme NAD(P)H:quinone oxidoreduc‐
tase-1 [92]. CagA status is suggested to be important in this action of H. pylori. HO-1 is also
found to be down-regulated in gastric epithelial cells of patients infected with cagA-positive
H. pylori but not in gastric epithelial cells of patients infected with cagA-negative H. pylori [93].
TfR1 and TfR2 on cell surface mediate the cellular uptake of Tf-bound iron from plasma [28].
H. pylori is known to affect host cell polarity and intracellular trafficking [94]. In H. pylori-
infected cell lines, it has been shown that Tfr was mislocalized to sites of H. pylori microcolony
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growth at the apical cell surface. H. pylori colonization of the polarized epithelium has been
shown to lead to increased apical release of Tf [95].
5. Factors that affect iron deficiency development in H. pylori infection
Although H. pylori gastric infection has been shown to be strongly associated with IDA, it is
only a small portion of patients with H. pylori gastritis that develop IDA. The main question
is why only a small portion of patients with H. pylori gastritis develop IDA, and what differ‐
entiates these patients.
The pattern of H. pylori-related gastritis is a significant predictor of the results of infection, and
it determines the different effects of the bacteria on gastric functions. The panelists of the
updated Sydney system suggested that most individuals infected with H. pylori develop a more
evident inflammation in the antrum (nearly double) compared to the corpus in the absence of
atrophy [96].
The relationship between chronic gastritis and gastric acid secretion is strictly dependent on
the topography of gastric inflammation [97]. It has been demonstrated that gastritis in the
corporal mucosa leads to decreased acid secretion with a consequent increase in intragastric
pH [98]. Severity of inflammation is also important in terms of clinical outcomes.
Additionally, H. pylori strains owning the cagA or the vacuolating cytotoxin A (vacA), which
are highly virulent, display potent mechanisms to produce or magnify ID in patients compar‐
ing less virulent strains [99, 100]. For example, Baysoy et al. have reported that cagA-positive
strains was associated with a greater decrease in gastric juice ascorbic acid compared to cagA-
negative strains [101]. Tan et al. reported that cagA and vacA contribute to iron uptake from
gastric epithelial cells in a cooperative manner. VacA induces apical mislocalization of TfR.
CagA alters internalization and intracellular transport of TfR. These pathogenic factors take
away iron from holo-transferrin of host and maintain colonization on the gastric epithelial cell
surface [95]. Moreover, Cardenas et al. found that patients infected with the cagA-positive
strains did not improve their ferritin levels after eradication treatment as much as those who
were cagA-negative [102].
6. Management of iron deficiency in H. pylori infection
Like other hematological conditions such as MALT lymphoma, vitamin B12 deficiency, and
idiopathic thrombocytopenic purpura, IDA is also included in the international consensus and
guidelines as an indication for “test and treat” of H. pylori [51, 62, 103,Table 4]. Whereas, it
should not substitute the other workup for IDA. The endoscopic evaluations for upper and
lower gastrointestinal tracts in men and postmenaposal women, celiac serology should be
performed in cases of IDA.
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Hematological Condition Level of Evidence
MALT lymphoma Evidence level: 1a Grade of recommendation: A
IDA
Evidence level: 1a
Grade of recommendation: A
Idiopathic thrombocytopenic purpura
Evidence level: 1b
Grade of recommendation: A
Vitamin B12 deficiency
Evidence level: 3b
Grade of recommendation: B
Abbrevations: Grades of recommendations and evidence levels in support of recommendations
Grade of recommendation: A; Evidence level: 1a: Systematic review of randomized controlled trial (RCT) of goog
methodological quality and with homogeneity
Grade of recommendation: A; Evidence level: 1b: Individual RCT with narrow CI
Grade of recommendation: B; Evidence level: 3b: Individual case-control study
Table 4. Evidence Based Relationship between H. pylori and the Etiology of other Hematological Conditions (in these
disorders, H. pylori should be sought and eradicated)
It is possible to rescue hematological and ferro-kinetic parameters after H. pylori eradication.
Its implication as an unexplained origin of ID was revealed in the international consensus and
management guidelines of H. pylori infection. It should be tested and eradicated in both adults
and children with unexplained origin of ID [104,105].
There has not been any concensus on the treatment of IDA in H. pylori-infected patients yet.
Three meta-analyses evaluated the effect of H. pylori eradication on IDA. Qu et al. reported
that eradication of H. pylori improved hemoglobin and serum ferritin levels but not signifi‐
cantly [27]. Whereas, Huang et al. reported another meta-analysis of 8 randomized controlled
trials (RCTs) in which five RCTs had used PPI-based triple therapy and three RCTs had used
bismuth-based triple therapy as eradication regimens. They found that anti-H. pylori treatment
combined with iron supplement was more effective than iron administration alone in the
treatment of IDA in H. pylori-infected patients. They also showed that bismuth-based triple
therapy had an advantage over PPI-based triple therapy [26]. However, this finding needs to
be confirmed. In another meta-analysis involving 956 patients and 16 RCTs in which 13 RCT
had used PPI-based triple treatment and 3 RCT used bismuth-based triple treatment, it was
shown that the increase in Hb, serum iron, and serum ferritin levels were significantly higher
with anti-H. pylori treatment plus oral iron compared with oral iron alone in patients with
documented H. pylori infection and IDA [24]. Recently in a study by Habib et al., sequential
and standard therapies were compared in children. It was shown that there was no significant
difference in H. pylori eradication success between two groups and there was no significant
relationship between eradication treatment and serum ferritin levels [106].
In conclusion, refractoriness to oral iron treatment and unexplained IDA may justify a “test-
and-treat” approach of H. pylori eradication as recommended by the Maastricht IV European
Consensus Conference [62], Second Asia–Pacific Consensus Guideline [51], and the III
Working Group Consensus Report 2015 [103]. Standard treatment regimens that are recom‐
mended in dyspeptic patients by current guidelines combined with iron supplement are
effective in IDA in patients with H. pylori infection. These eradication regimens are listed in
Table 5 based on current guidelines [Table 5,51, 62, 103].
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First-line therapy Duration Drugs and doses




+ Amoxicillin 1g 2x1
+ Clarithromycin 500 mg 2x1
or
(in the presence of penicillin allergy)
PPI 2x1
+ Metronidazole 500 mg 2x1
+Clarithromycin 500 mg 2x1
or
(in areas of low clarithromycin resistance)
PPI 2x1
+ Amoxicillin 1 g 2x1
+ Metronidazole 400 mg 2x1
First 5 days PPI 2x1 + Amoxicillin 1 g 2x1
Sequential therapy PPI 2x1
Followed by 5 days
+ Metronidazole or tinidazole 500 mg 2x1





+ Amoxicillin 1g 2x1
+ Metronidazole or tinidazole 500mg 2x1
+ Clarithromycin 500 mg 2x1
Second-line therapy Duration Drugs and doses
*Bismuth-containing quadruple therapy
(when bismuth is available)
7–14 days
PPI 2x1
+ Bismuth salts 4x1 or 2x2
+ Tetracycline, 500mg 3x1
+ Metronidazole, 500mg 3x1
Levofloxacin-containing triple therapy 10 days
PPI 2x1
+ Amoxicillin 1g 2x1
+ Levofloxacin, 500mg 1x1 or 250mg 2x1
or
(in the presence of penicillin allergy)
PPI 2x1
+ Clarithromycin 500 mg 2x1
+ Levofloxacin, 500mg 1x1 or 250mg 2x1
Rifabutin-based triple therapy: 7–10 days
PPI 2x1
+Rifabutin 150 mg 2x1
+Amoxicillin 1 g 2x1
Third-line therapy
After failure of second-line therapy, treatment should be guided by antimicrobial susceptibility testing, whenever possible
*In areas of high clarithromycin resistance, bismuth-containing quadruple therapy is recommended for first-line em‐
pirical treatment.
Abbrevations: PPI: Proton pump inhibitor
Table 5. Treatment regimens recommended for first- and second-line therapy of Helicobacter pylori infection
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7. Summary
Iron is an essential element for all living organisms. Iron metabolism is controlled mainly by
absorption. ID is the most common nutritional deficiency and causes clinically important
outcomes. One of the most common results of ID is IDA. ID results from increased physio‐
logical needs, blood losses, inadequate intake, and diminished absorption. H. pylori infection
is one of the important causes of IDA especially in undetermined and refractory cases.
In the literature case series, sero-epidemiological studies and meta-analysis showed strong
evidence regarding the relationship between IDA and H. pylori. Several mechanisms have been
proposed for IDA in H. pylori infection. First, blood loss from gastrointestinal lesions related
with H. pylori; second, malabsorption due to hypo- or achlorhydria resulting from gastric body
inflammation and atrophy; third, bacterial competition for dietary iron with several mecha‐
nisms; and last, changing regulatory pathways especially hepcidin levels in iron metabolism
by the bacteria.
Although H. pylori infection is more prevalent, frequency of IDA related with H. pylori is low.
Influencing factors for developing IDA in H. pylori infection include topographic distribution
of gastric inflammation, severity of inflammation, virulence factor of the bacteria.
Once IDA is diagnosed in H. pylori-infected patient, other most common causes of IDA should
be evaluated carefully. Depending on “test and treat” strategy, the H. pylori infection should
be eradicated based on recommendations by the current guidelines.
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Abstract
Helicobacter pylori colonizes the stomach and causes chronic gastritis, which most often re‐
mains asymptomatic. However, in a small proportion of infected persons, it causes peptic
ulcers and gastric cancer. We reviewed recent evidence of the association between H. py‐
lori infection and diabetes mellitus (DM). Numerous studies have shown a positive asso‐
ciation between H. pylori infection and DM, however, findings are still conflicting. Such a
link is biologically plausible, given the importance of the stomach in the homeostasis of
systems outside the digestive tract; however, the mechanisms by which H. pylori might
affect the risk of DM are not clear. Current knowledge indicates that H. pylori infection
can affect the regulation of ghrelin and leptin, two hormones that play central roles in en‐
ergy homeostasis in humans. Yet, methodological limitations are present in studies that
addressed the relationships of H. pylori infection with DM and with possible risk factors
for DM, including inadequate control of confounders. The important question of whether
H. pylori eradication might be beneficial for glycemic control in diabetic patients is still
unresolved. Future well-designed studies are needed to address these research questions,
which are of clinical and great public health significance.
Keywords: Helicobacter pylori, diabetes mellitus, epidemiology
1. Introduction
Helicobacter pylori is a gram-negative bacterium that colonizes the stomach and causes persis‐
tent infection. The infection is typically acquired in the first few years of life [1–3]. The
associated risk factors of H. pylori infection include living in crowded households, low
socioeconomic conditions and infected family members [4–6]. The infection is common
worldwide with highest prevalence rates reaching 80–90% in developing countries and
underprivileged communities [7], while a much lower prevalence of 20–50% is recorded in
developed countries [7].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
H. pylori infection has two phases: an acute phase and a chronic course. Acute H. pylori infection
is rarely diagnosed. Following establishment of the infection, chronic gastritis develops;
however, most infected people remain asymptomatic and only 10–20% of them develop peptic
disease during their lifetime [7]. H. pylori causes gastric and duodenal ulcers, and in rare
occasions distal gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma [7].
These diseases are the main indications to test and treat H. pylori infection [8], in addition to
unexplained iron deficiency anemia (IDA) and idiopathic thrombocytopenic purpura [8].
Although H. pylori infection is acquired in childhood, peptic ulcer disease typically occurs in
adulthood.
Following H. pylori colonization, rigorous local and systemic immune responses develop.
However, these do not clear the infection but rather contribute to the damage of the gastric
mucosa [7, 9, 10]. H. pylori simulates the innate immune response, as well as humoral and cell-
mediated immune responses [9, 10]. The predominant human T cell response is the T-helper
1 mediated response, which is associated with releasing proinflammatory cytokines and
activation of phagocytes [9, 10]. H. pylori also induces Th2 and T-regulatory (Tregs) responses
[9, 10]. The importance of Treg response is in both controlling inflammation and promoting
the persistence of the infection [9, 10].
H. pylori-associated gastric pathology develops over time in a progressive manner [11–13], and
the damage to gastric mucosa can be observed even in asymptomatic persons [14]. Today it is
clear that host (e.g., age, genetic susceptibility), agent (virulence antigens) and environment-
related factors are important in the development of H. pylori-associated gastroduodenal diseases
[9]. For example, host genetic polymorphisms that lead to increased release of proinflammato‐
ry cytokines are associated with increased gastric cancer risk [9]. Pathogenesis is dependent on
a Th1-acquired immune response and on hormonal changes including hypergastrinemia [9].
Regarding pathogen virulence factors, most H. pylori strains carry the cag pathogenicity island
that  encodes for a type IV secretory apparatus,  which allows translocation of  cytotoxin-
associated gene A (CagA) protein into the host cell. This, together with the vacuolating cytotoxin
(VacA), plays a major role in the pathogenesis of gastroduodenal diseases [7, 9, 15–17]. Novel
H. pylori antigens have been identified recently [18], some of which were found to be associat‐
ed with atrophic gastritis and gastric cancer risk such as GroEL [18], Helicobacter cysteine-
rich protein (HcpC) [19], outer membrane protein (Omp) and others [20, 21].
Several studies have shown associations between H. pylori infection and various extragastric
diseases [22]. H. pylori infection was positively linked with adulthood chronic diseases such
as cardiovascular disease [23–25], dementia [26–28], insulin resistance and diabetes mellitus
(DM) [22, 29, 30]. The mechanisms of such associations are not fully understood, and it is not
clear whether such associations are causal or not. This chapter will focus on the association
between H. pylori infection and DM.
2. H. pylori infection, changes in gastric physiology and metabolic
hemostasis
Although the role of H. pylori infection in the pathogenesis of gastroduodenal diseases [7, 9,
17, 31] is well established, its impeding effects on metabolic homeostasis and DM are not clear.
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview142
H. pylori infection has two phases: an acute phase and a chronic course. Acute H. pylori infection
is rarely diagnosed. Following establishment of the infection, chronic gastritis develops;
however, most infected people remain asymptomatic and only 10–20% of them develop peptic
disease during their lifetime [7]. H. pylori causes gastric and duodenal ulcers, and in rare
occasions distal gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma [7].
These diseases are the main indications to test and treat H. pylori infection [8], in addition to
unexplained iron deficiency anemia (IDA) and idiopathic thrombocytopenic purpura [8].
Although H. pylori infection is acquired in childhood, peptic ulcer disease typically occurs in
adulthood.
Following H. pylori colonization, rigorous local and systemic immune responses develop.
However, these do not clear the infection but rather contribute to the damage of the gastric
mucosa [7, 9, 10]. H. pylori simulates the innate immune response, as well as humoral and cell-
mediated immune responses [9, 10]. The predominant human T cell response is the T-helper
1 mediated response, which is associated with releasing proinflammatory cytokines and
activation of phagocytes [9, 10]. H. pylori also induces Th2 and T-regulatory (Tregs) responses
[9, 10]. The importance of Treg response is in both controlling inflammation and promoting
the persistence of the infection [9, 10].
H. pylori-associated gastric pathology develops over time in a progressive manner [11–13], and
the damage to gastric mucosa can be observed even in asymptomatic persons [14]. Today it is
clear that host (e.g., age, genetic susceptibility), agent (virulence antigens) and environment-
related factors are important in the development of H. pylori-associated gastroduodenal diseases
[9]. For example, host genetic polymorphisms that lead to increased release of proinflammato‐
ry cytokines are associated with increased gastric cancer risk [9]. Pathogenesis is dependent on
a Th1-acquired immune response and on hormonal changes including hypergastrinemia [9].
Regarding pathogen virulence factors, most H. pylori strains carry the cag pathogenicity island
that  encodes for a type IV secretory apparatus,  which allows translocation of  cytotoxin-
associated gene A (CagA) protein into the host cell. This, together with the vacuolating cytotoxin
(VacA), plays a major role in the pathogenesis of gastroduodenal diseases [7, 9, 15–17]. Novel
H. pylori antigens have been identified recently [18], some of which were found to be associat‐
ed with atrophic gastritis and gastric cancer risk such as GroEL [18], Helicobacter cysteine-
rich protein (HcpC) [19], outer membrane protein (Omp) and others [20, 21].
Several studies have shown associations between H. pylori infection and various extragastric
diseases [22]. H. pylori infection was positively linked with adulthood chronic diseases such
as cardiovascular disease [23–25], dementia [26–28], insulin resistance and diabetes mellitus
(DM) [22, 29, 30]. The mechanisms of such associations are not fully understood, and it is not
clear whether such associations are causal or not. This chapter will focus on the association
between H. pylori infection and DM.
2. H. pylori infection, changes in gastric physiology and metabolic
hemostasis
Although the role of H. pylori infection in the pathogenesis of gastroduodenal diseases [7, 9,
17, 31] is well established, its impeding effects on metabolic homeostasis and DM are not clear.
Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview142
The stomach plays a major role in the homeostasis of systems outside the digestive tract.
Therefore, the link between H. pylori-chronic gastritis and metabolic homeostasis and DM
seems biologically plausible.
H. pylori-induced inflammation and its severity affect gastric physiology. For example, H.
pylori leads to hormonal changes in the stomach, such as reduced production of somatostatin
and hypergastrinemia [9]. H. pylori-gastritis also alters the secretion of gastric acid [32, 33];
increased secretion of gastric acid is associated with antral-predominant phenotype and
increased risk of duodenal ulcers [9, 10]. H. pylori infection can reduce gastric acid production,
and this is typically associated with corpus-predominant gastritis and increased likelihood of
gastric ulcer and gastric adenocarcinoma [9, 10]. Moreover, H. pylori infection is associated
with reduced gastric ascorbic acid levels [34]. H. pylori affects the levels of pepsinogen (PG) I
and PGII; proenzymes of the digestive enzyme pepsin. PGI is secreted from cells in the corpus
and PGII is also secreted from cells in the antrum and duodenum [35, 36]. About 1% of PGs
can be found in the serum. Serum PGI and PGII are increased in H. pylori infected vs. uninfected
individuals, and higher levels are found in more severe gastritis. As the severity of gastritis
progresses and corpus atrophic lesions appear, the PGI level decreases, while the PGII level
remains stable; the result is a decrease in the PGI:PGII ratio [37, 38]. These markers have clinical
significance, and they predict various gastric pathologies [16, 37–40].
In addition, H. pylori infection can affect the regulation of ghrelin and leptin [41–47], two
hormones  that  play  central  roles  in  energy  homeostasis  [48].  Ghrelin  reduces  energy
expenditure and promotes weight gain [48–50], while leptin decreases appetite and increas‐
es energy expenditure [48]. Both hormones are secreted by the epithelial cells in the stom‐
ach [48, 51]. The relationship between H. pylori and these hormones appears to be complex.
While several studies reported no association between H. pylori  infection and circulating
leptin [43, 45, 46, 52–54] and ghrelin levels [45, 52, 54], others found lower levels of one or
the two hormones in H. pylori  infected vs. uninfected individuals [41, 42, 44]. There also
appears to be differences in gastric mucosa levels of these hormones, according to H. pylori
infection [41, 42, 47, 52–54]. Moreover, H. pylori eradication seems to affect these hormones









Isomoto et al. [44]
H. pylori infection ↓ ↓ ND ND
H. pylori
eradication
NS NS ND ND




Jun et al. [52] H. pylori infection NS NS NS ↑
Nishi et al. [53] H. pylori infection ND ND NS ↑
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Azuma et al. [47]
H. pylori infection ND ND ↑
H. pylori
eradication
ND ND NS ↓
Jang et al. [54]
H. pylori
eradication
NS ↑ NS ND







Breidert et al. [43] H. pylori infection ND ND NS
Antrum: NS
Corpus:↑
NS, no significant difference; ND, not determined;, ↑ increase;, ↓ decrease.
Table 1. Selected studies that addressed associations of H. pylori infection and H. pylori eradication with ghrelin and
leptin levels
Altogether, these studies suggest that H. pylori can alter gastric physiology, which can in turn
affect metabolic homeostasis and the risk of DM.
3. H. pylori infection and diabetes mellitus
DM refers to a group of metabolic disorders that manifest with hyperglycemia. DM is classified
based on the pathogenic course that results in hyperglycemia, with two broad categories
designated as type 1 DM (T1DM) and type 2 DM (T2DM). T1DM is the result of interaction
among genetic, environmental and immunological factors that eventually leads to destruction
of beta cells in the pancreas and complete or near-complete insulin deficiency. T2DM consists
of various disorders with variable levels of insulin resistance, impaired insulin secretion and
increased glucose production. T1DM usually occurs in childhood and adolescence, and
comprises 5–10% of all DM cases [55]. T2DM typically develops in adulthood and is responsible
for the majority (90–95%) of DM cases [55].
DM is a major public health problem [56–60], causing an enormous burden to patients and
their families, as well as to health care systems. The prevalence of T2DM is increasing globally
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[56–60] due to increases in life expectancy and obesity [56, 58]. It is estimated that 240 million
people have T2DM, and that in 2025 about 380 million will have the disease, while 418 million
will have impaired glucose tolerance (IGT) [56]. The burden of DM is amplified given its
significant macro and microvascular complications (such as cardiovascular disease, kidney
disease), in addition to peripheral neuropathy [55].
There are well-established risk factors for T2DM [61–67], including sociodemographic factors
[64, 68, 69], lifestyle factors (e.g., obesity, physical inactivity, poor diet [61–67]) and high
glucose levels reflecting IGT [65, 66]. Changes in diet (i.e., higher consumption of whole grain
products and exchanging unsaturated fat for saturated fat), and in particular physical activity
and avoidance of obesity, can prevent T2DM through changes in body fat and other mecha‐
nisms [61, 67, 70–72]. These may reduce the incidence of DM by 28–59% [72]. Such interventions
are also important for better control of diabetes [70, 73]. Current evidence suggests that there
must be additional factors besides lifestyle that contribute to the occurrence of DM.
In addition to the association mentioned above, between H. pylori infection and ghrelin and
leptin [41, 45, 74–80], associations have been reported of H. pylori infection with glycated
hemoglobin  levels  (Hb1Ac)  [81],  as  well  as  with  disturbances  in  metabolic  homeostasis
including insulin resistance; the latter according to a recent literature review and a systemat‐
ic review [22, 82]. These findings support the postulation that H. pylori  infection may be
involved in the etiology of the emerging pandemic of obesity and DM, and in diabetes-
related complications.
Associations of H. pylori infection with DM incidence [30, 83, 85] have been reported. Recent
meta-analyses showed a significant 1.7 to 2-fold higher prevalence of H. pylori infection in
persons with T2DM vs. non-diabetic individuals [84, 85]. In some of the studies that reported
a positive association between H. pylori infection and DM [30, 86–88], the association became
non-statistically significant after adjustment for potential confounders such as age and
socioeconomic status [87, 88]. Other studies reported no significant association between H.
pylori and DM [89–92], or a significant association only in persons with BMI>25 [81] (Table 2).
Several studies did not control adequately for socioeconomic status and for traditional risk
factors of DM, such as obesity and physical inactivity. Furthermore, most of the evidence is
based on small-scale hospital-based case–control studies, in which the source population,
selection of control population and representativeness of the sample were not fully described.
For these reasons, inference and generalizability of findings from such studies should be done
with caution. On the other hand, recent well-designed studies show convincing evidence of
the potential involvement of H. pylori infection in the occurrence of DM, and possibly in IGT.
A large population-based follow-up investigation of elderly persons has demonstrated a
significant two-fold increased risk of DM in H. pylori infected vs. uninfected persons, even after
controlling for possible confounders, while such an association was not observed for other
pathogens [30]. A large well-designed and thoroughly analyzed survey that utilized nation‐
wide data (N~13,000) from the United States indicated no significant association between H.
pylori infection and self-reported diabetes. However, among individuals with BMI>25 kg/m2
who were assessed in the 1999–2000 National Health & Nutrition Examination Survey
(NHANES), DM was more prevalent among those who were H. pylori seropositive than those
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who were H. pylori-seronegative[81] (Table 2). Moreover, that study showed that H. pylori
infected persons, especially those infected with CagA strains, had significantly elevated mean
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BMI, body mass index; CI, confidence intervals; DM, diabetes mellitus; DBP, diastolic blood pressure; ELISA, enzyme-
linked immunosorbent assay; Hp, Helicobacter pylori; HR, hazard ratio; HSV-1, Herpes simplex virus 1; IgA, immunoglobulin
A; IgG, immunoglobulin G; NHANES, National Health & Nutrition Examination Survey; OR, odd ratio: SES, socioeco‐
nomic status; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UBT, urea breath test.
Table 2. Selected epidemiological studies that examined an association between H. pylori infection and diabetes
mellitus
4. H. pylori infection and glycemic control among diabetic patients
Given the observed associations between H. pylori infection and various metabolic and
glycemic measures, the question arises of whether H. pylori infection and/or H. pylori eradica‐
tion can affect glycemic control in diabetic patients. If indeed H. pylori infection plays a role in
glycemic control, H. pylori eradication might be beneficial to diabetic patients. A recent meta-
analysis that included 14 observational studies involving 1781 diabetic patients (both T1DM
and T2DM) showed no significant difference in mean HbA1c values among H. pylori infected
individuals compared with those uninfected; mean difference 0.19% (95% CI: −0.18 to 0.46),
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(Pv=0.16) [93]. In contrast, another meta-analysis involving 11 studies and 513 patients
reported significantly higher HbA1c values among H. pylori-infected diabetic persons than
among uninfected ones: weighted mean difference 0.43 (95% CI: 0.07–0.79), (Pv=0.02) [94]. The
discrepancy in results between the two meta-analyses can be explained by differences in their
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Table 3. Helicobacter pylori eradication and glycemic control in diabetic patients
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The question of whether H. pylori eradication can improve glycemic control was assessed in a
limited number of observational studies, most of them were small scale [95–101] (Table 3).
Findings from these studies were conflicting, ranging from no difference, to small non-
significant or borderline improvements from baseline to up to 2-years after eradication [95–
101] and to a significant decrease from baseline, in HbA1c at 3 months after H. pylori eradication
[95]. A pooled analysis of two studies that compared mean differences in HbA1c between
diabetic individuals who had undergone successful H. pylori eradication and those whose H.
pylori eradication therapy had failed, showed no significant difference between the groups [94].
The optimal study design to examine the effect of H. pylori eradication therapy on glycemic
control is a randomized controlled trial with intention-to-treat analysis, in which diabetic
patients are assigned to either an H. pylori eradication group or a placebo control group.
However, to-date such trials are lacking, and the current evidence is based on observational
studies, which are evidently prone to biases and confounders. Therefore, the question of
whether H. pylori infection affects glycemic control in diabetic patients remains unresolved.
5. H. pylori infection and metabolic syndrome
Metabolic syndrome is a cluster of metabolic risk factors that are associated with increased
risk for atherosclerotic cardiovascular disease, T2DM and their complications. These factors
include atherogenic dyslipidemia (elevated triglycerides and apolipoprotein B, increases small
low-density lipoproteins [LDL], and low concentration of high-density lipoproteins [HDL]),
elevated blood pressure and elevated fasting glucose levels known as impaired fasting glucose
(IFG) or prediabetes [102, 103], which lead to a prothrombotic and proinflammatory state. The
main risk factors for metabolic syndrome include obesity, mainly abdominal obesity and
insulin resistance [103], as well as aging, physical inactivity and diet rich with saturated fat
and cholesterol [103].
Recent studies have tested the hypothesis of a positive association between H. pylori and
metabolic syndrome [22, 104–106]. While the underlying mechanisms remain to be deter‐
mined, the inflammatory response to infection and secretion of cytokines such as tumor
necrosis factor alpha (TNF-α) and interleukin-1 (IL-1), IL-6 and IL-8 likely play a role in the
postulated association. Additionally, H. pylori-induced atrophic gastritis, which develops with
aging, reduces the levels of vitamin B12 and folate, which increase homocysteine levels, a
known risk factor for insulin resistance [104].
The evidence from epidemiological studies on the association between H. pylori infection and
metabolic syndrome has been evolving over the past few years.
A recent large cross-sectional study conducted among 3578 persons aged 18–64 years from
Taiwan has demonstrated that H. pylori infected persons (according to urea breath test [UBT])
had a significantly increased prevalence of metabolic syndrome than uninfected persons; 12.4
vs. 7.4% (Pv<0.001) in men and 7.4 vs. 2.5% in women (Pv<0.001) [105]. In this study, metabolic
syndrome was defined based on National Cholesterol Education Program (NCEP) Adult
Treatment Panel (ATP) III Criteria, which were adjusted to the Taiwanese population [105].
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The observed positive associations between H. pylori infection and metabolic syndrome were
attenuated in multivariable analyses, while adjusting for confounders such as age, smoking
and alcohol drinking; adjusted odds ratio (OR) 1.91 (95% CI: 1.03–3.53) in women, while in
men the association was not statistically significant: adjusted OR: 1.38 (95% CI: 0.97–1.95) [105].
A population-based study conducted among adults aged 25 years or over in Iran also reported
a 1.5-fold significantly increased prevalence of metabolic syndrome (according to NCEP-ATP-
III criteria) among H. pylori (based on serum IgG detection) infected men and women compared
with uninfected ones [107]. The same study reported positive associations in relation to
exposure to other infectious agents as well such as Chlamydia pneumoniae, Herpes simplex virus
1 (HSV-1) and Cytomegalovirus (CMV) [107]. From this study, it is not clear whether the results
were adjusted for confounders, and which ones [107].
Gunji et al. [106], in a well-designed study carried out among 5488 Japanese men (mean age
47± 5 years) and 1906 women (mean age 46±4 years), demonstrated a significant positive
relationship between H. pylori seropositivity (according to the presence of IgG antibodies) and
metabolic syndrome (based on the Japanese diagnostic criteria); adjusted OR: 1.39 (95% CI:
1.18–1.62) Pv<0.001 [106]. This association was independent of known risk factors for metabolic
syndrome namely age, sex, diet and smoking [106].
While there is a growing compelling evidence from large epidemiological studies supporting
the existence of a positive association between H. pylori infection and metabolic syndrome,
other studies reported no signification association [108] or reported small magnitude associ‐
ation measures [109]. Therefore, the question of whether H. pylori infection is associated with
metabolic syndrome, although biologically plausible, remains to be determined, as well as the
source of variation among the studies in their findings. Multi-national studies employing
similar clinical, epidemiological and diagnostic protocols and methods will be needed to assess
true population-to-population variations.
6. Conclusions and future directions
Current evidence is conflicting regarding the question of whether H. pylori may be associated
with an increased risk of DM, metabolic syndrome and poor glycemic control. Although an
association between H. pylori infection and DM is biologically plausible [110], the nature of
such an association is not yet understood. This is due, in part, to important methodological
limitations apparent in studies that addressed the relationship between H. pylori infection and
DM, including inadequate control for socioeconomic status and for known DM risk factors.
Moreover, most studies focused on DM, and less on the reversible conditions of IGT, and IFG.
Understanding the role in this association of pathogen-related factors, i.e., virulence antigens
such as CagA and VacA is still limited. In addition, it is not clear which biological mechanisms
may contribute to the postulated excess risk of DM and/or metabolic syndrome in H. pylori
infected persons compared with uninfected ones. Importantly, it is not yet clear whether H.
pylori eradication may be beneficial for glycemic control in diabetic patients. Randomized
placebo-controlled trials assessing such research questions are lacking.
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Addressing these research questions is of great public health and clinical significance given
the high prevalence of H. pylori infection and significant burden of DM. If H. pylori infection
is truly involved in the etiology of DM, even to a small magnitude (i.e., small relative risks),
the public health impact is expected to be great, given the high prevalence of the infection.
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Helicobacter pylori is an ancient microorganism that co-evolved with humans for 
many years and typically colonizes the human stomach and is being recognized as 
the most common infectious pathogen of the gastroduodenal tract. Some years after 
bacterium isolation, epidemiological studies have revealed a correlation between its 
infection and some diseases localized outside the stomach, such as hematological, 
hepatobiliary, pancreatic, cardiovascular, neurological, dermatological and respiratory 
diseases. Different mechanisms of action have been proposed, ranging from the 
induction of a low-grade inflammatory state to the occurrence of molecular mimicry 
mechanisms. This book is an overview of contributors surrounding the association 
of H. pylori infection with extragastric diseases, based on evidence, bacterial-host 
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